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Abstract 
The disulfide oxidative pathway in bacteria is responsible for disulfide bond formation in 
secreted proteins including many virulence factors. The archetypal Escherichia coli DsbA 
and DsbB enzymes form a redox relay that catalyses disulfide bond formation and 
constitutes the oxidative folding pathway. DsbA orthologs from a broad range of bacteria 
have been characterised and while the enzymes have similar structural and biochemical 
characteristics they vary in redox chemistry and surface properties. An overview of the 
DsbA and DsbB enzymes from different bacteria is provided in Chapter 1. Chapter 1 also 
provides an overview of antibiotics with well-known and novel targets, including bacterial 
oxidative folding. 
 
Chlamydia trachomatis is an obligate intracellular pathogen responsible for blinding 
trachoma and the sexually transmitted infection chlamydia that can lead to infertility and 
ectopic pregnancy. C. trachomatis has a biphasic developmental cycle that is dependent 
on coordinated disulfide bond formation and reduction for differentiation between the two 
distinct cell types: reticular body (RB) and elementary body (EB) (reviewed in chapter 1).  
 
Chapter 2 presents a biochemical and structural characterisation of a truncated soluble 
form of DsbA from C. trachomatis (CtDsbA), which was published in PLOS ONE. CtDsbA 
is the first structurally characterised DsbA having two small, uncharged amino acids 
separating the two active site cysteines (Cys-Ser-Ala-Cys). Characterisation of CtDsbA 
shows that is has oxidase activity and is structurally similar to other DsbAs. However, 
CtDsbA is distinct in that it is the weakest oxidising DsbA so far described. This is 
consistent with the analysis of the 2.7 Å resolution crystal structure showing a lack of 
factors stabilising the nucleophilic thiolate anion of Cys38. CtDsbA is also distinguished 
from most other DsbAs by having a disulfide bond, linking helix 2 and helix 5, that has only 
been reported in three other structurally characterised DsbAs, including Wolbachia 
pipientis DsbA1 (WpDsbA1).  
 
Chapter 3 describes my studies of the interaction between CtDsbA and CtDsbB. In the 
oxidative pathway of E. coli, DsbA (EcDsbA) is kept in its active, oxidised state by the 
integral membrane protein DsbB (EcDsbB) in a mechanism dependent on a quinone co-
factor. A BLAST search identified a protein (CtDsbB) in the genome of C. trachomatis with 
21% sequence identity to EcDsbB and a predicted secondary structure topology 
equivalent to EcDsbB. Chapter 3 presents the characterisation of the interaction between 
CtDsbA and CtDsbB showing that crude membranes containing heterogeneously 
expressed CtDsbB are able to oxidize CtDsbA. However, purified, detergent solubilised 
CtDsbB is not able to oxidise CtDsbA in the presence of ubiquinone-1 suggesting that 
purified CtDsbB is inactive in detergent micelles or that ubiquinone-1 is not a suitable co-
factor for CtDsbB. In contrast to what was found for Wolbachia DsbA1, the non-catalytic 
disulfide of CtDsbA does not regulate interaction with CtDsbB. Interestingly, mutating the 
cysteines forming the non-catalytic disulfide to serines has minimal effect on CtDsbA 
thermal stability, and only marginally decreases the difference in melting temperature 
between reduced and oxidised forms of the enzyme.  
 
In Chapter 4, I report on my attempts to generate a dsbA loss-of-function mutant. As 
disulfide cross-linking of the outer membrane plays an important role in C. trachomatis 
development and infection, CtDsbA might play a specialised role to regulate the redox 
state of the cysteines that form cross-links in the outer membrane. This hypothesis is 
supported by the observation I made that CtDsbA expression correlates with RB to EB 
differentiation (Chapter 3). To pursue this further, I attempted to obtain a loss-of-function 
dsbA mutant by chemical mutagenesis with ethyl methanesulfonate (EMS). In a forward 
genetics approach, using sensitivity to dithiothreitol (DTT) as a phenotypic read out, 
approximately 2000 subpopulations of EMS treated C. trachomatis were screened. 14 
subpopulations exhibited increased sensitivity towards DTT. Despite a hypothesis that a 
loss-of-function dsbA mutant would exhibit increased sensitivity to DTT, none of the 14 
subpopulations had a mutation in the dsbA gene. In the reverse genetics approach 
approximately 14400 subpopulations were screened using Targeting Induced Local 
Lesions in Genomes (TILLING), but again no dsbA mutation was identified. 
 
CtDsbA is the first DsbA to be characterised that has a catalytic dipeptide containing two 
small, uncharged amino acid residues. Characterisation revealed that CtDsbA is weakly 
oxidising with a mildly destabilising active site disulfide. Hence, characterisation of CtDsbA 
provides new insight into the diversity amongst DsbA proteins and supports the ongoing 
effort to develop inhibitors of DsbA enzymes. By comparison to E. coli, CtDsbB can form a 
redox-relay with CtDsbA. The forming of a functional redox relay was confirmed by the 
finding that crude membranes expressing CtDsbB facilitates CtDsbA activity. Despite 
screening more than 16000 subpopulations of EMS treated C. trachomatis LGV-2, no 
mutant was identified in the dsbA gene. Further experiments will be required to unpick the 
biological role of CtDsbA, and I discuss what these experiments could entail in Chapter 5. 
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SD   Standard deviation 
SDS   Sodium dodecyl sulfate 
SDS-PAGE  sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SeDsbA  Salmonella enterica Typhimurium DsbA 
SeDsbB  Salmonella enterica Typhimurium DsbB 
SPG   Sucrose-phosphate-glutamic acid 
STI   Sexually transmitted infection 
T3SS   Type III secretion system 
TCA   Trichloroacetic acid 
TCEP   Tris-(2-carboxyethyl)fosfin  
THF   Tetrahydrofolate 
TILLING   Targeting Induced Local Lesions IN Genomes 
TM1-4   Transmembrane helix 1 to 4 in DsbB 
Tm   Melting temperature 
TP   Threonine-cisProline 
UQROCX The University of Queensland Remote Operated Crystallisation X-ray 
Facility 
UQ-x    Ubiquinone with x isoprenoid chain length 
qPCR   Quantitative reverse transcription polymerase chain reaction 
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VcDsbA  Vibrio cholerae DsbA 
VcDsbB  Vibrio cholerae DsbB 
VKOR   Vitamin K epoxide reductase 
VP   Valine-cisProline  
WpDsbA1  Wolbachia pipientis DsbA1 
WpDsbB  Wolbachia pipientis DsbB 
Wt   Wild type 
XfDsbA  Xylella fastidiosa DsbA 
XfDsbB  Xylella fastidiosa DsbB 
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1.1 Overview of introduction 
The focus of this thesis is the oxidative folding pathway in the obligate, intracellular pathogen 
Chlamydia trachomatis. Characterisation of this pathway will broaden our knowledge of the diversity 
of the bacterial oxidative folding machinery, and of its application as a target for drug discovery. The 
recent rise in antibiotic resistance combined with a drying up of the antibiotic pipeline has led to a 
push to develop new antibiotics with novel methods of action. The proteins in the bacterial disulfide 
oxidative pathway are potential targets for a new class of antimicrobial drugs.  
 
This introductory chapter gives a brief overview to the history of antibiotic discovery and resistance 
development, followed by a summary of potential strategies for new antibiotic discovery. This 
chapter also reviews what is known about the bacterial disulfide oxidative pathway, including a 
comparison of the DsbA-DsbB redox pair across different bacteria. In the final section, I review the 
treatment options and treatment failures of C. trachomatis infections, outline the unusual biphasic, 
disulfide dependent, developmental cycle of C. trachomatis, and summarise the aims and structure 
of the thesis.  
1.1 The rise and fall of the golden age of antibiotics 
In 1929 Sir Alexander Fleming discovered that the fungus Penicillium notatum inhibits the growth 
of the Gram-positive bacterium Staphylococcus aureus [1]. More than a decade later, the antibiotic 
penicillin was first prescribed to treat serious infections. Between 1935 and 1970, several classes of 
antibiotic drugs were marketed, including sulfonamides, β-lactams, tetracyclines, rifamycins and 
quinolones (Figure 1.1). The discovery of antibiotics is one of the greatest discoveries in modern 
medicine and has resulted in successful treatment of many diseases that were once lethal. One 
example is subcutaneous sulphanilamide, which decreased the mortality rate of meningococcal 
meningitis from 70-90 % to approximately 10 % [2]. However, even in the 1940s, less than a decade 
after introduction of the first sulfonamides, clinical resistance was observed (Figure 1.1). In fact, 
bacteria have developed resistance to all classes of clinical antibiotics, and infections by resistant 
bacteria were responsible for an estimated 8.6 million deaths globally in 2015 [3]. 
 
The classic antibiotics target a limited range of vital bacterial processes and pathways to kill or 
severely inhibit bacterial growth. Processes targeted by antibiotics include cell wall synthesis, protein 
synthesis, DNA synthesis, RNA synthesis and metabolism (Figure 1.2) (reviewed in [4]).  
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Figure 1.1 Timeline of antibiotic discovery and emergence of resistance. 
 For each class of antibiotic, clinical resistance (lower timeline) has been observed within 10 years 
of introduction of clinical use (upper timeline). Year of discovery is stated next to antibiotic class. 
Modified from [5]. 
The β-lactams are an example of a class of antibiotics targeting the cell membrane. The β-lactams 
target enzymes involved in synthesis of the bacterial cell wall thereby inhibiting growth [6].  
 
Daptomycin is a cyclic lipoprotein targeting the cell membrane in most Gram-positive bacteria. 
Insertion of daptomycin into the bacterial cell membrane causes rapid membrane depolarisation and 
consequent efflux of potassium [7].  
 
Several antibiotics, including rifampicin, inhibit RNA synthesis. Rifampicin binds at the β-subunit of 
the bacterial RNA polymerase thereby blocking the path of the elongating RNA when the transcript 
becomes two to three nucleotides long [8]. para-aminobenzoic acid (PABA) is required for formation 
of dihydrofolic acid (DHFA) production in bacteria; DHFA is a precursor of folic acid. Sulfonamides 
are structural analogues of PABA and consequently act as competitive antagonists of PABA thereby 
blocking synthesis of folic acid [9].  
 
Tetracyclines inhibit protein synthesis by binding to the 30S ribosomal subunit in the mRNA 
translation complex thereby inhibiting the binding of aminoacyl-tRNA to the mRNA-ribosome 
complex [10, 11]. 
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Figure 1.2 Bacterial targets for antibiotics and mechanism of resistance.  
Traditional antibiotics target the cell wall and cell membrane, protein synthesis, metabolism (e.g. 
folate synthesis) and DNA and RNA synthesis (left). Bacteria utilise a range of mechanisms (right) to 
respond to antibiotics (green). This includes altering the antibiotic target (dark blue), efflux pumps 
(pink), antibiotic-altering enzymes (light blue) and antibiotic degrading enzymes (orange). 
Targeting bacterial growth and viability induces a high degree of selective pressure for the 
development of antibiotic resistance. Consequently, bacteria have developed different mechanisms 
to deal with the threat of the antibiotics e.g. by pumping the antibiotic out of the cell or degrading the 
antibiotic (Figure 1.2). Other strategies involve altering the antibiotic target or enzymatic alteration 
of the antibiotic itself such that it is no longer effective (reviewed in [12]).  
 
The bacterium Klebsiella pneumoniae has developed resistance to β-lactams by several mechanisms 
including production of β-lactamase that degrades β-lactams, altering the entry channel porins and 
increased expression of an efflux pump [13].  
 
In addition to resistance to tetracyclines acquired by expression of efflux pumps, bacteria have also 
developed mechanisms to alter these antibiotics; acetylation of tetracyclines leads to inactivation of 
the antibiotic and is an example of antibiotic alteration [14, 15].  
 
A major mechanism for resistance development to rifampicin is through mutations in the β-subunit 
of the bacterial RNA polymerase to prevent binding of the drug [16-18].  
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1.1.1 New strategies for developing antimicrobial drugs 
Much effort has been directed towards identification of new classes of antibiotics as well as 
development of analogues of existing antibiotics. However, only six new classes of antibiotics have 
been marketed since the 1960s [19] (Figure 1.1). According to the Pew Trust [20] 39 antibiotics are 
in Phase I–III clinical trials as of March 2017, but the antibiotic pipeline is currently not efficient in 
getting new antibiotic drugs to the market. Historically only 33 % of antibiotics that reach clinical 
trials are marketed [21]. Further, most of the new antibiotics are not novel with respect to target or 
mechanism of action. Consequently, discovery of new antibiotics, especially antibiotics or 
antibacterials with novel mechanisms of action, are urgently needed. Several strategies are being 
taken including antimicrobial peptides, bacteriophages, therapeutic antibodies, potentiators of 
existing antibiotics and anti-virulence agents. These are discussed in turn below. 
 
Antimicrobial peptides (AMPs) are oligopeptides consisting of five to more than a hundred amino 
acids, and are a part of the innate immune system of all classes of life. AMPs are inserted into the 
bacterial membrane causing displacement of lipids and alteration of membrane structure [22]. Due to 
their targeting of the bacterial membrane, AMPs are potentially active against a broad range of 
bacteria. In fact, they have been demonstrated to kill Gram-negative and Gram-positive bacteria as 
well as viruses and fungi [23]. Resistance to AMPs has developed through alteration of bacterial 
membrane composition, or lipid organisation, or destruction of the AMPs [24]. However, most AMPs 
lack recognition sites for proteases and membrane reorganisation is an energetically expensive 
solution for the bacteria [25]. Accordingly, AMPs are predicted to have a low risk of resistance 
development [25]. However, they can be toxic to eukaryotic cells [25, 26].  
 
Bacteriophages are viruses with antibiotic activity due to their ability to lyse and kill bacteria [27]. 
Bacteriophages are highly host-specific and treatment with bacteriophages consequently decreases 
the risk of destroying commensal microbiota. However, bacteria can develop resistance against 
bacteriophages by digestion of the phage DNA, or by arresting bacteriophage infection by abortive 
infection, which promotes cell death and thus limits phage replication within the bacterial population 
before it produces virions [28]. 
 
Two types of therapeutic antibodies have activity against bacteria; one type binds the pathogen 
directly thereby making it susceptible to phagocytosis [29]. The other type neutralises toxins or other 
virulence factors produced by the bacteria [30]. As some therapeutic antibodies are already approved 
for clinical use in cancer treatment, many safety and pharmacokinetic concerns have already been 
addressed, which make them interesting for antibiotic development purposes. However, they are not 
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very cost-effective, and efficient diagnostic tools are yet to be developed to make the use of 
therapeutic antibodies feasible [26].  
 
Potentiators of existing antibiotics reverse the resistance mechanism of the bacteria, or sensitise 
naturally resistant strains, allowing the antibiotic to work. A successful example is β-lactamase 
inhibitors that block the ability of bacterial enzymes to degrade β-lactam antibiotics [31]. 
Unfortunately resistance to these potentiators has also been reported [32]. 
1.1.2 Targeting virulence rather than viability as a strategy for drug 
development  
Targeting virulence rather than bacterial growth or viability is a promising strategy for the 
development of new antimicrobial drugs with novel mechanisms of action [33-36]. Since the effect 
on viability of the pathogen may be minimised, anti-virulent antimicrobial drugs are hypothesised to 
limit resistance selection compared with traditional antibiotics, though this is yet to be confirmed 
[34]. High specificity for particular species potentially delays the occurrence of resistance in bacteria 
that are not dependent on the specific virulence factor targeted [34]. Further, high host-specificity 
limits the effect on the commensal microbiota, decreasing the risk of secondary infections and 
colonisation by drug-resistant bacteria [37]. Toxins [38], quorum sensing [37], biofilm production, 
secretion systems [39] and host cell adhesion [40] have all been explored as targets for anti-virulence 
drugs.  
 
Another molecular target for anti-virulence therapy is oxidative protein folding. This step in protein 
folding is crucial for the assembly of a diverse range of bacterial virulence factors [41]. Consequently, 
targeting the disulfide bond machinery is a promising strategy for the development of an anti-
virulence antimicrobial drug. Many virulence factors, including constituents of the type III and type 
IV secretion systems [42-47], flagella assembly [48] and several toxins [49-52], are dependent on the 
formation of disulfide bonds. Thus, inhibiting bacterial disulfide bond formation disrupts a broad 
range of virulence pathways, and leads to reduction or attenuation of virulence in many pathogens, 
including Escherichia coli [48], Salmonella enterica Typhimurium [46, 53], Campylobacter jejuni 
[54], Yersinia pestis [47], Pseudomonas aeruginosa [55, 56], Vibrio cholerae [50] and Burkholderia 
pseudomallei [57]. Due to the severe effect on virulence upon disruption of disulfide bond formation 
in many bacteria, the proteins involved in the oxidative pathway are of interest as targets for 
development of anti-virulent anti-microbial agents.  
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1.2 The disulfide oxidative pathway in bacteria 
E. coli DsbA (EcDsbA) is the primary oxidase in the disulfide oxidative pathway of E. coli [58] and 
catalyses the introduction of disulfide bonds into folding proteins (Figure 1.3). By accepting electrons 
from the substrate protein, the active site cysteines of DsbA become reduced. In order to return to the 
active, oxidised state, DsbA is reoxidised in a reaction catalysed by the membrane protein partner 
DsbB - using quinones as electron acceptors - and ultimately delivering electrons to molecular oxygen 
via the respiratory pathway [59]. 
 
 
Figure 1.3 Introduction of disulfide bonds in E. coli.  
DsbA (pink) is a periplasmic protein that introduces disulfide bonds (S-S) into folding proteins 
(green) that have more than one cysteine. In turn, the active site disulfide bond of DsbA is reduced 
(SH). DsbA is regenerated to its active oxidised state by the membrane protein DsbB (blue) that 
donates electrons to quinone (Q) and ultimately to the electron transport chain [60]. 
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1.2.1 Structure and function of the primary oxidase DsbA in E. coli 
EcDsbA was the first DsbA enzyme to be structurally and functionally characterised and serves as 
the canonical model for DsbA enzymes [58, 61, 62]. The structure of EcDsbA consists of a 
thioredoxin domain (a five stranded β-sheet (B1-5) sandwiched between three α-helices (H1, H6 and 
H7)) and an inserted α-helical bundle domain (H2 to H5 and the N-terminal end of helix H6) [62, 63] 
(Figure 1.4A). The thioredoxin domain contains the active site with a Cys-Pro-His-Cys (CPHC) motif 
located at the N-terminal region of helix H1. A short sequence of three residues (Glu38-Val39-Leu40) 
is responsible for a kink in helix H1. Loop L1 links helix H1 and β-strand B3. Loop 2 links helix H6 
and β-strand B4 and contains a cisPro residue highly conserved in the thioredoxin fold [52]. The 
residue preceding the cisPro residue in EcDsbA is a valine. A long loop (L3) connects helix H7 and 
B5. Hydrophobic residues from loop L3 and strand B1 form the base of a large hydrophobic groove 
on the catalytic surface of EcDsbA, and hydrophobic residues from loop L2 and helix H1 contribute 
to the roof of this groove. The hydrophobic groove and a hydrophobic patch on the catalytic surface 
of EcDsbA create a hydrophobic environment surrounding the surface exposed cysteine (Cys30) and 
allows for binding of unfolded protein substrates and the redox partner DsbB (Figure 1.4B) [47, 48, 
62, 64-67].  
 
The surface exposed Cys30 at the active site of EcDsbA has an unusually low pKa value of 4.5 and 
is consequently present as a thiolate anion at physiological pH [68]. Several factors contribute to 
stabilising the thiolate anion including electrostatic stabilisation by His31 of the catalytic motif and 
the cisPro in loop L2 that is in close proximity to the catalytic motif [68]. A major factor contributing 
to stabilisation of the thiolate anion in dithiol oxidoreductases is the helix dipole of helix H1 [69]. 
Due to stabilisation of the thiolate anion the reduced state is more stable than the oxidised state of the 
enzyme, evidenced by a melting temperature (Tm) of 350 K for the reduced state compared to 342 K 
for the oxidised state [70]. This destabilisation of the oxidised state provides a driving force for the 
highly oxidising redox potential of EcDsbA (-122 mV) [71]. 
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Figure 1.4 The structure of E. coli DsbA.  
A) EcDsbA (PDB code 1FVK) contains a thioredoxin domain (green) with a five stranded β-sheet 
(B1-5) sandwiched between three α-helices (H1, H6 and H7). The catalytic CPHC motif (cysteine 
sulfurs shown as yellow spheres) is located at the N-terminal region of the H1 helix. Helices H2 to 
H5 and the N-terminus of helix H6 make up the inserted helical domain (orange). B) Surface 
representation of EcDsbA (PDB code 1FVK) shows a large hydrophobic groove (red) close to the 
active site cysteines (yellow). Surface groove was identified by CastP [72] and images were 
generated in pymol [73]. 
1.2.2 DsbA enzymes from different organisms have a broad spectrum of redox 
properties and surface features 
Despite low sequence identity (generally 15 %-40 %) all DsbA orthologs that have been structurally 
characterised adopt a fold containing similar structural features to that of EcDsbA: a thioredoxin 
domain, a catalytic disulfide and an inserted helical domain [41, 57, 65, 74-81]. Structural variations 
to this core fold are responsible for differences in redox properties among the DsbA enzymes. 
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1.2.2.1  DsbA enzymes in Gram-negative bacteria 
S. enterica Typhimurium DsbA (SeDsbA) [81], K. pneumoniae DsbA (KpDsbA) [74] and Proteus 
mirabilis DsbA (PmDsbA) [82], share 86 %, 81 % and 59 %, sequence identity with EcDsbA, 
respectively (Table 1.1). Both the catalytic CPHC motif and the Val-cisPro (VP) motif are conserved 
in all three enzymes, and their structures and functional properties resemble closely those of EcDsbA. 
The pKa value of the surface exposed cysteine is 4.2, 4.4 and 4.0 for SeDsbA, KpDsbA and PmDsbA, 
respectively. Also, the oxidising power is equivalent to EcDsbA with redox potentials between -129 
mV and -116 mV. Like EcDsbA, the reduced state of each enzyme is more stable than the oxidised 
state: the difference in melting temperature is 9K, 12K and 10K for SeDsbA, KpDsbA and PmDsbA, 
respectively and is thereby in the same range as the 8 K difference in melting temperature seen in 
EcDsbA (Table 1.1). 
Table 1.1 Comparison of structural and functional properties of DsbA orthologs 
 Identity  CXXC Cis- 
Pro 
Second 
disulfide 
Tm(K)  ΔTm pKa E° 
(mv) 
Ref 
Red Ox   
EcDsbA 100  % CPHC VP  350  342  8 4.5 -122 [70]  
[72-73] 
SeDsbA 86 % CPHC VP  351  342  9 4.2 -126 [81] 
KpDsbA 81 % CPHC VP  347 335 12 4.0 -116 [74] 
PmDsbA 59 % CPHC VP  348 338 10 4.0 -129 [82] 
VcDsbA 40 % CPHC VP  357 346 11 5.1 -116 [76] 
AbDsbA 32 % CPHC VP  - - - - -101 [83] 
PaDsbA1 31 % CPHC VP  356 346 10 - -94 [41] 
BpsDsbA 26 % CPHC VP  - - - 2.8 -94 [57] 
XfDsbA2 25 % CPAC TP  - - - - -100 [65] 
NmDsbA2 25 % CPHC TP  343 326 17 3.3 -79 [77] 
NmDsbA1 21 % CPHC TP  348 333 15 3.0 -79 [77] 
NmDsbA3 21% CVHC TP  335 320 15 3.0 -81 [77] 
PaDsbA2 21 % CPFC TP X - - - - -68 [75] 
XfDsbA 19 % CPHC TP  - - - - -94 [65] 
BsDsbA 18 % CPSC TP  - - - - -80 [79] 
MtbDsbA 17 % CPAC TP X 352 339 13 4.2 -99 [78] 
SaDsbA 14 % CPYC TP  345 346 1 3.4 -131 [84] 
WpDsbA1 10 % CYHC TP X 337 331 6 4.7 -163 [80] 
FtDsbA A 10 % CMYC TP  - - - - -132 [29] 
FtDsbA B 10 % CMYC AP  - - - - -159 [29] 
Properties are listed for DsbA from E. coli (EcDsbA, PDB code 1FVK), S. enterica Typhimurium 
(SeDsbA, PDB code 3L9S), K. pneumoniae (KpDsbA, PDB code 4MCU), P. mirabilis (PmDsbA PDB 
code 4OCE), V. cholerae (VcDsbA, PDB code 4DVC), A. baumannii (AbDsbA, PDB code 4P3Y), B. 
pseudomallei (BpsDsbA, PDB code 4K2D), P. aeruginosa (PaDsbA1, PDB code 3H93 and PaDsbA2, 
PDB code 4N30), X. fastidiosa (XfDsbA, PDB code 2REM and XfDSbA2), N. meningitidis 
(NmDsbA1, PDB code 3DVW, NmDsbA2 and NmDsbA3, PDB code 3DVX), M. tuberculosis 
(MtbDsbA, PDB code 4K6X), S. aureus (SaDsbA, PDB code 3BCI), B. subtilis (BsDsbA, PDB code 
3EU3), W. pipientis (WpDsbA1, PDB code 3F4R) and Francisella tularensis (FtDsbA A and FtDsbA 
B). Sequence identity to EcDsbA is calculated based on mature processed proteins. “-“ not measured.  
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V. cholerae DsbA (VcDsbA, also known as TcpG) shares 40 % sequence identity with EcDsbA, and 
also conserves the same catalytic motif (CPHC) and VP cisPro motif [76]. However, the structure 
varies slightly from that of EcDsbA, SeDsbA, PmDsbA and KpDsbA. Specifically, the three-residue 
sequence in H1 is replaced by a proline residue, which results in helix H1 being less bent than in 
EcDsbA. Helix H7, which forms part of the hydrophobic groove in EcDsbA, is six residues shorter 
in VcDsbA than in EcDsbA resulting in a truncation of the hydrophobic groove [76] (Figure 1.5). 
Despite a higher pKa of the solvent exposed cysteine (5.1), the difference in melting temperature (11 
K) and the redox potential (-116 mV) are similar to those reported for EcDsbA (Table 1.1). 
 
One of two DsbAs encoded in P. aeruginosa (PaDsbA1 (31 % sequence identity to EcDsbA)), as 
well as B. pseudomallei DsbA (BpsDsbA (26 % sequence identity to EcDsbA)) and Xylella fastidiosa 
DsbA (XfDsbA (19 % sequence identity with EcDsbA)) are less closely related to EcDsbA. The 
catalytic CPHC motif is conserved in all three of these DsbAs and the VP cisPro motif is conserved 
in PaDsbA1 and BpsDsbA (Table 1.1). However, the residue preceding the cisPro in XfDsbA is 
threonine rather than valine (TP motif) (Table 1.1). Like VcDsbA, PaDsbA1 [41], BpsDsbA [57] and 
XfDsbA [65] have a less pronounced bend in helix H1 than EcDsbA. Helix H7 is four residues longer 
in XfDsbA than in EcDsbA but the loop connecting strand B5 and helix H7 are six residues shorter 
resulting in a truncated hydrophobic groove. A similar pocket is seen in BpsDsbA and XfDsbA 
(Figure 1.5). Despite the structural similarities with VcDsbA, PaDsbA1, BpsDsbA and XfDsbA all 
have redox potentials of -94 mV and are therefore more oxidising than both EcDsbA and VcDsbA 
(Table 1.1). The pKa of the solvent exposed cysteine has not been determined for PaDsbA1 or 
XfDsbA, but for BpsDsbA the thiolate anion is highly acidic with a pKa of 2.8 [57]. The thermal 
stability of the different redox forms has not been determined for BpsDsbA and XfDsbA, but for 
PaDsbA1 the melting temperature of the reduced state is 10 K higher than for the oxidised state. X. 
fastidiosa encodes a second DsbA, XfDsbA2, with 41 % sequence identity to XfDsbA and 25 % 
sequence identity to EcDsbA. XfDsbA2 has not been structurally characterised, but its redox potential 
has been determined to -100 mV [65]. 
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Figure 1.5 DsbA Surface properties.  
Surface view of EcDsbA (PDB code 1fvk), VcDsbA (PDB code 4DVC), BpsDsbA (PDB code 4K2D), 
WpDsbA1 (PDB code 3F4R), BsDsbA (PDB code 3EU3) and MtbDsbA (PDB code 4K6X) showing 
the electrostatic surface potential and groove or pocket (black ring) close to the active site disulfide 
(yellow S). Electrostatic surface potential is plotted between -7.5 (red) and +7.5 (blue) and was 
calculated in ABPS [85] using the PARSE force field. Calculations are based on an ionic strength of 
150 mM, with protein and solvent dielectric constants of 2 and 78, respectively. Pockets were 
identified by CastP [72] and images were generated in pymol [73]. 
The second DsbA encoded in the P. aeruginosa genome (PaDsbA2) shares 21 % sequence identity 
with EcDsbA and has a less bent helix H1 [75]. PaDsbA2 diverges from the previously described 
DsbAs by having an altered topology of the central β-sheet. Specifically, the B1 strand in PaDsbA2 
is hydrogen bonded to the opposite end of the central β-sheet compared with EcDsbA. This β-sheet 
arrangement was first described for Wolbachia pipientis DsbA1 (WpDsbA1) [80] (Figure 1.6). 
Further, PaDsbA2 does not have a groove on the catalytic surface and the residues contributing to the 
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hydrophobic groove in EcDsbA are replaced with polar and charged residues in PaDsbA2. PaDsbA2 
is the most oxidising of all the DsbA enzymes characterised to date with a redox potential of -68 mV 
and it contains an additional disulfide bond linking helix H2 and helix H5 [75].  
 
 
Figure 1.6 β-sheet topology of EcDsbA and WpDsbA1. 
 In EcDsbA (left) strand B1 (red) is hydrogen-bonded to strand B5 in the central β-sheet (grey) 
whereas strand B1 (red) is hydrogen-bonded to strand B3 in WpDsbA1 (right) resulting in different 
β-sheet topology in the two DsbA enzymes. 
Acinetobacter baumannii (AbDsbA) shares 32 % sequence identity with EcDsbA, and 44 % sequence 
identity with PaDsbA1. Accordingly, AbDsbA is more closely related to PaDsbA1, BpsDsbA and 
XfDsbA. Like XfDsbA, AbDsbA has a conserved CPHC motif and a TP motif though with a slightly 
less oxidising redox potential (-101 mV) (Table 1.1). Interestingly, AbDsbA binds elongation factor 
thermo unstable (EFTu) non-covalently at a binding site different to the binding site for DsbB [83]. 
An avirulent strain of A. baumannii encodes a DsbA with a point mutation in the catalytic motif 
(H36L); this mutation results in a significant decrease in redox potential of the enzyme from -101 
mV (wild-type) to -134 mV (mutant) [83]. 
 
The Neisseria meningitidis genome encodes three DsbA homologs; NmDsbA1, NmDsbA2 and 
NmDsbA3 that all share between 20 % and 25 % sequence identity with EcDsbA (Table 1.1). 
NmDsbA1 and NmDsbA2 are lipid-anchored to the inner membrane whereas NmDsbA3 is predicted 
to be soluble and localised to the periplasm [77]. All three N. meningitidis DsbAs have a TP motif, 
but the CPHC motif is conserved only in NmDsbA1 and NmDsbA2; NmDsbA3 has a Cys-Val-His-
Cys (CVHC) catalytic motif. The structures of NmDsbA1 and NmDsbA3 have been reported and are 
similar to PaDsbA1 (RMSD 2.2 and 2.3 Å, respectively), though with differing surface properties 
[77]. Whereas the surface groove of NmDsbA3 is hydrophobic – similar to EcDsbA - the groove in 
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NmDsbA1 is more acidic [77]. The redox potentials of the three N. meningitidis DsbAs are -79 mV, 
-79 mV and -81 mV, respectively, all more oxidising than EcDsbA. This is also reflected in the more 
acidic surface exposed cysteines (pKa = 3.0, 3.3 and 3.0) compared with EcDsbA, and a larger 
difference in melting temperature between the reduced and oxidised states of the enzymes (15K–17K 
compared to 8 K in EcDsbA) (Table 1.1). 
 
WpDsbA1 shares just 10 % sequence identity with EcDsbA and is, except for NmDsbA3, the only 
structurally characterised DsbA that doesn’t have a proline in the catalytic motif. In WpDsbA1 the 
proline in the catalytic motif is replaced with a tyrosine residue (CYHC). The cisPro motif in 
WpDsbA1 is TP. WpDsbA1 has the alternate β-sheet topology also found in PaDsbA2, (Figure 1.6) 
[80] and also contains an additional disulfide that links helices H2 and H5. In addition, due to 
deletions in the sub-domain made up of strand B4 and B5 as well as helix H7, WpDsbA1, like 
PaDsbA2, does not have a catalytic surface groove. Additionally, the catalytic surface of WpDsbA1 
is relatively basic (Figure 1.5). Further, the melting temperature of reduced WpDsbA1 is just 6 K 
higher than that of oxidised WpDsbA1, and the pKa of the surface exposed cysteine (4.7) is less acidic 
than most other characterised DsbAs (except VcDsbA). Accordingly, the redox potential of 
WpDsbA1 (-163 mV) is significantly lower than that of EcDsbA (Table 1.1). 
 
Francisella tularensis DsbA (FtDsbA) shares 10 % sequence identity with EcDsbA and is 
distinguished from other DsbA enzymes by being dimeric and harbouring both oxidase and isomerase 
activity [29]. Moreover, FtDsbA is anchored to the outer membrane [86]. FtDsbA has a Cys-Met-
Tyr-Cys (CMYC) catalytic motif where neither the proline nor a histidine from EcDsbA is conserved. 
The cisPro motif encodes a single polymorphism between type A and type B F. tularensis. Type A 
FtDsbA has a Thr-cisPro motif and a redox potential of -159 mV, whereas type B FtDsbA has an 
Ala-cisPro (AP) motif and a more oxidising redox potential of -131 mV (Table 1.1) [29]. 
1.2.2.2  DsbA enzymes in non-Gram-negative bacteria 
Three DsbAs from non-Gram-negative bacteria have been characterised to date. These are the acid-
fast bacteria Mycobacterium tuberculosis DsbA (MtbDsbA) and the two Gram-positive bacteria S. 
aureus DsbA (SaDsbA) and Bacillus subtilis DsbA (BsDsbA). Common to these three DsbAs is a TP 
cisPro motif and a catalytic motif with only the proline conserved in the dipeptide separating the two 
cysteines (Table 1.1). Accordingly, the catalytic motif is CPSC, CPAC and CPYC in BsDsbA, 
MtbDsbA and SaDsbA, respectively. Additionally these DsbA enzymes share the β-sheet topology 
of WpDsbA1 and PaDsbA2 [78-79, 84]. 
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BsDsbA has a redox potential of -80 mV and is therefore one of the strongest oxidases yet 
characterised. By contrast, SaDsbA with a redox potential of -131 mV is among the weakest DsbA 
oxidases. Interestingly, the reduced and oxidised states of SaDsbA are almost equally stable with the 
melting temperature of the reduced state just 1 K higher than that of the oxidised state (Table 1.1). 
With a redox potential of -99 mV the oxidase power of MtbDsbA lies between that of BsDsbA and 
SaDsbA.  In contrast to SaDsbA the difference in melting temperature between reduced and oxidised 
MtbDsbA is 13 K (Table 1.1).  
 
MtbDsbA is distinguished from other DsbA enzymes by having an additional eighth helix, H8, 
packing against helices H1 and H7, as well as a second disulfide like that of PaDsbA2 and WpDsbA1 
[78]. Loop L3 is shorter in MtbDsbA than in EcDsbA and consequently doesn’t have the distinct 
groove of the EcDsbA catalytic surface, but the hydrophobic nature is partly preserved in MtbDsbA 
(Figure 1.5) [78]. In contrast, the catalytic surface is primarily acidic in BsDsbA and SaDsbA 
(illustrated by BsDsbA in Figure 1.5). BsDsbA is the only of the characterised DsbA enzymes from 
Gram-positive bacteria that has a pocket at the surface close to the active site (Figure 1.5). 
1.2.2.3  A second non-catalytic disulfide is present in some DsbAs 
A disulfide bond that links helices H2 and H5 is present in three structurally characterised DsbAs: 
MtbDsbA, PaDsbA2 and WpDsbA1. Further the cysteines forming this disulfide are conserved across 
α-Proteobacteria [80]. In WpDsbA1 the disulfide is predicted to introduce local stress, which is 
associated with a functional rather than a structural role [87]. This is consistent with the observation 
that the presence of the second disulfide inhibits interaction with partner protein W. pipientis DsbB 
[80]. Disruption of this second disulfide has limited effect on the enzymatic properties, changing the 
redox potential minimally from -163 mV to -161 mV. In contrast, disruption of the second disulfide 
in PaDsbA2 leads to a significant change by decreasing the redox potential from -68 mV to -118 mV 
[75]. The role of the second disulfide in MtbDsbA has not been determined but has been suggested 
to play a structural role [78, 88]. 
1.2.2.4  Correlation of structure and function in DsbA enzymes 
There is a general trend that DsbAs with a more acidic surface exposed cysteine (defined by pKa), 
have a greater melting temperature difference between their reduced and oxidised states, and are more 
oxidising (defined by redox potential) (Table 1.1). Further, as a general rule, those DsbAs with a 
threonine rather than a valine in the cisPro motif have higher redox potential values. In some cases, 
this is due to additional stabilisation of the thiolate anion by the threonine side-chain [65, 66, 77]. 
The exception to this is SaDsbA and WpDsbA1, which despite the enhanced oxidising properties of 
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the threonine in the cisPro motif is amongst the least oxidising DsbAs characterised. However, the 
distance between threonine oxygen and cysteine sulfur in these two enzymes is 4.0-4.4 Å (compared 
with 3.0 to 3.5 Å for other DsbAs with a cisPro-Thr motif).  Consequently, the positioning of the 
threonine is critical to its ability to stabilise the thiolate anion and contribute to oxidising power. 
 
A bioinformatic study of prokaryotic genomes reveals that the dipeptide separating the two cysteines 
in the catalytic motif are highly conserved in DsbA enzymes [89]; in 78 % of DsbA proteins the first 
residue of the dipeptide is a proline and in 87 % the second residue is either aromatic, polar or charged. 
This is interesting, as the dipeptide separating the two cysteines in the catalytic motif has been shown 
to greatly influence the redox properties of dithiol oxidoreductases [71]. In the two characterised 
DsbAs where the proline is not conserved, NmDsbA3 and WpDsbA1, the redox potential is slightly 
higher or significantly lower than in EcDsbA, respectively. Moreover, the redox potential is slightly 
higher than EcDsbA in XfDsbA2 and MtbDsbA - the two characterised DsbAs that do not have a 
basic, aromatic or polar residue in the second position of the CXXC motif [65, 78]. Likewise, 
mutating the histidine in the catalytic motif of AbDsbA to the small uncharged residue Leucine 
increases the redox potential from -101 mV to -134 mV [83]. FtDsbA represents the first 
biochemically characterised DsbA where neither of the amino acids in the EcDsbA catalytic motif 
are conserved. The two FtDsbA variants have redox potentials of -159 mV and -131 mV and are 
thereby among the least oxidising DsbA enzymes characterised. 
 
Even though the difference in stability between reduced and oxidised EcDsbA contributes 
significantly to EcDsbA catalysis [71], SaDsbA has oxidising activity despite the active site disulfide 
not being destabilising. Curiously, the S. aureus genome does not encode a DsbB homolog suggesting 
that SaDsbA does not require a protein re-oxidation partner. The equivalent stabilities of the reduced 
and oxidised state of SaDsbA led Heras et al. to speculate that extracellular oxidants may be 
responsible for oxidation of SaDsbA to return it to the active state, although the mechanism for this 
remains unknown [84]. 
1.2.2.5  Substrate range of DsbA enzymes 
Most DsbA enzymes display broad substrate specificity. In fact, EcDsbA has been estimated to 
interact with up to several hundred different substrates [48, 90] and more than 50 substrates are 
identified for FtDsbA (type B) [29]. Curiously, the surface of the active, oxidised, form of EcDsbA 
is more flexible than the reduced form [91]. This might allow for adaption to different substrates. The 
disulfide bonds introduced by EcDsbA are primarily buried in the protein core of the substrate [92]. 
Consequently, introduction of disulfide bonds into the substrate protein must occur in its unfolded 
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state. As the hydrophobic core will be exposed in the unfolded protein this is consistent with binding 
to the large hydrophobic groove in EcDsbA. The diversity in length, depth and electrostatic potential 
of the groove at the catalytic surface suggests that different DsbAs might have different substrate 
specificity. 
 
Most DsbA proteins are soluble and localised to the periplasm; the exceptions are the two lipoproteins 
NmDsbA1 and NmDsbA2 as well as PaDsbA2 that has a predicted N-terminal transmembrane helix 
(predicted by TMHMM [93]). MtbDsbA has an N-terminal sequence that could be either a signal 
peptide or a transmembrane helix [78]. NmDsbA1 and NmDsbA2 have a different substrate range to 
that of the soluble periplasmic NmDsbA3. Specifically, NmDsbA1 and NmDsbA2, but not 
NmDsbA3, are required for correct folding of type IV pili and the protein PilQ that is required for 
DNA uptake [94]. PaDsbA2 cannot complement a PaDsbA1 mutant in vivo suggesting that the two 
DsbAs in P. aeruginosa also have different substrate specificities and thus different roles [75].  
 
Of the more than 50 substrates that have been identified for the outer membrane located FtDsbA (type 
B) several are outer membrane proteins and known virulence factors [29, 95]. The formation of the 
correct native disulfide bonds in the proteins of the F. tularensis envelope is maintained by the 
oxidase and isomerase activity of FtDsbA. This has been suggested to provide additional protection 
against phagosomal reactive oxygen species for this intracellular pathogen [29]. 
1.2.2.6  A classification system for DsbA enzymes 
A structural classification system for DsbA enzymes has been developed based on 13 DsbAs that 
have been extensively characterised structurally and functionally. On this basis, these 13 DsbAs were 
divided into two subclasses based on β-sheet topology [96]. DsbAs with the same β-sheet topology 
as EcDsbA are classified as DsbA-I and DsbAs with β-sheet topology resembling the topology in 
WpDsbA1 (Figure 1.6) are classified as DsbA-II (Table 1.2). DsbA-I enzymes are further divided 
into subclasses based on loop conformations. Specifically, the conformation of loop L2, which in 
DsbA-Ia enzymes faces the catalytic disulfide and points away from the catalytic disulfide in DsbA-
Ib enzymes and the length of loop L3. The surface of the DsbA-II enzymes is generally less 
hydrophobic than the DsbA-I enzymes, and differences in electrostatic surface potential divides the 
DsbA-II enzymes into two subclasses (Table 1.2). The surface of enzymes in the DsbA-IIa class is 
more negatively charged (BsDsbA and MtbDsbA in Figure 1.5) whereas the surface of WpDsbA1, 
the only member of the DsbA- IIb class, is more positively charged (Figure 1.5). 
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Table 1.2 DsbA enzymes are divided into four subclasses 
Class DsbA Seq. Identity to 
reference DsbA 
RMSD to reference 
DsbA (Å) 
DsbA – Ia  EcDsbA 100 % 0.9 
SeDsbA 86 % 1.0 
KpDsbA 81 % 1.2 
VcDsbA 40 % 0.9 
DsbA – Ib  BpsDsbA 100 % - 
PaDsbA1 44 % 1.8 
XfDsbA 30 % 1.9 
NmDsbA1 29 % 2.4 
NmDsbA3 27 % 2.6 
DsbA – IIa  MtbDsbA 100 % 0.3 
SaDsbA 21 % 2.4 
BsDsbA 20 % 2.0 
DsbA – IIb  WpDsbA1 100 % - 
Sequence identity and RMSD of a structural alignment (TM-align [97]) are listed compared to the 
reference DsbA in each subclass (bold text) [57]. SeDsbA (PDB code 3L9S), KpDsbA (PDB code 
4MCU) and VcDsbA (PDB code 4DVC) were aligned with EcDsbA (PDB code 1FVK). PaDsbA1 
(PDB code 3H93), XfDsbA (PDB code 2REM), NmDsbA1 (PDB code 3DVW) and NmDsbA3 (PDB 
code 3DVX) were aligned with BpsDsbA (PDB code 4K2D). SaDsbA (PDB code 3BCI) and BsDsbA 
(PDB code 3EU3) were aligned with MtbDsbA (PDB code 4K6X). WpDsbA1 (PDB code 3F4R) is 
the only DsbA classified as DsbA-IIb. RMSD for the two reference proteins EcDsbA and MtbDsbA is 
based on structural alignment of individual protomers A and B. 
The enzymes within the DsbA-Ia class, and to a lesser extent the DsbA-Ib class, are more closely 
related to each other in sequence and structure than the DsbA-II enzymes (Table 1.2). This is also 
reflected in the redox properties for each class. The DsbA-Ia enzymes have redox potentials varying 
from -122 mV to -116 mV. The redox potential of the DsbA-Ib enzymes are all larger than this – 
varying from -94 mV to -79 mV. The DsbA-IIa class, however, includes one of the most oxidising 
DsbAs (BsDsbA with a redox potential of -80 mV) and one of the least oxidising DsbAs (SaDsbA 
with a redox potential of -131 mV) (Table 1.1). Identification of subclasses of DsbA enzymes with 
distinct structural and functional characteristic opens the possibility of developing drugs that target a 
specific subclass of DsbA. 
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1.2.3 EcDsbB oxidises EcDsbA via a quinone-dependent mechanism 
The redox partner for DsbA in E. coli is the membrane protein DsbB (EcDsbB) [98]. EcDsbB has 
four transmembrane helices (TM1-4) arranged in a four-helix bundle and two periplasmic segments 
(P1 and P2) each containing two cysteine residues capable of forming disulfide bonds. Both disulfide 
bonds are required for EcDsbB catalysis [99].  The redox potentials for the two redox pairs 
Cys41/Cys44 and Cys104/Cys130 are -210 mV and -250 mV, respectively [100]. This is curious, as 
they are less oxidising than the substrate they oxidise, EcDsbA that has a redox potential of -122 mV. 
The EcDsbB-mediated oxidation of EcDsbA is thought to be driven by electron flow to the very much 
more oxidising ubiquinone (UQ) (+110 mV) under aerobic conditions, or menaquinone (MK) (-74 
mV) under anaerobic conditions [60].  
 
Two different mechanisms of EcDsbB mediated oxidation of EcDsbA have been proposed [101]; the 
slow and the rapid pathway (Figure 1.7). Both pathways are initiated by nucleophilic attack on the 
EcDsbB Cys104-Cys130 disulfide by EcDsbA Cys30 thiolate resulting in an intermolecular disulfide 
between Cys104 of EcDsbB and Cys30 of EcDsbA (Figure 1.7). In the slow pathway, an interloop 
disulfide is formed between Cys41 and Cys130 of EcDsbB prior to release of EcDsbA. In the rapid 
pathway, formation of the interloop Cys41-Cys130 disulfide bond in EcDsbB follows release of 
EcDsbA. In both pathways, the native Cys41-Cys44 and Cys104-Cys130 disulfide bonds of EcDsbB 
are re-established in an UQ-dependent manner leaving UQ reduced. The majority of EcDsbA is 
oxidised via the rapid pathway [101]. 
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The structure of the membrane protein EcDsbB has been solved in three different 
conformations, capturing different steps of catalysis (Figure 1.8). The crystal structure 
of EcDsbB Cys41Ser is solved in complex with a monoclonal antibody Fab fragment 
(3.4 Å resolution) and represents the initial state of DsbB where a Cys104-Cys130 
disulfide is present and available for nucleophilic attack by Cys30 of EcDsbA [101] 
(Figure 1.8A). In the crystal structure of the EcDsbA-EcDsbB complex (3.7 Å 
resolution), EcDsbB is locked in an intermediate state containing an intermolecular 
Cys30-Cys104 disulfide (Figure 1.8B) [101]. In the NMR-structure of the EcDsbB 
[CSSC] construct both Cys44 and Cys104 are mutated to serines (Figure 1.8C). The 
construct mimics the reaction intermediate containing the interloop disulfide between 
Cys41 and Cys130 [102] (Figure 1.8C).  
 
Figure 1.8 Three EcDsbB structures represent different stages of EcDsbB catalysis.       
A) Side and top view of EcDsbB C41S (PDB code 2ZUQ) that was co-crystallised with 
a monoclonal Fab antibody fragment (not shown). Residues Arg109-Trp113 lack 
electron density and were not modelled. The four transmembrane helices (TM1-TM4) 
form a four-helix bundle with a periplasmic region between TM1 and TM2 (P1) and 
between TM3 and TM4 (P2). Periplasmic region P1 contains a Cys41Ser mutation 
(red) and Cys44 (yellow). Periplasmic region P2 contains Cys104 and Cys130 (yellow). 
EcDsbB C41S mimics the initial state of EcDsbB catalysis (box diagram). B) Side and 
top view of the complex between EcDsbB C130S – EcDsbA C33A (PDB code 2ZUP) 
(only residues Phe28 to Gln35 of EcDsbA are shown (grey)). The EcDsbB structure is 
overall similar to that shown in A, but residues 116 to 120 adopt a short membrane-
parallel helix separating periplasmic region P2 into two loops containing Cys104 and 
Cys130, respectively. Further, the distance between Cys104 (yellow) and Cys130Ser 
(red) is increased from 6.3Å in panel A to 8.9 Å in this structure. EcDsbB C130S – 
EcDsbA C33A represents the state of EcDsbB catalysis where EcDsbB is covalently 
bound through a disulfide bond between Cys104 in EcDsbB and Cys30 in EcDsbA (box 
diagram). C) In EcDsbB CSSC (PDB code 2K73) Cys44 and Cys104 are mutated to 
serines (red). The top and side views are generally similar to A and B. However, Cys130 
(yellow) is 3 Å apart from to Cys41 (yellow) compared to 10 Å and 8.2 Å in A and B, 
respectively consequently this represents the catalysis intermediate containing an 
interloop disulfide bond between Cys41 and Cys130 (box diagram)  
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In all three structures EcDsbB adopts a four helix-bundle conformation consisting of four 
transmembrane helices (TM1-4) with periplasmic regions between helix TM1 and TM2 (P1) and 
between helix TM3 and TM4 (P2). Residues 116 to 120 in periplasmic region P2 form a short 
membrane parallel helix [101]. The amphipathic nature of the helix and the neighbouring residues 
are responsible for peripherally tethering the helix to the membrane; the hydrophobic residues 
Leu114, Leu116, Val120, Val123 and Phe125 are oriented towards the membrane, whereas Asp117, 
Lys118 and Gln122 face the periplasmic space. The membrane-tethered helix separates P2 into two 
loops; one containing Cys104 and one containing Cys130 allowing the two loops to undergo 
independent conformational changes and allows for the two cysteines to move independently (Figure 
1.8B+C) [101].  
 
Upon EcDsbB interaction with EcDsbA, Pro100-Phe106 (in periplasmic region P2) of EcDsbB binds 
to the hydrophobic groove of EcDsbA (Figure 1.9). The binding to EcDsbA induces a significant 
conformational change in P2 of EcDsbB; the Pro100 to Cys104 region shifts outward towards the 
four-helix bundle leading to separation of Cys104 and Cys130. In the EcDsbB-EcDsbA complex the 
distance between Cys104 and Cys130 is 8.9 Å (Figure 1.8B) compared to 6.3 Å in EcDsbB C41S-
Fab (Figure 1.8A), that represents EcDsbB prior to interaction with EcDsbA. The physical separation 
of Cys104 and Cys130 hinders electron flow from EcDsbB to EcDsbA and is therefore essential for 
hindering reoxidation of the Cys104-Cys130 disulfide bond of EcDsbB, which is more energetically 
favoured than oxidation of the Cys30-Cys33 disulfide bond of EcDsbA [101].  
 
In the structure of EcDsbB C41S, residue Cys130 is in close proximity to Cys104 forming an 
interloop disulfide bond (Figure 1.8A). In the EcDsbB-EcDsbA complex, the Asp129-Cys130 region 
of EcDsbB is adjacent to highly conserved Phe63-Gly65 segment of loop L1 in EcDsbA and is 
separated from Cys104 (Figure 1.8B) [101]. In contrast, Cys130 in EcDsbB CSSC approaches Cys41 
in loop P1 to form an interloop disulfide bond (Figure 1.8C) [102]. The transient association of 
Cys130 of EcDsbB with loop L1 of EcDsbA separates Cys130 from Cys104 and Cys41, thereby 
allowing Cys33 of EcDsbA to attack the intermolecular disulfide, prior to the attack on Cys41 to 
Cys130. The resulting reduction of EcDsbA and subsequent release of EcDsbB is thought to increase 
flexibility in the Asp129-Cys130 region and allow Cys30 of EcDsbA to quickly approach the Cys41-
Cys44 disulfide in EcDsbB to form a transient disulfide with Cys41. This mechanism has been 
suggested to be responsible for the dominance of the rapid pathway [101]. A smaller proportion of 
the EcDsbB catalysis enters the slow pathway when the flexible nature of the region allows Cys130 
of EcDsbB to detach from loop L1 of EcDsbA and approach Cys41 of EcDsbB while EcDsbB is still 
attached to EcDsbA [101].  
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Figure 1.9 Pro100 to Phe106 of EcDsbB binds to the hydrophobic groove of EcDsbA. 
 A) EcDsbB (green) binds to the hydrophobic groove of EcDsbA (grey) in the EcDsbB C130S – 
EcDsbA C33A complex (PDB code 2ZUP). B) EcDsbA (grey) is turned 90° around the horizontal 
axis compared to A. Only residues 100-106 of EcDsbB are shown as spheres (green). The segment 
spanning from Pro100 to Phe106 binds to the hydrophobic groove of EcDsbA where Cys104 of 
EcDsbB (orange) forms a disulfide bond with Cys30 of EcDsbA. 
1.2.3.1 Ubiquinone forms a charge-transfer complex with Cys44 in EcDsbB 
UQ acts as an electron acceptor for EcDsbB and is required for the final steps in EcDsbB-mediated 
oxidation of EcDsbA (Figure 1.7). The UQ binding site is found at the periplasmic site of EcDsbB 
between TM1, TM2 and TM4 in the four-helix bundle with the isoprenoid tail running between TM1 
and TM4 (Figure 1.10) [102]. The binding site for the 1,4-benzoquinone head group of UQ consists 
of Gln33 in the C-terminal region of TM1, residues 29 to 48 in the N-terminal region of TM2 and 
residues in loop P1. Especially Arg48, Gln33 and Met142 at the N-terminal end of helix TM2 are 
expected to be involved in binding of UQ [101-103]. The S atom of Cys44 is 3.1 Å away from C1 of 
the quinone ring and a charge-transfer complex is formed between UQ and the thiolate anion of Cys44 
[104] (Figure 1.10). The guanidinium moiety of Arg48 is 3.0 Å away from the S atom of Cys44 
(Figure 1.10) potentially stabilising the charge-transfer complex by forming a hydrogen bond with 
the thiolate form of Cys44.  
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Figure 1.10 UQ forms a charge transfer complex with Cys44 of EcDsbB. 
 In the structure of EcDsbB C41S (PDB code 2ZUQ) UQ (pink) is bound at the N-terminal end of 
helix TM2 forming a charge-transfer complex with Cys44. The charge transfer complex is stabilised 
by the guanidinium moiety of Arg48. Gln33 and Met142 are also proposed to be involved in UQ 
binding 
1.2.3.2  The UQ binding site and an amphiphilic segment is conserved in DsbB orthologs 
With the exception of the DsbA-IIa enzymes from Gram-positive bacteria, all the organisms 
categorised with a DsbA belonging to the DsbA-I and DsbA-II subclasses encode at least one DsbB 
ortholog. P. aeruginosa encodes two DsbBs (PaDsbB1 and PaDsbB2) that both are capable of 
oxidising both PaDsbA1 and PaDsbA2 [75]. Sequence alignment of the DsbB orthologs reveals that 
they share the same overall topology with four membrane-spanning sections (TM1-4) and two 
periplasmic regions (P1 and P2) (Figure 1.11). The DsbBs that are predicted redox partners for the 
DsbAs in DsbA-I have identical membrane topology predictions. For other DsbBs, the membrane 
topology predictions (made using TMHMM [93]) are more diverse although the proteins are still 
predicted to have the same overall topology and periplasmic loops of generally similar length as 
EcDsbB. For example, in BpsDsbB, loop P1 is slightly longer than in EcDsbB whereas loop P2 is 
shorter. On the other hand, periplasmic loop P2 is eight and 11 residues longer in N. meningitidis 
DsbB (NmDsbB) and X. fastidiosa DsbB (XfDsbB), respectively. Considering the uncertainty of this 
topology prediction for helix termini, the findings on loop length should be taken with reservation. 
 
The location of the two cysteines in the periplasmic region P2 is conserved at the N-terminal end and 
C-terminal end of P2, respectively in the aligned DsbB enzymes. However, the second cysteine in 
the P2 loop of B. pseudomallei DsbB (BpsDsbB) is in the predicted TM4 helix. This could indicate 
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that the shorter P2 loop of BpsDsbB is an artefact of the topology prediction. Interestingly, the 
amphiphilic pattern of residues 114-125 in periplasmic region P2 is conserved in all aligned DsbB 
enzymes (Figure 1.11) suggesting that the membrane tethered-helix is conserved and important for 
catalysis.   
 
Arg48 – thought to be responsible for stabilising the charge-transfer complex between UQ and Cys44 
- is conserved in all DsbBs in the alignment, whereas Gln33 - also suggested to be involved in UQ 
binding - is conserved in eight out of ten DsbBs. In the other two, WpDsbB and PaDsbB2, this residue 
is replaced by glutamic acid. Met142 is conserved in six out of ten DsbBs. Leucine or isoleucine is 
found at this position in the remaining four DsbBs suggesting that a hydrophobic residue in this 
position is required for UQ binding. The DsbA binding region from Pro100-Phe106 is partly 
conserved in S. enterica Typhimurium DsbB (SeDsbB), K. pneumoniae DsbB (KpDsbB) and V. 
cholerae (VcDsbB). Pro100-Phe101 and Tyr103-Cys104-Asp105 are conserved in all three DsbBs. 
Residues 102 and 106 vary amongst the three DsbBs, but except for a glutamine in position 102 in 
KpDsbB the hydrophobic nature of the residues are conserved. The predicted DsbA binding segments 
are not conserved in the remaining DsbBs, though the segment is predominantly hydrophobic. The 
lower degree of conservation of the DsbA binding segment compared to the UQ binding site and 
amphiphilic pattern in P2 is likely to reflect differences in the DsbB binding site in the corresponding 
DsbA. 
 
The Gram-positive bacterium M. tuberculosis encodes no DsbB, but MtbDsbA is oxidised by the 
integral membrane protein vitamin K epoxide reductase (VKOR), proposed to be a functional 
homolog of DsbB. In contrast to DsbB enzymes, VKORs have five transmembrane helices. But 
equivalent to DsbB enzymes, VKORs have two periplasmic loops each containing two cysteines that 
are required for catalysis [81]. 
 
Figure 1.11 Sequence alignment of DsbB orthologs.  
Sequence alignment using Clustal Omega [105] with manual alignment of cysteine residues in loop 
P2 of DsbB orthologs from E. coli, S. enterica Typhimurium (SeDsbB), K. pneumoniae (KpDsbB), 
V. cholerae (VcDsbB), B. pseudomallei (BpsDsbB), N. meningitidis (NmDsbB), X. fastidiosa 
(XfDsbB), P. aeruginosa (PaDsbB1 and PaDsbB2) and W. pipientis (WpDsbB). Topology prediction 
in TMHMM [93] revealed that all orthologs have four transmembrane helices, TM1-4 (blue) and two 
periplasmic loops, P1 and P2 (green). Cysteines corresponding to the cysteines in the two periplasmic 
loops in EcDsbB are marked with a black box. Residues involved in UQ binding are marked with a 
pink box. The segment responsible for EcDsbA binding in EcDsbB as well as the segment forming 
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the membrane-parallel helix in loop P2 in EcDsbB are labelled. “*” indicates fully conserved 
residues. Conservation of residues with highly similar properties (above 0.5 in the Gonnet PAM 250 
matrix) are marked with “:”. Conservation of residues with weakly similar properties (below 0.5 in 
the Gonnet PAM 250 matrix) is marked with “.”. 
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1.2.4 The oxidative pathway in E. coli is not conserved in all bacteria 
Even though the oxidative pathway in E. coli, constituted by EcDsbA and EcDsbB, has served as the 
canonical model for oxidative folding in bacteria, the oxidative pathway is not conserved in all 
bacteria. Whereas most proteobacteria encode both DsbA and DsbB, many Gram-negative bacteria 
have an extended repertoire of Disulfide Bond (DSB) proteins. Additional to the DsbA-DsbB redox 
pair, the uropathogenic E. coli strain, CFT073, encodes another redox pair (DsbL and DsbI) 
responsible for the specific oxidative folding of aryl-sulphate sulphotransferase [106]. Another 
example is the periplasmic redox proteins DsbJ and DsbH [107] that are conserved in the Chlamydia 
phylum. 
 
 N. meningitidis, S. enterica Typhimurium, P. aeruginosa and W. pipientis all encode more than one 
DsbA. Indeed, a bioinformatics screen of DSB proteins revealed that out of 421 genomes, 51 had 
more than one DsbA-like protein encoded [89]. N. meningitidis and W. pipientis both encode a single 
DsbB homolog. WpDsbB only oxidises one of the W. pipientis DsbA orthologs, WpDsbA1 [108]. P. 
aeruginosa, on the other hand, encodes two DsbB homologs (PaDsbB1 and PaDsbB2) that are both 
capable of oxidising PaDsbA1 and PaDsbA2 [75]. 
 
In contrast, there were 156 bacterial genomes for which no DsbA was identified [89]. In particular, 
many Gram-positive bacteria have a limited suite of DSB proteins. For example S. aureus, B. subtilis 
and Listeria monocytogenes encode DsbA, but not DsbB [109]. Many bacteria that encode DsbA but 
lack DsbB, for example, M. tuberculosis and Streptomyces coelicolor, encode the DsbB analogue 
VKOR. Some bacteria, like Streptococcus pyogenes, encode neither DsbA nor DsbB and are 
proposed to utilise isopeptide bonds for stabilisation of secreted proteins rather than disulfide bonds 
[110]. 
1.2.5 Targeting the oxidative pathway as a strategy for development of anti-
virulence drugs 
Disruption of disulfide bond formation is a promising strategy for development of anti-virulence 
antimicrobials [33] and several components in the oxidative pathway have been targeted for 
inhibition. Many DsbA enzymes have a broad substrate range, and consequently, inhibiting DsbA 
oxidase activity will potentially disrupt a number of virulence pathways simultaneously.  
 
Previous, EcDsbA inhibitors have been developed using a Fragment-Based Drug Discovery 
approach. Screening of a library of more than 1000 fragments identified 37 hits, from five different 
chemical classes, that bound non-covalently to EcDsbA [111]. Structure guided development of 
 40 
analogues of one chemical class of these EcDsbA binding molecules resulted in two inhibitors with 
IC50 values of 185 ± 10 µM and 310 ± 16 µM, respectively. Treatment of E. coli K-12 cells with one 
compound led to reduced motility, with no effect on bacterial growth; a phenotype that is consistent 
with inhibition of EcDsbA. Inhibitors of EcDsbA have also been developed based on peptides 
mimicking the EcDsbB periplasmic loop segment that binds to EcDsbA [112]. This approach led to 
identification of a peptide that inhibits the activity of EcDsbA with an IC50 of 8.8 ± 1.1 µM. This 
peptide also binds to PmDsbA, an enzyme that is structurally closely related to EcDsbA [112], 
supporting the hypothesis that inhibitors can be developed to target DsbAs belonging to the same 
class of DsbA enzymes. 
 
EcDsbB has also been explored as an anti-virulence target. In a Fragment-Based Drug Discovery 
approach [113] 93 initial hits were tested in an enzymatic assay for the ability of EcDsbB to reoxidise 
EcDsbA or reduce the cofactor UQ-5. Eight fragments significantly inhibited EcDsbB activity either 
by competing for quinone binding, or for binding of both EcDsbA and quinone to EcDsbB. Other 
inhibitors were developed by applying structure-activity relationship principles. In particular, one 
compound with an IC50 of 1.1 µM inhibited both EcDsbA and EcDsbB by covalent addition of a 
propionyl group to cysteines or lysines [114]. In a third example, screening of more than 51,000 
compounds in a cell based assay identified six specific inhibitors of EcDsbB (that did not inhibit M. 
tuberculosis VKOR). One of these compounds inhibited binding of UQ, emphasising the important 
role of UQ in EcDsbB catalysis [115]. 
1.3 Targeting disulfide bond formation in C. trachomatis  
In vitro and in cell studies of the disulfide bond formation in many bacteria has identified the oxidative 
pathway as a strategy for development of new antimicrobials for pathogens that are resistant to 
antibiotics. In this thesis, the oxidative pathway of C. trachomatis has been explored to provide 
fundamental knowledge that could underpin future efforts aimed at developing inhibitors of DSB 
enzymes. 
1.3.1 Undiagnosed infections with Chlamydia trachomatis can have severe 
consequences for fertility and eye sight 
Members of the Chlamydia phylum are intracellular obligate Gram-negative bacteria infecting 
eukaryotic cells. Chlamydia trachomatis is one of three Chlamydialae under the phylum Chlamydia 
that infects humans. Infection with serovars A to C leads to blinding trachoma, which is the leading 
cause of preventable blindness worldwide [116, 117]. Infection causes roughening of the inner 
surface of the eyelid. This can lead to pain in the eyes, breakdown of the outer surface or cornea, 
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visual impairment and, ultimately, blindness. The infection can be treated with antibiotics and surgery 
to prevent blindness after scarring has occurred. However, blindness caused by C. trachomatis is 
irreversible [118, 119]. 
 
The sexually transmitted infection (STI) Chlamydia is caused by infection with serovars D to K 
whereas serovars L1 to L3 lead to infection in the lymphatic system [117]. Chlamydia infections, 
especially in the female genital tract, are often asymptomatic and consequently are often 
underdiagnosed. An untreated infection carries a high risk of prolonged exposure of the epithelium 
of the fallopian tube to C. trachomatis, or its released antigens. This can lead to scarring and 
disruption of tubal integrity with severe consequences such as infertility, ectopic pregnancy and 
premature termination of pregnancy. Other consequences of genital tract infections include pelvic 
inflammatory disease, endometriosis, and perihepatitis [120].  
1.3.2 The chlamydial developmental cycle is dependent on formation and 
degradation of disulfide bonds 
All species in the chlamydial phylum, including C. trachomatis, have a biphasic developmental cycle 
alternating between two morphologically and functionally distinct cell types. These are the infectious 
extracellular elementary body (EB) and the intracellular replicating reticulate body (RB). The 
Chlamydial Outer Membrane Complex (COMC) is a network of highly disulfide cross-linked outer 
membrane and outer membrane-associated proteins formed in the EB (Figure 1.12) [121-125].  
 
The Major Outer Membrane Protein (MOMP) comprises 60 % of the outer membrane protein mass 
[126]. Other constituents of the COMC are the two cysteine-rich proteins OmcA and OmcB, eight of 
the nine polymorphic membrane proteins (Pmp) found in C. trachomatis and components of the Type 
III Secretion System (T3SS) [124, 127-130]. Disulfide cross-linking of the COMC is required for the 
integrity of the EB, by conferring resistance to osmotic pressure and proteolysis [131, 132]. 
 
C. trachomatis infection is initiated by attachment of the EB form of the bacterium to the host cell. 
This is facilitated by a trimolecular bridge between bacterial adhesion molecules, host cell receptors 
and host heparin sulphate proteoglycans and involves OmcB, MOMP and the Pmps [125, 133-139]. 
Following attachment to the host cell, chlamydial effector proteins synthesised in the previous 
infection cycle and packed into the EB are translocated into the host cell by the T3SS where they 
promote internalisation and induce actin filament formation [140]. The EB is internalised to a 
membrane-derived vesicle called the inclusion body (Figure 1.13). 
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Figure 1.12 Composition of the Chlamydial Outer Membrane Complex. 
 The COMC consists of cysteine-rich outer membrane proteins and periplasmic proteins associated 
with the outer membrane. The location of cysteine residues and disulfide bonds with experimentally 
validated locations is shown in orange. Other cysteines are shown in red. Proteins associated with 
the COMC are linked with a dashed line. The structure of MOMP (green) is based on the model of 
Atanu et al. [141]. MOMP are inserted in the membrane as trimers with all cysteines located in the 
predicted extracellular loops. For two of the three monomers (depicted as semi-transparent) in the 
MOMP trimer, the loops and disulfides are not labelled for visualisation purposes. It is still unclear 
if MOMP is disulfide linked to the other proteins of the COMC. OmcA (dark blue) has a cysteine 
content of ~15 % and is associated with the membrane via a lipid anchor. OmcB (light blue) has a 
cysteine content of 4-6 % with no cysteines in the membrane-spanning region. With the exception of 
PmpD, all Pmps have been identified in the COMC (yellow). PorB (brown) and Pal (turquoise) have 
also been identified as belonging to the COMC, whereas it is still uncertain if Omp85 (pink) is 
associated with the COMC. In the T3SS (purple) CdsF forms homomeric disulfide bonds. CdsC forms 
homomeric disulfide bonds as well as heteromeric disulfide bonds with CdsD. CdsC is also suggested 
to form intermolecular disulfide bonds with the COMC. 
Within the first two hours of infection the disulfide cross-links of the COMC are reduced [142-145]. 
Reduction of the COMC is associated with differentiation to RBs [131]. The increased fluidity of the 
membrane after disulfide bond reduction permits replication by binary fission. EB to RB 
differentiation also leads to an increase in size as well as decondensation of chromatin causing the 
genome to become transcriptionally active [131]. Proteins synthesised early (6-8 hours post-
infection) in the replicative phase are responsible for remodelling of the inclusion membrane, 
redirection of exocytic vesicles to the inclusion and facilitating interaction with the host cell [146]. 
Shortly after, components of the COMC are synthesised, including MOMP, the T3SS needle protein, 
CdsF, as well as PmpE and PmpF [143, 144, 147-150]. Several dithiol oxidoreductases are 
synthesised during the replicative phase, including DsbA, DsbB, Suppression of Copper Sensitivity 
B (ScsB) [151] as well as DsbJ and DsbH [147]. 
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After several rounds of replication, the RBs differentiate into EBs in an asynchronous manner and 
the disulfide cross-linking network is re-established (Figure 1.13). OmcA and OmcB expression is 
upregulated in the late stages of replication or early stages of RB to EB differentiation [143, 147-
149]. Whereas MOMP is inserted in the outer membrane in the reduced thiol form, OmcA and OmcB 
are oxidised simultaneously with expression [143, 148]. MOMP as well as T3SS components are 
oxidised during RB to EB differentiation and are, at least partly, oxidised at the time of host cell lysis 
when new infectious progeny are released [143-145, 148, 152].  
 
Stress caused by nutrient deprivation, exposure to host cytokines or β-lactam antibiotics can cause 
the RB to significantly alter its metabolism and gene transcription causing the RB to enter a persistent 
state where the bacteria cease to replicate but remain viable (Figure 1.13) [153-156]. The persistent 
state is reversed upon removal of the factor causing the stress and RB replication is resumed [157, 
158]. 
 
The importance of disulfide cross-linking of the COMC in C. trachomatis is emphasised by the 
finding that treatment with the reducing agent dithiothreitol (DTT) prior to infection significantly 
reduces infectivity [131, 137, 142]. However, limited information is available about the processes 
responsible for redox regulation of the COMC. Host cell Protein Disulfide Isomerase (PDI) and 
intracellular glutathione are involved in reduction of the disulfide cross-linking of the COMC during 
internalisation [159-161]. However, a study [143] shows that inhibition of chlamydial protein 
synthesis inhibits reduction of MOMP whereas inhibition of host cell protein synthesis does not. This 
suggests that PDI and glutathione are not solely responsible for reduction of the COMC. No 
chlamydial proteins have been identified as redox regulators of the COMC, but given that DsbJ is 
exclusively found in members of the Chlamydia phylum, DsbJ has been proposed to be involved in 
regulating the redox state of the COMC proteins. For example, DsbJ may regulate the reducing 
activity of the periplasmic oxidase DsbH [145]. 
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1.3.3 Treatment and treatment failure of infections with C. trachomatis 
C. trachomatis is routinely treated with azithromycin, doxycycline, erythromycin, levofloxacin or 
ofloxacin. These antibiotics are able to pass through lipophilic plasma membranes to reach the RB, 
which are more susceptible to antibiotics than EBs [162].  
 
C. trachomatis has been shown to develop resistance in vitro against several classes of antibiotics 
including rifamycins and fluoroquinolones, such as azithromycin [87, 163-174]. Even though 
antibiotic resistance can be selected for in vitro, only 15 cases of resistant strains isolated from 
patients have been reported [175-179]. However, in 11 out of 15 reported cases the apparent antibiotic 
resistance was due to treatment failure and no resistant strains have been reported since 2000. Several 
factors can be responsible for the treatment failure e.g. reinfection, heterotypic resistance, persistence, 
and infection of anatomic sites where C. trachomatis is unavailable to antibiotics. In fact, treatment 
failure is a substantial problem with chlamydial infection; studies show treatment failure in up to 14 
% of women despite no post-treatment sexual contact [180].  
 
In heterotypic resistance, a subset of individual bacteria show reduced sensitivity to antibiotic 
treatment. All of the 15 reported cases of antibiotic resistance showed characteristics of heterotypic 
resistance where <1-10 % of the population were not susceptible to antibiotic treatment [175-179]. 
Due to the asynchronous RB to EB differentiation, a mid-stage inclusion will contain replicating RBs 
as well as non-replicating EBs. As EBs are less susceptible to antibiotics the asynchronous 
differentiation might ensure the survival of a subset of the population thereby causing heterotypic 
resistance [181]. 
 
Persistence can occur upon treatment with β-lactam antibiotics or in response to tryptophan starvation 
caused by the release of gamma interferon (IFN-ϒ) as part of the host immune response [182, 183]. 
The emergence of persistent Chlamydia has been linked to reduced sensitivity to antibiotics in vitro 
and might contribute to treatment failure [170, 181, 184-186]. 
 
Treatment of Chlamydia is further complicated by the common occurrence of co-infections with 
Treponema pallidum and Neisseria gonorrhoeae [187, 188]. Both T. palladium and N. gonorrhoeae 
are routinely treated with β-lactam antibiotics. Consequently, the treatment of T. palladium and N. 
gonorrhoeae could potentially induce persistence of C. trachomatis. 
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Antibiotic treatment of C. trachomatis infections can have severe effects on the native microbiota, 
and cause vaginal and gut dysbiosis. The bacterium, Lactobacillus, is the dominant species in the 
vaginal microbiota in most women of fertile age [189]. Lactobacillus inhibits C. trachomatis 
infectivity by producing antibacterial compounds such as hydrogen peroxide and lactic acid, causing 
co-aggregation, competitive exclusion, immunomodulation and potentially downregulation of toxin 
production by C. trachomatis [190, 191]. Antibiotic treatment can potentially deplete Lactobacillus 
populations thereby increasing the risk of reinfection with C. trachomatis.  
 
Even though C. trachomatis is susceptible to many broad-spectrum antibiotics the high degree of 
treatment failure as well as the effect on the microbiota in the gut and, especially, in the vagina calls 
for new drugs targeting C. trachomatis with a narrower host range. Significantly, a BLAST search 
using DsbA sequences from E. coli and C. trachomatis against the Lactobacillus genomes (Taxid: 
1578) identified no DsbA homologs suggesting that targeting CtDsbA will not have any off-target 
effects on lactobacillus. 
1.4 Thesis objectives 
The increase in antibiotic-resistant bacteria over the last decade underpins the need for development 
of antimicrobial drugs with new modes of action. Considering the requirement for oxidative folding 
of virulence factors in many pathogens, the proteins involved in the disulfide oxidative folding 
pathway have gained interest as potential targets for development of anti-virulence antimicrobial 
drugs. The diversity in redox activity and surface properties amongst DsbA proteins suggest that 
drugs can be developed that target a specific subset of DsbA enzymes. 
 
The objective of the research reported in this thesis was to characterise the oxidative pathway in C. 
trachomatis, especially with a focus on the role of DsbA in vitro and in vivo. Characterising DsbA is 
done for two purposes, to provide: (i) new fundamental understanding that expands our knowledge 
of the diversity of DsbA enzymes and oxidative pathways in bacteria and (ii) a specific exploration 
of the oxidative pathway in C. trachomatis as a target for narrow spectrum anti-virulence inhibitor 
development. Considering the importance of disulfide bonds in infection and development in C. 
trachomatis the oxidative pathway might play a specialised role in C. trachomatis by regulating the 
redox state of the proteins in the chlamydial outer membrane complex. 
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To shed new light on the oxidative pathway in C. trachomatis three aims were investigated: 
 
• Aim 1 (Chapter 2, published work) - characterise the structure and function of C. trachomatis 
DsbA (CtDsbA). Knowledge of differences and similarities between CtDsbA and other 
characterised DsbA enzymes contributes to building a structural library of DsbA enzymes to 
guide development of broad and narrow spectrum drugs targeting DsbA enzymes. 
 
• Aim 2 (Chapter 3) - characterise the oxidative pathway in C. trachomatis. The goal was to 
explore similarities with, as well as deviations from, the oxidative pathways in E. coli by 
studying (i) the interaction between CtDsbA and C. trachomatis DsbB (CtDsbB) and (ii) UQ 
binding of CtDsbB. In addition, the determination of expression levels of CtDsbA was 
monitored during C. trachomatis infection of mouse fibroblasts (McCoy cells) to contribute 
to our understanding of the role of CtDsbA in C. trachomatis infection. 
 
• Aim 3 (Chapter 4) - investigate approaches to generate a dsbA loss-of-function mutant in C. 
trachomatis for studying the impact on virulence. Genetic manipulation of C. trachomatis is 
challenging due to the biphasic lifecycle, so a random mutagenesis approach was taken in an 
effort to obtain loss-of-function mutations. 
 
Chapter 5 summarises the results and broad conclusions of the three research chapters. Moreover, it 
discusses the potential of the results of this thesis to guide further development of antimicrobial drugs 
and explores the potential of targeting the oxidative pathway in C. trachomatis for development of 
drugs against C. trachomatis. The biological role of CtDsbA is reviewed based on the characterisation 
of CtDsbA and the interaction between CtDsbA and CtDsbB. I also outline further steps needed to 
address the biological function of the oxidative pathway in C. trachomatis.  
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Chapter 2: Structural and biochemical 
characterisation of Chlamydia trachomatis 
DsbA reveals a cysteine-rich and weakly 
oxidising oxidoreductase  
 
 
The following chapter is a manuscript published in PLOS ONE with Dr. Morten Grøftehauge and 
myself as co-first authors. The manuscript addresses aim 1 of this thesis by presenting the structural 
and biochemical characterisation of CtDsbA thereby contributing to the structural library of DsbA 
enzymes. 
 
Dr. Róisín McMahon and Dr. Morten Grøftehauge solved the structure of CtDsbA with assistance 
from Karl Byriel. Ms. Emily Furlong performed the initial attempt of the scrambled RNase assay and 
the remaining biochemical characterisation and analysis was performed by myself. I wrote the first 
draft of the paper, and the final manuscript was reviewed and edited by myself, Dr. Morten 
Grøftehauge, Dr. Wilhelmina M. Huston, Dr. Begoña Heras, Prof. Jennifer L. Martin and Dr. Róisín 
M. McMahon. 
 
Please note that formatting is changed from the version published in PLOS ONE. 
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2.3 Abstract 
The Gram-negative bacteria Chlamydia trachomatis is an obligate intracellular human pathogen that 
can cause pelvic inflammatory disease, infertility and blinding trachoma. C. trachomatis encodes a 
homolog of the dithiol oxidoreductase DsbA. Bacterial DsbA proteins introduce disulfide bonds to 
folding proteins providing structural bracing for secreted virulence factors, consequently these 
proteins are potential targets for antimicrobial drugs. Despite sharing functional and structural 
characteristics, the DsbA enzymes studied to date vary widely in their redox character. In this study 
we show that the truncated soluble form of the predicted membrane anchored protein C. trachomatis 
DsbA (CtDsbA) has oxidase activity and redox properties broadly similar to other characterised DsbA 
proteins. However CtDsbA is distinguished from other DsbAs by having six cysteines, including a 
second disulfide bond, and an unusual dipeptide sequence in its catalytic motif (Cys-Ser-Ala-Cys). 
We report the 2.7 Å crystal structure of CtDsbA revealing a typical DsbA fold, which is most similar 
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to that of DsbA-II type proteins. Consistent with this, the catalytic surface of CtDsbA is negatively 
charged and lacks the hydrophobic groove found in EcDsbA and DsbAs from other 
enterobacteriaceae. Biochemical characterisation of CtDsbA reveals it to be weakly oxidising 
compared to other DsbAs and with only a mildly destabilising active site disulfide bond. Analysis of 
the crystal structure suggests that this redox character is consistent with a lack of contributing factors 
to stabilise the active site nucleophilic thiolate relative to more oxidising DsbA proteins. 
2.4 Introduction 
Disulfide bond proteins (DSB) are thiol-disulfide oxidoreductases found in the periplasm of Gram-
negative bacteria, which catalyse the oxidative folding of disulfide bond containing substrate proteins. 
The first DSB protein to be described was that of the primary oxidase DsbA from Escherichia coli 
(EcDsbA) [192]. EcDsbA is a highly oxidising protein with a redox potential of     -122 mV [192] 
which introduces disulfide bonds into folding proteins resulting in its own active site reduction. 
EcDsbA is subsequently returned to its active oxidised state by interaction with an integral membrane 
partner protein EcDsbB. The structure of EcDsbA consists of a thioredoxin catalytic domain 
(containing the active site motif CPHC) with an inserted helical domain [62].  
 
Extensive efforts over many years have yielded a structural library of over a dozen bacterial DsbA 
proteins. These have recently been classified into two groups (DsbA-I and DsbA-II) on the basis of 
structural and functional features [96]. DsbA-I and DsbA-II proteins are demarcated primarily on the 
basis of altered central b-sheet topology, a distinction that also approximately separates DsbA 
proteins from Gram negative and Gram-positive bacteria.   
 
Each DsbA group can be further subdivided into two subclasses on the basis of surface features. Type 
DsbA-Ia and Ib groups are relatively well represented with four and five protein members 
respectively. By comparison, DsbA-II proteins are less well characterised; to date only three DsbA 
proteins have been classified as DsbA-IIa (DsbA from Mycobacterium tuberculosis, Staphylococcus 
aureus and Bacillus subtilis) whilst DsbA-IIb is solely represented by DsbA1 from the endosymbiont 
Wolbachia pipientis. Within DsbA-Ia and DsbA-Ib, member proteins have similar redox 
characteristics with redox potentials falling within a 10 mV or 15 mV range, respectively [70, 74, 76, 
77, 84]. Among the DsbA-IIa proteins redox potentials are much more varied, ranging from -131 mV 
[84] to -80 mV [79].  
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It is well documented that pathways responsible for disulfide bond formation can vary markedly 
amongst different bacterial species [89]. In C. trachomatis, in silico analysis suggests that the 
disulfide oxidative pathway, and to some extent the isomerase pathway, resembles the canonical DSB 
pathways of E. coli K12. C. trachomatis possesses a gene predicted to be a homolog of the E. coli 
DsbA [89] hereafter referred to as CtDsbA. Immediately upstream of dsbA C. trachomatis also 
encodes a homolog of E. coli DsbB. This protein is predicted to be a transmembrane protein with four 
transmembrane helices and two cysteine-residue containing periplasmic loops. DsbB is presumably 
responsible for oxidising CtDsbA in a manner analogous to the E. coli DsbA-DsbB interaction. 
Notably C. trachomatis does not encode a homolog of the E. coli isomerase DsbC but has a gene with 
significant homology to E. coli DsbD, a membrane bound electron transporter and partner protein of 
E. coli DsbC. Drawing on recent extensive phylogenetic analysis of the DsbD superfamily in 
eubacteria [151], this gene is most likely a member of the sub-family ScsB. Finally C. trachomatis 
was found to contain homologs to genes coding for two periplasmic C. pneumonia proteins:  DsbH 
and DsbJ. DsbH and DsbJ are suggested to play a role in maintaining a reducing periplasm, and have 
not yet been reported outside of chlamydial species [107].  
 
Here we investigated the DsbA enzyme from Chlamydia trachomatis, responsible for human 
urogenital Chlamydia infections. This infection is among the most common sexually transmitted 
infections worldwide with an estimated 131 million urogenital cases reported globally in 2012 by the 
World Health Organization [193]. A common complication of genital chlamydial infection in women 
is pelvic inflammatory disease, which, if untreated, can lead to infertility. Furthermore, strains of C. 
trachomatis can also infect the ocular mucosa where it can cause blinding trachoma [194].  
 
In the present study we confirm that CtDsbA has oxidising enzymatic activity and a structure similar 
to that of other DsbA-II type proteins that contain a second non-catalytic disulfide bond. We find that 
CtDsbA has a particularly weak oxidising potential for a DsbA enzyme, which appears to stem in 
part from its uncommon active site dipeptide motif of two uncharged amino acids. Characterisation 
of CtDsbA expands the DsbA structural library, provides further insight into the diversity of bacterial 
DsbA proteins and supports continued exploration of the potential for DsbA inhibitors with multi-
species activity. 
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2.5 Materials and Methods 
2.5.1 Protein expression and purification  
The recombinant CtDsbA expressed and characterised in this study was generated using residues 34 
to 238 of C. trachomatis dsbA (NCBI Gene with ID 5858475, currently annotated as DsbG). A variant 
form of the protein (called CtDsbA-SSS) was produced by mutating each of the three non-active site 
cysteines to a serine (C66S, C80S and C141S). Both constructs were synthesised and inserted into a 
modified pET21a vector by ligation independent cloning as described [195]. Both genes were codon-
optimised for expression in Escherichia coli. The vector includes a N-terminal His6-tag followed by 
a linker containing a recognition site for the tobacco-etch virus (TEV) protease. Design of the 
constructs was informed by bioinformatics analysis (HMMTOP [196, 197], and PSIPRED [198] to 
remove the predicted N-terminal transmembrane helix, and maximise solubility of the purified 
protein. Sequence verified plasmids were routinely amplified in E. coli TOP10 cells cultured at 37°C 
with orbital shaking (200 rpm) in LB broth supplemented with ampicillin (100 µg/mL), and 
subsequently isolated with a QIAprep Spin Miniprep Kit (QIAGEN).  
 
For biochemical assays CtDsbA and CtDsbA-SSS were expressed in Escherichia coli BL21 (DE3) 
pLysS cells using ZYP-5052 autoinduction medium [199] in the presence of ampicillin (100 µg/mL) 
and chloramphenicol (34 µg/mL). Cultures were incubated at 30 °C, for 16 h with orbital shaking at 
200 rpm. Harvested cells were re-suspended in a solution of 25 mM HEPES pH 7.5, 150 mM NaCl 
(Buffer 1), DNAse and protease inhibitors and lysed using a constant pressure cell disrupter. Clarified 
lysate was purified with Talon® resin (Clontech, Australia) washing with 25 mM HEPES pH 7.5, 
500 mM NaCl, 2.5 mM imidazole and eluting with Buffer 1 and 500 mM imidazole. Purified protein 
was dialysed against Buffer 1 to remove imidazole prior to cleavage of the N-terminal His6-tag by 
treatment with a His-tagged TEV protease. TEV cleaves leaving two non-endogenous amino acids 
(S -1 and N 0) at the N-terminus of the protein. Contaminating TEV protease and uncleaved CtDsbA 
were removed by a second immobilised metal affinity chromatography step prior to a final size 
exclusion step in Buffer 1 using a Superdex S75 column. As required CtDsbA and CtDsbA-SSS were 
reduced and oxidised by 20 fold molar excess of DTT or 100 fold molar excess of oxidised 
glutathione, respectively. The protein redox state was confirmed by Ellman’s reagent [200]. 
For crystallisation experiments CtDsbA was prepared as described above with the following 
differences. Harvested cells were re-suspended in a solution of 50 mM Tris pH 7.6, 500 mM 
(NH4)2SO4 (Buffer 2), 0.5 % Triton X-100, DNAse and protease inhibitors, and lysed by sonication. 
Immobilised-Metal Affinity Chromatography (IMAC) purification was performed with Profinity 
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resin (Biorad) equilibrated in Buffer 2 supplemented with 10 mM imidazole. Following wash steps 
(5 column volumes of Buffer 2), purified protein was eluted in Buffer 2 supplemented with 500 mM 
imidazole. Purified protein was dialysed against 50 mM HEPES pH 7.6, 500 mM (NH4)2SO4 and 0.5 
mM of the reducing agent tris-(2-carboxyethyl)fosfin (TCEP) prior to TEV cleavage and a second 
IMAC step. Protein purity (>95 %) was confirmed by SDS-PAGE analysis.  
2.5.2 Insulin reduction assay 
DsbA proteins catalyse the reduction of the disulfide bond formed between chain A and B of insulin. 
When the disulfide bond is reduced, chain B of insulin precipitates. This reaction can be monitored 
by an increase in absorbance at 650 nm [201]. Reaction mixtures were prepared in 1 mL cuvettes 
with 10 µM protein, 0.33 mM DTT and 2 mM EDTA in 100 mM NaH2PO4/ Na2HPO4 pH 7.0. The 
reaction was started by adding insulin (IO516, Sigma Aldrich, Australia) at a final concentration of 
0.13 mM. Plotted data shows mean and standard deviation (SD) for three biological replicates. 
2.5.3 Peptide oxidation assay 
The redox activity of a disulfide bonded protein can be assessed by its ability to oxidatively fold the 
peptide CQQGFDGTQNSCK which has a N-terminal europium ion (EuIII) in an amide-coupled 
tetraazacyclododecane-1,4,7,10-tetraaceticacid (DOTA) chelate and a C-terminal coumarin 
chromophore (AnaSpec, USA) [108, 202, 203]. Upon oxidative folding the two terminal tags come 
in close proximity resulting in a detectable fluorescent resonance energy transfer (FRET) effect. The 
assay was performed in a 384-well plate (Perkin Elmer, USA). A solution of 50 mM MES, 50 mM 
NaCl, 2 mM EDTA, pH 5.5, 2 mM GSSG and protein concentration of 80 nM (EcDsbA) or 320 nM 
(CtDsbA, MtbDsbA and αWpDsbA1) were added to the wells in 25 µL aliquots. Adding 25 µL 
peptide to a final concentration of 25 µM started the reaction. Change in fluorescence at 340 nm was 
followed using a Synergy H1 Multimode plate reader (BioTek, USA). Plotted data shows mean and 
SD for two biological replicates. 
2.5.4 Scrambled-RNaseA assay  
The ability of CtDsbA to isomerise disulfide bonds was evaluated by a scrambled RNaseA 
(ScRNaseA) assay. To generate scrambled RNaseA, disulfides were first reduced and unfolded by 
incubating RNaseA overnight in 50 mM Tris-HCl, pH 8 in the presence of 6 M GdmCl and 150 mM 
DTT at room temperature. The reduced and unfolded protein was acidified with 100 mM acetic 
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acid/NaOH pH 4 and purified over a GE-25 Sephadex desalting resin. The eight free thiols were 
confirmed by Ellman’s reagent. To randomly oxidised disulfides, the reduced and unfolded RNaseA 
was diluted to 0.5 mg/ml in 50 mM tris-HCl, pH 8.5, 6 M GdmCl and incubated in a dark room at 
room temperature for at least 5 days. The randomly oxidised RNaseA (ScRNase) was concentrated, 
acidified and purified as described above, and oxidation of the disulfide bonds was confirmed by 
Ellman’s reagent. Isomerase activity was evaluated by following the renaturation of ScRNaseA 
spectrophotometrically. RNase A with native disulfide bonds is able to cleave cyclic-2’,3’-
cytidinemonophosphate (cCMP) into 3’-cytidinemonophospate (3’CMP) resulting in an increase in 
absorption at 296 nm. EcDsbA, EcDsbC and CtDsbA (10 µM final concentration), were added to 100 
mM sodium phosphate pH 7, 1 mM EDTA and 10 µM DTT and incubated for 5 min. To start the 
assay ScRNase was added at a final concentration of 40 µM. Native RNase and ScRNase (40 µM) 
were included as controls. At multiple time points from 0 to 360 min after initiation of the assay a 50 
µL aliquot of each reaction was added to 150 µL of 3mM cCMP and the increase in absorbance at 
296 nm was monitored every 10 second for 3 min. 3 biological replicates were performed for CtDsbA. 
2.5.5 Motility assay 
In order to investigate whether CtDsbA can complement EcDsbA, the CtdsbA gene was cloned into 
the expression vector pBAD33 [204] under the control of an arabinose inducible promoter and 3’ of 
an E. coli specific signal peptide sequence. EcdsbA was likewise cloned into pBAD33 as a control. 
E. coli strains deficient in EcDsbA (JBC817) and EcDsbA and DsbB (JBC818) [58] were transformed 
with pBAD33-CtDsbA and pBAD33-EcDsbA and grown on LB agar. Liquid cultures (20 mL) were 
grown in M63 minimal media lacking cysteine and methionine. Each culture was normalised to an 
OD600 of 1.0. 2 µL culture containing ~107 cells was used to carefully inoculate M63 minimal media 
soft agar in the presence or absence of arabinose (1 mg/mL). Plates were incubated at 37 °C. The 
zone of motility was measured after approximately 7 h. 
2.5.6 Relative stability of oxidised and reduced forms of DsbA  
The thermal unfolding of reduced and oxidised CtDsbA was determined using a Jasco J-810 circular 
dichroism (CD) spectropolarimeter. Measurements were carried out with 10 µM protein in 100 mM 
NaH2PO4/Na2HPO4, 0.1 mM EDTA, pH 7.0 in a 1 mm quartz cuvette. The unfolding was monitored 
as a change in molar ellipticity at 220 nm with a heat rate of 0.5 K/min from 298 K to 398 K. Plotted 
data shows mean and SD for two biological replicates. 
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2.5.7 Determination of the redox potential 
The standard redox potential of CtDsbA was determined following a shift in electrophoretic mobility 
upon reduction of the active site disulfide. Samples were prepared with fully oxidised CtDsbA-SSS 
in degassed 100 mM sodium phosphate pH 7.0, 1 mM EDTA and 20 mM oxidised DTT and varying 
concentration of DTT (0 µM-16 mM) and equilibrated at 30°C. After 24 hours the reaction was 
stopped by adding 1/5 of the reaction volume of 10 % 2,4,6-Trichloroanisole (TCA). The precipitated 
protein was collected by centrifugation at 13,300 g for 10 min at 4 °C. The pellets were washed with 
200 µL ice cold 100 % acetone and dissolved in 10 µL 50 mM Tris-HCl pH 7.0, 1 % SDS, 2 mM 
AMS. The difference in migration between the reduced and oxidised CtDsbA-SSS was determined 
on a 12 % SDS Bis-Tris PAGE (Life Technologies, USA). The gel was stained and the intensity of 
the bands were analysed by ImageLab (BIO-RAD) The equilibrium constant Keq and the redox 
potential E0 were calculated as described previously [80]. Plotted data shows mean and SD for four 
biological replicates. 
2.5.8 Determination of pKa of Cys38 of CtDsbA 
The pKa of the nucleophilic active site cysteine, Cys38, of CtDsbA was determined by following the 
pH-dependent specific absorption of the thiolate anion at 240 nm. The pH-dependent absorbance at 
240 nm was measured for the oxidised protein as a reference. 
 
20 µM samples of reduced and oxidised CtDsbA were prepared in 10 mM K2HPO4, 10 mM boric 
acid, 10 mM sodium succinate, 200 mM KCl and 1 mM EDTA over a pH range of 1.6 – 8.0, in a 
total volume of 200 µL. Absorbance at 240 nm and 280 nm was measured in a Synergy H1 multimode 
plate reader (Biotek, USA). The pH-dependent absorbance of the thiolate anion was corrected for, 
buffer absorbance, non-specific absorption at 240 nm and variations in protein concentrations and 
fitted to the Henderson-Hasselbalch equation 
2.5.9 Crystallisation of CtDsbA  
CtDsbA was crystallised using The University of Queensland Remote Operated Crystallisation X-
ray Facility (UQROCX), the vapour-diffusion method and hanging drops. 96-well plates (200 nL of 
protein and 200 nL of reservoir solution, against 75 µL reservoir solution) were set using a Mosquito 
crystallisation robot (TTP Labtech) against commercially available crystallisation screens. All 
crystallisation experiments were maintained at 298 K. Screening of commercially available 
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crystallisation screens with CtDsbA at a concentration of 26 mg/mL identified an initial condition 
(100 mM BisTris propane pH 9.0, 3.1 M potassium formate) that yielded both salt crystals as well as 
protein crystals. Subsequent investigation of additives was performed in 24-well plates with (2 µL 
protein and 2 µL crystallisation condition, against a 500 µL reservoir volume) and resulted in an 
optimised crystallisation condition of 100 mM BisTris propane pH 9.0, 3.1 M Sodium formate and 4 
% Tacsimate™. 
2.5.10 X-ray data collection, structure solution and refinement 
Crystals were cryocooled in liquid nitrogen without additional cryoprotectant. X-ray data were 
collected at 100 K at UQROCX using a Rigaku FR-E Superbright X-ray generator and a Rigaku 
Saturn 944 CCD area detector.  Data were collected over a 360° rotation at a wavelength of 1.54187 
Å. Using the autoPROC software toolbox [205] the data were indexed and integrated with XDS [206], 
prior to further processing with Pointless and scaling with Aimless [207]. A high resolution limit of 
2.7 Å was applied to the data following evaluation of the half-dataset correlation coefficient, Rmeas 
and completeness values in Aimless. As a result of this prioritisation, the I/σI value in the highest 
resolution shell is high (5.9). The space group was determined to be P21212 with two copies of 
CtDsbA in the asymmetric unit. We note that Xtriage analysis flagged L-test anomalies that may stem 
from data quality deficiencies. Merohedral and pseudo-merohedral twin laws are not possible in this 
lattice. All phasing and model refinement procedures were implemented within the Phenix software 
suite. The data were phased using molecular replacement methods with AutoMR using Bacillus 
subtilis BdbD (PDB ID, 3EU3, [79]) as a search model. The search model was prepared for molecular 
replacement using Sculptor, with additional trimming of predicted loop regions informed by 
inspection of sequence alignment analysis with CtDsbA. The resulting model was subject to 
automated building and rebuilding using AutoBuild followed by iterative rounds of refinement 
(phenix.refine [208]) -  including refinement using hydrogen atoms using a riding model -  and model 
building using COOT [209]. The quality of the final model was assessed with Molprobity [210] 
throughout the refinement process.  
 
The electron density map supported building of an almost continuous model of residues in chain A 
from residue 6 – 203. There was insufficient density to model residues 133 – 135 inclusive in a loop 
connecting H4 and H5. Lys16 and Tyr17 on chain A are modeled as alanine as it was not possible to 
resolve the side chain atoms of either residue satisfactorily. Chain B extends from residues 3 to 203 
with breaks from 110 - 111 and 133 - 134 inclusive in two separate loop regions. Both molecules in 
the asymmetric unit are structurally highly similar, and superpose with a RMSD of 1.08 Å (191 
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equivalent Ca atoms). Inspection of the structural alignment indicates that the main-chain atoms of 
all major secondary structure elements superimpose almost exactly. Structural differences between 
the two molecules are limited to the most N-terminal residues (residues 3 – 18) and several loop 
regions connecting: B1-B2 (residues 23-28), H2-H3 (residues 88-93), H3-H4 (residues 109-116 and 
H4-H5 (residues 132-136). As noted above the H4-H5 loop is incomplete in both chains, and the H3-
H4 loop is incomplete in chain B. Additionally there are minor deviations in the position of the C-
terminal end of H7. Notably the loops that constitute the catalytic surface – including the active site 
– are structurally equivalent. Further analysis of CtDsbA is restricted to chain B. All figures depict 
chain B.  
 
There is additional electron density adjacent to the non-catalytic disulfide bridge (Cys 84-Cys 145) 
suggestive of a small molecule ligand. We attempted to identify this ligand by searching a library of 
200 common ligands using the Ligand Identification module in Phenix. This relatively blind search 
strategy proposed succinic acid (a component of the crystallisation reagent Tacsimate™) as a 
potential ligand. Refinement of a model including succinic acid resulting in an acceptable fit to the 
electron density but an elevated Rfree factor. For comparison we also modelled another potential ligand 
(2-oxoglutaric acid) identified by the search which we do not believe to have been present during 
protein purification or crystallisation, and this yielded a similar density fit and elevated Rfree factor.  
User guided searching and modelling of other known crystallisation components did not yield a better 
fitting ligand. In light of the moderate resolution of the data and as we cannot identify a ligand with 
confidence, this density remains unmodelled. 
 
Data-collection and refinement statistics are summarised in  
 
 
 
Table 2.1. The final refined structure has been deposited in the Protein Data Bank (PDB ID 5KBC.) 
All structural figures were generated using Pymol (PyMOL Molecular Graphics System, version 1.6 
Schrodinger, LLC, http://pymol.org) and Adobe Illustrator. 
2.6 Results 
2.6.1 The Chlamydia trachomatis genome encodes a DsbA with multiple cysteine 
residues.  
C. trachomatis DsbA was first identified using a bioinformatic interrogation of all publicly available 
and complete prokaryotic genomes, using the Complete Microbial Resource at the Craig Venter 
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Institute and the DsbA sequences from E. coli, S. aureus and W. pipientis as query terms [89]. This 
analysis returned a single gene in C. trachomatis (strain: 434/Bu, serotype: L2) predicted to encode 
a DsbA-like protein (Gene ID 5858475; UniProt CTL0429) and hereafter referred to as CtDsbA. We 
note that this gene is currently annotated as DsbG in UniProt, but based on its 15 % sequence identity 
with EcDsbA, and 20 % and 21 % sequence identity with SaDsbA and Mycobacterium tuberculosis 
DsbA, respectively, we hypothesised that it is in fact a DsbA-like protein. Unlike EcDsbA or SaDsbA, 
but in common with MtbDsbA, P. aeruginosa DsbA2 and WpDsbA1, the predicted CtDsbA encodes 
additional cysteine residues outside of the active site motif. The full-length encoded CtDsbA protein 
has six cysteines in total. Bioinformatic analysis using multiple algorithms indicated that CtDsbA has 
a predicted transmembrane region from residues 11/12 - 28/29. From residue 29 onwards the protein 
sequence is predicted to face the outside of the cytoplasmic membrane (as described in Materials and 
Methods). We designed an expression construct restricted to the expected mature soluble CtDsbA 
protein starting at residue 34 to ensure no inadvertent inclusion of the predicted transmembrane helix. 
This construct has five cysteines.  
2.6.2 CtDsbA catalyses the reduction of insulin  
To investigate CtDsbA activity we first evaluated its redox activity in the classic insulin reduction 
assay. Isomerases such as EcDsbC catalyse this reaction very rapidly whereas oxidases, such as 
EcDsbA, catalyse the reaction much more slowly. We found that CtDsbA is able to catalyse the 
reduction of insulin more slowly than EcDsbA and EcDsbC (Figure 2.1A). The weak insulin 
reduction activity of CtDsbA relative to EcDsbC suggests that CtDsbA is more likely to be an oxidase 
than isomerase or reductase. 
2.6.3 CtDsbA has oxidase activity in vitro 
The oxidase activity of CtDsbA was further investigated by its ability to oxidise a fluorescently 
labelled peptide substrate containing two cysteine residues. Like EcDsbA, CtDsbA was able to 
oxidise the model peptide substrate but a similar response required a concentration of CtDsbA four 
times that of EcDsbA (Figure 2.1B). At equivalent concentrations, the activity of CtDsbA is similar 
to the DsbA-IIb protein, WpDsbA1 but markedly less than that of the DsbA-IIa protein MtbDsbA. 
These results indicate that CtDsbA has oxidase activity in this assay, but either is intrinsically less 
active than EcDsbA and the class IIa protein MtbDsbA or does not interact with the substrate as 
avidly as EcDsbA and MtbDsbA.  
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Figure 2.1 Biochemical characterisation of CtDsbA. 
 A) Reduction of insulin (131 µM) was measured as increase in absorbance at 650 nm in 0.1 mM 
sodium phosphate buffer, pH 7, 2 mM EDTA. The reaction was performed in the absence (■) or 
presence of 10 µM EcDsbC (●), EcDsbA (♦) or CtDsbA (○). Representative data are shown for the 
absence and presence of 10 µM EcDsbA. Mean and SD are shown for two biological replicates (three 
biological replicates for CtDsbA). B) 80 nM EcDsbA () and 320 nM CtDsbA (●), MtbDsbA (■) and 
WpDsbA1 () oxidise a fluorescently labeled protein in the presence of 2 mM GSSG. GSSG shows 
only limited oxidising activity in the absence of a DsbA protein (♦). The buffer only control (○) shows 
no oxidising activity. For MtbDsbA, WpDsbA1, EcDsbA and CtDsbA mean and SD of two biological 
replicates are shown (for each biological replicate, four technical replicates were performed). For 
the buffer and GSSG only controls, mean and SD for four technical replicates are shown. C) 
Isomerase activity was assessed as the ability to refold scrambled RNAseA. ScRNase (40 µM) was 
incubated in 0.1 M sodium phosphate buffer pH 7.0,1 mM EDTA, 10 µM DTT in the absence and 
presence of 10 µM EcDsbA (■), EcDsbC (○) and CtDsbA (●). RNase activity was monitored as the 
cleavage of cCMP which leads to an increase in absorbance at 296 nm. Mean and SD for three 
biological replicates is shown for CtDsbA. EcDsbC and EcDsbA is able to restore ~80 % and ~20 % 
of RNaseA activity, which is equivalent to what has been reported previously [84]. D) Temperature 
induced unfolding of oxidised (○) and reduced (●) CtDsbA was determined by far UV CD 
spectroscopy. The thermal unfolding of CtDsbA results in an increase in molar ellipticity at 220 nm 
showing that the reduced form of CtDsbA is more stable than the oxidised form. Mean and SD are 
shown for two biological replicates.  
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2.6.4 CtDsbA does not have isomerase activity in the scrambled RNase assay 
To determine whether CtDsbA has disulfide isomerase activity we measured the ability of CtDsbA 
to isomerise the non-native disulfide bonds of scrambled RNaseA (ScRNaseA). Whereas the 
isomerase EcDsbC was able to restore about 80 % of RNaseA activity over the course of the 
experiment, CtDsbA was only able to restore approximately 20 % of RnaseA activity in this same 
time period (Figure 2.1C); this is comparable to the activity of the oxidase EcDsbA. Together these 
data indicate that CtDsbA does not have isomerase activity and behaves more like an oxidase in this 
assay.  
2.6.5 The active site disulfide in CtDsbA is destabilising 
The disulfide bond in DsbA proteins is typically destabilising, in contrast to most proteins where 
disulfide bonds generally confer stability. We found that CtDsbA also has a destabilising disulfide as 
the melting temperature (Tm) for the reduced form (339.1 K ± 0.2) is 4 K greater than the oxidised 
form (335.1 K ± 0.1) (Figure 2.1D).  
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2.6.6 CtDsbA is less oxidising than E. coli DsbA 
The redox potential of CtDsbA in equilibrium with DTT was determined by monitoring the difference 
in electrophoretic mobility between the reduced and oxidised form (Figure 2.2). To measure the redox 
potential of the active site disulfide, we used the CtDsbA-SSS construct that only contains the two 
cysteines in the active site. We found a Keq of 3.7 ± 0.8 × 10-4 M corresponding to a redox potential 
of -229 mV. This makes CtDsbA a much weaker oxidase than EcDsbA (E° -122 mV) and to our 
knowledge, the most reducing DsbA characterised to date. 
 
Figure 2.2 Redox potential determination for CtDsbA-SSS by electrophoretic motility shift.  
A) SDS-PAGE gel of oxidised CtDsbA (3 µM) incubated for 24 h with increasing concentration of 
DTT (0 µM -12 mM).  B) The fraction of thiolate as a function of reduced DTT versus oxidised DTT 
is plotted. Fitting of the data revealed a Keq of 3.8 ± 0.8 x 10-4 M equivalent to a redox potential of -
229 mV. Mean and SD calculated from 4 biological replicates are plotted. 
2.6.7 CtDsbA cannot rescue deletion of dsbA in E. coli  
Deletion of the dsbA gene leads to pleiotropic phenotypes in E. coli [58]. One phenotype associated 
with DsbA-deficient E. coli is the loss of motility due to a failure to assemble functional flagella 
[211]. CtDsbA was expressed in ΔdsbA and ΔdsbA/dsbB backgrounds to determine if CtDsbA can 
complement EcDsbA. Exogenous expression of EcDsbA restored motility in ΔdsbA E. coli on soft 
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agar (zone of motility 21 mm in comparison to 6 mm in the uninduced control; Figure 2.3) but as 
expected could not rescue the phenotype in ΔdsbA/dsbB bacteria. Expression of CtDsbA did not 
restore motility in either the ΔdsbA or ΔdsbA/dsbB bacteria, suggesting that CtDsbA cannot 
complement EcDsbA deficiency in E. coli. 
 
Figure 2.3 CtDsbA does not complement EcDsbA.  
dsbA null E. coli are unable to swarm on soft agar. Exogenous expression of EcDsbA under an 
arabinose inducible promoter is able to complement this non-motile phenotype as shown by the 
swarming halo around the original inoculation point (upper panel, EcDsbA induced). CtDsbA is not 
able to restore the phenotype. Neither EcDsbA nor CtDsbA is able to restore mobility in a 
ecdsbA/ecdsbB double null E. coli strain (lower panels) indicating the requirement for EcDsbB to 
maintain a pool of oxidised DsbA.  
2.6.8 The crystal structure of CtDsbA features an uncommon dipeptide 
catalytic motif  
We solved the crystal structure of CtDsbA, which was determined to 2.7 Å resolution by using 
molecular replacement methods. The resulting model was refined to a final Rfactor and Rfree of 24.8 % 
and 28.2 %, respectively. Full details of data collection and refinement parameters, and additional 
model quality indicators can be found in Table 2.1.  
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Table 2.1 X-ray data measurement and refinement statistics for CtDsbA  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Values in parentheses refer to the highest resolution shell 
Data collection and processing 
Wavelength (Å) 1.54187    
Resolution range (Å) 43.3-2.7 (2.8-2.7) 
Space group P 21 21 2 
Unit cell (Å, °) 92.2  98.1   44.8   90.0   90.0   90.0 
Rmerge 0.101 (0.401) 
Rmeas (within I+/I-) 0.110 (0.429) 
Rmeas (all I+ & I-) 0.109 (0.432) 
Total number of observations 82358 (737) 
Total number unique 11646 (102) 
Mean((I)/sd(I)) 19.6 (5.9) 
Mn(I) half-set correlation CC(1/2) 0.998 (0.880) 
Completeness (%) 100 (86.4) 
Multiplicity 7.1 (7.2) 
Refinement and model quality 
Refinement  
R-factor (%) 24.76 (30.84) 
R-free (%) 28.23 (38.54) 
Number of atoms 6176 
  Macromolecules 3083 
  Ligands  
  Water 22 
Protein residues 390 
R.M.S.D from ideal geometry 
RMS(bonds) (Å) 0.003 
RMS(angles) (°) 0.69 
Molprobity analysis 
Ramachandran favored (%) 96.84 
Ramachandran outliers (%) 0.26 
Clashscore* 6.36 (100th percentile* (N=186, 2.706 Å ± 0.25Å)) 
Molprobity score** 1.74 (100th percentile* (N=5290, 2.706 Å ± 0.25Å) 
Average B-factor (Å2) 45.90 
  Macromolecules 45.90 
  Solvent 44.20 
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‡ , where defines the unique reflections 
§ Rfree calculated over 5.0 % of total reflections excluded from refinement 
* Clashscore: 100th percentile is the best among structures of comparable resolution; 0th percentile 
is the worst. For clashscore the comparative set of structures was selected in 2004, for MolProbity 
score in 2006 
** MolProbity score combines the clashscore, rotamer, and Ramachandran evaluations into a single 
score, normalised to be on the same scale as X-ray resolution. 
Consistent with all structurally characterised DsbA proteins, CtDsbA comprises a thioredoxin domain 
into which a second helical domain is inserted (Figure 2.4A). The catalytic face of DsbA proteins is 
composed of a canonical Cys-Xaa-Xaa-Cys motif (where Xaa is any amino acid) positioned at the N-
terminal end of H1, and three additional neighboring loops: Loop 1 (linking B3 and H2), the so-called 
cisPro Loop 2 (linking H6 and B4) and Loop 3 (linking B5 and H7) (Figure 2.4A). Together these 
loops determine DsbA enzymatic activity, modulate redox character and govern interactions with 
both substrate proteins and the redox partner protein DsbB [195].  
 
In CtDsbA, the active site motif is Cys-Ser-Ala-Cys (Figure 2.4B). Commonly the active site motif 
of DsbA proteins features a Pro at the X1 position: 78 % of DsbA proteins identified in prokaryotic 
genomes have a Pro at this position [89]. Furthermore the active site motif commonly includes an 
aromatic, polar or positively charged side chain at position X2 (just 13 % of DsbA proteins identified 
in prokaryotic genomes lack such a residue at this position [89]). Via extensive mutational and 
biochemical analyses it has been established that the dipeptide sequence is a very important – 
although not the sole - determinant of thiol-disulfide oxidoreductase potential and function [71, 212, 
213]. CtDsbAs dipeptide sequence is notable in that it lacks a Pro at X1 and has a non-polar aliphatic 
residue (Ala) at X2. This is the first structural description of such an active site configuration. In the 
crystal structure Cys38 and Cys41 are oxidised, with a disulfide bond length of 2.03 Å (Figure 2.4B). 
This is unusual in that X-ray crystal structures of oxidised DsbA proteins often capture a radiation-
induced reduced state (e.g. [57]). The electron density maps for CtDsbA clearly support the presence 
of the oxidised form (Figure 2.4C). 
 
 
 
Rfactor = Fobs h − Fcalc hh∑ / Fobsh∑ h h
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Figure 2.4 Crystal structure of CtDsbA.  
A) The crystal structure of CtDsbA contains a thioredoxin domain (light green) and a helical domain 
(dark green.) Loops on the catalytic surface that constitute the active site of CtDsbA and determine 
redox activity are colored orange and labeled. The active site catalytic disulfide is highlighted with 
sulfurs shown as yellow spheres. The non-catalytic disulfide (between Cys84 and Cys145) and the 
single thiol (Cys70) in L1 are shown in stick representation. The most N-terminal region of CtDsbA 
is unstructured. Crystal packing interactions with the second monomer in the asymmetric unit and a 
symmetry related molecule (shown in white) stabilise this region of the protein such that is well 
resolved in the electron density map.  B) Close view of the four loops (L1, cisPro L2, L3 and the Cys-
Ser-Ala-Cys motif) which constitute the active site surface of CtDsbA. C) In the crystal structure the 
active site cysteines are oxidised. Analysis of bond distances indicates that the Cys 38 thiolate could 
be stabilised by favorable bond interactions with Thr 172 (3.4 Å between Thr 172 OH and Cys 38 SG 
in the oxidised structure) of the neighboring cisPro L2 consistent with an oxidising protein character. 
The Cys 41 sulfur atom is 3.5 Å from the Thr 172 hydroxyl in the oxidised structure. 2Fo-Fc and Fo-
Fc electron density maps for the active site and cisPro Loop 2 were generated from calculated phases 
using phenix.maps and are shown contoured at 1.0 σ and 3.0 σ respectively. The maps are shown 
within a 1 Å radius of each atom of each loop.  
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Spatially close to the active site CSAC motif is the cisPro L2 loop (3) (Ala-Thr-cisPro) connecting 
H6 and B4. This motif (typically Xaa-Val/Thr-cisPro, where Xaa is usually an aliphatic residue) is 
very highly conserved among DsbA homologs and is critical for activity. In the oxidised CtDsbA 
structure the Cys 38 sulfur atom is 3.6 Å from the carbonyl oxygen and 3.3 Å from the side chain 
hydroxyl of the cisPro-1 residue Thr 172 (Figure 2.4C). As with other DsbA proteins, it is conceivable 
that in the reduced form these atoms may facilitate hydrogen bond mediated stabilisation of the 
enzyme. We note that the Cys 38 sulfur is 3.3 Å from the side chain hydroxyl of Thr 172, which is 
within the range of observed atomic distances (3.1 – 4.6 Å) for DsbA proteins [96]. 
 
L1 and L3 play a role in partner protein interaction in other DsbA proteins. In CtDsbA L1 is 7 residues 
in length (Val-Cys-Phe-Ile-Arg-Gly-Ser) and is oriented towards the active site. Notably L1 contains 
an unpaired cysteine residue, which to our knowledge is the first structural report of an unpaired 
cysteine in a surface loop adjacent to the active site in DsbA (Figure 2.4). In EcDsbA, Loop 1 residues 
contribute to the binding interface with EcDsbB. In particular when Met 64, located in the middle of 
EcDsbA L1, is mutated to Ala the KM of the DsbA-DsbB interaction is significantly increased [64]. 
In CtDsbA, Cys 70 is positioned at the C-terminus of the B3 strand, and directed towards Ser 75 and 
Met 76 of the adjacent H2; as the side chain of Cys 70 is relatively buried in comparison to Cys 38 it 
is unlikely to play a role in interaction with substrate or redox partner proteins unless this loop 
undergoes a significant conformational change during the catalytic cycle. Finally CtDsbA Loop 3, 
connecting B5 and H7 is short (Asp184-Pro185-Tyr186) and adopts a tight turn facilitated in part by the 
central proline residue.  
2.6.9 CtDsbA has a negatively charged catalytic surface without significant 
pockets 
Unlike EcDsbA and other enterobacteriaciae DsbA proteins, CtDsbA does not have a pronounced 
groove along its active site surface, nor are there notable pockets adjacent to the active site (Figure 
2.5A). Small discrete pockets are present on the non-catalytic face sandwiched between H1 and H3 
(pocket 1), and formed between the long N-terminal extension and H6 (pocket 2) (Figure 2.5A). 
Inspection of the electrostatic potential of the active site surface indicates it to be predominantly 
acidic. Of particular note is the highly acidic patch immediately adjacent to the active site cysteines 
on the catalytic surface (Figure 2.5B).  
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Figure 2.5 Surface properties of CtDsbA.  
A) Surface representation for CtDsbA of the catalytic (left) and non-catalytic (right) faces. The active 
site residues Cys-Ser-Ala-Cys are colored yellow and the nucleophilic cysteine sulfur highlighted in 
orange. Pockets formed on the posterior face of the protein between H1 and H3 (pocket 1) and the 
N-terminal unstructured region and H6 (pocket 2) are labeled. B) Electrostatic surface 
representation of CtDsbA. Views are oriented as above. Electrostatic surface potential is contoured 
between -5 (red) and +5 (blue) kT/e. The nucleophilic cysteine is annotated with an S. 
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2.6.10 CtDsbA has a second non-catalytic disulfide bond 
Notably CtDsbA has a second disulfide bridge formed between Cys 84 (H2) and Cys 145 (H5) 
stapling this helical bundle (Figure 2.4A and Figure 2.6). A similar non-catalytic disulfide has been 
observed previously in the structures of WpDsbA1 [80], MtbDsbA [78] and PaDsbA2 [75]. 
Superposition of these four structures reveals that the position of this non-catalytic disulfide is highly 
similar among these four structures in each case linking equivalent helices (Figure 2.6). 
 
 
 
Figure 2.6 CtDsbA has a second non–catalytic disulfide bond.   
A) CtDsbA (green) is structurally most similar to WpDsbA1 (light blue), MtbDsbA (pink) and 
PaDsbA2 (orange) although it features an extended N-terminal unstructured region and lacks an 
additional eighth C-terminal helix present in MtbDsbA (not visible in this orientation.) Each of the 
four structures has a second non-catalytic disulfide bond which are very similarly positioned bracing 
H2 and H5 (or equivalent helices in PaDsbA2), the location of which is highlighted by a rectangular 
box. For clarity, depth cueing has been applied to focus on the foreground of the superimposed 
structures. B) Enlarged view of H2 and H5 and the non-catalytic disulfide bonds in each of the four 
superimposed structures. The view is oriented as in the rectangular box in panel A. 
CtDsbA is the fourth structure of a DsbA protein with a second (structural) disulfide bond, permitting 
a detailed examination of these enzymes as a group.  Overall the sequence identity of CtDsbA, 
WpDsbA1, PaDsbA2 and MtbDsbA is modest (15-2 %; Figure 2.7, Table 2.2) The cisPro Ala-Thr-
Pro motif is conserved among the four proteins but the active site dipeptide is different in each and 
there is only limited sequence similarity in the residues immediately following the non-catalytic 
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cysteines. Structurally they are similar overall, superimposing on CtDsbA with a RMSD of 2.5 - 2.6 
Å (for 163-176 equivalent Ca atoms) (Table 2.2) although MtbDsbA is distinct at its C-terminus 
where it has an additional and unique eighth helix. Aside from this, structural differences are confined 
to loop regions. CtDsbA has a particularly extended and disordered C-terminus and two elongated 
loop regions: residues 128-137 linking H4 and H5, and 88-94 linking H2 and H3 relative to the other 
proteins. These loops are aligned in a parallel manner adjacent to one another creating a horse shape 
protrusion on the back of the protein, encasing a number of small pockets.  
2.6.11 Classification of CtDsbA 
DsbA proteins have previously been segregated into distinct structural classes [96]. Assignment to 
one of the two major classes (DsbA-I and DsbA-II) is defined primarily by the b-sheet topology of 
the thioredoxin domain [96]. In the thioredoxin domain of CtDsbA, B1 hydrogen bonds to B3 to give 
a b-sheet topology of 1-3-2-4-5, assigning CtDsbA to the DsbA-II enzyme class. Previously identified 
members of DsbA-II include DsbA from the Gram positive species S. aureus and B. subtilis, the acid 
fast bacteria M. tuberculosis and the endosymbiont Gram negative species W. pipientis. Consistent 
with its assignment to DsbA-II, interrogation of the Protein Data Bank using DaliLite [214] identified 
that CtDsbA is structurally similar to the DsbA-II proteins B. subtilis BdbD (PDB ID 3EU3, 1.9 Å 
rmsd, 28 % sequence identity) and W. pipientis DsbA1 (PDB ID 3F4R, 2.3 Å rmsd, 20 % sequence 
identity) as well as PaDsbA2  (PDB ID 4N30, 2.6 Å rmsd, 15 % sequence identity) which although 
not previously classified also shares the b-sheet topology of other DsbA-II proteins and a second non-
catalytic disulfide bond observed in 3 of the 4 previously assigned DsbA-II proteins (Figure 2.4, 
Table 2.2) 
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2.7 Discussion 
In the present study we demonstrate that the C. trachomatis encodes a DsbA protein (Gene ID 
5858475 (UniProt CTL0429), which has oxidase activity and the structural features of a DsbA-II type 
protein. The weak activity of CtDsbA in the insulin reduction assay relative to EcDsbC, suggests that 
CtDsbA is a thiol disulfide oxidase and not an isomerase. Consistent with this, CtDsbA is able to 
oxidise the folding of a model peptide substrate in vitro, albeit less efficiently than the canonical 
oxidase EcDsbA.  Our finding that CtDsbA is significantly less active than the isomerase EcDsbC in 
the ScRNase assay further supports the assertion that CtDsbA is an oxidase without disulfide 
isomerase activity.  
 
Heterologous complementation studies shows that CtDsbA is not able to complement EcDsbA 
deficient E. coli. However this is not unprecedented among DsbA proteins. The DsbA-II proteins 
MtbDsbA and WpDsbA1, as well as the DsbA-Ib protein N. meningitis DsbA3 (NmDsbA3) are all 
DsbA proteins that are not able to complement EcDsbA deficiency. In common with CtDsbA these 
proteins are relatively structurally distinct from EcDsbA (RMSD between 2.76 and 3.71 Å, over 152-
175 Ca atoms). Successful rescue of function relies upon an ability of the exogenous DsbA to interact 
with both the substrate flagella proteins and EcDsbB. The observed structural diversity may preclude 
one or both interactions and explain why they are not able to rescue DsbA activity in dsbA deficient 
E. coli. 
 
Whilst DsbAs can be broadly very similar in their structure and function, the redox character of 
individual enzymes can vary considerably [195]. Like other DsbA proteins CtDsbA active site has a 
destabilising disulfide bond that lowers the melting temperature of the oxidised protein by 4 K relative 
to the reduced state. Tm differences between oxidised and reduced DsbAs range from 1 (SaDsbA) to 
15 K (NmDsbA1) (Table 2.3). This puts CtDsbA at the lower end of the range of a destabilising 
disulfide placing it between SaDsbA, which, with a ΔTm of 1 K has a melting temperature that is 
barely affected by oxidation [62], and WpDsbA1 with a ΔTm of 6 K. Furthermore it suggests that the 
destabilising effect of oxidation in CtDsbA is relatively mild compared to that of the enterobacterial 
DsbAs (ΔTm of 8 – 12 K for EcDsbA, SeDsbA and KpDsbA) or NmDsbA1 (ΔTm 15 K). The redox 
potential of CtDsbA is -229 mV. This is substantially less oxidising than that of EcDsbA (-122 mV) 
and is to our knowledge, the most reducing redox potential reported for a DsbA protein. It is most 
similar to the redox potential of WpDsbA1 (-163 mV), and approaches that of the reducing enzyme 
thioredoxin (-270 mV, [215, 216]. 
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Figure 2.7 Sequence alignment of DsbAs with two disulfide bonds.  
Sequence alignment of structurally characterised DsbAs with two disulfide bonds. Sequences were 
aligned using Clustal Omega and visualised using ESPript 3.0 [217]. Secondary structural elements 
are shown for the structure of CtDsbA. Disulfide bonds are indicated with black connecting lines and 
labeled S-S. The single unpaired cysteine C70 is highlighted in yellow.  
The reactivity of DsbA proteins is greatly influenced by the pKa of the nucleophilic active site 
cysteine. In reduced EcDsbA the thiol group of the surface exposed Cys 30 has a pKa of 3.3 [192] 
which is notably lower than the typical value for a cysteine residue (~8.5). Preliminary experiments 
indicate that the pKa of the nucleophilic cysteine in CtDsbA is slightly higher than that of EcDsbA. 
This observation is based on a single experiment (described in Methods) that could not be reliably 
repeated due to the instability of oxidised CtDsbA below pH 7. Thus the pKa of the nucleophilic 
active site cysteine Cys38 in CtDsbA has not been determined. The interatomic distances suggests 
that the thiolate anion is somewhat stabilised by hydrogen bond interactions with the Cys41 amide N 
(2.8 Å in the oxidised structure) and the active site dipeptide X2 Ala40 amide N (3.6 Å distance in 
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the oxidised structure, Figure 2.4C) as is observed in other DsbA proteins (summarised in [96]). 
However, the primary factor stabilising the nucleophilic thiolate in dithiol oxidoreductases is the N-
helix dipole of H1 [71, 218], which is very sensitive to the microenvironment of the helix terminus. 
 
Table 2.3 Comparison of melting temperatures, pKa and redox potential of different DsbA 
proteins 
 
Errors are provided were available. ND Not determined.  
 Tm(K) 
reduced 
Tm (K) oxidised pKa Keq (M) E° (mV) 
EcDsbA [70, 192] 350.9 ± 0.2 341.7 ± 0.2 3.3 ± 0.09 8.1 ± 0.2 × 10-5 -122 
SeDsbA [195] 351.2 ± 0.2 342.8 ± 0.4 3.3 ± 0.06 12.8 ± 0.3 × 10-5 -126 
KpDsbA [78] 347.1 ± 0.2 335.8 ± 0.3 3.2  6.14 ± 0.1 × 10-5 -116 
VcDsbA [76],[219] 357 ± 0.2 346 ± 0.2 5.1 7.7 ± 0.03 × 10-5 -116 
NmDsbA1 [77] 348 ± 2 333 ± 2 3.0 3.7 × 10-6 -79 
SaDsbA [84] 345.1 ± 0.08 345.6 ± 0.09 3.4 ± 0.07 2.09 ± 0.27 × 10-
4 
-131 
MtbDsbA [78] ND ND 4.2 ± 0.2 17.37 ± 0.1 × 10-
6 
-99 
WpDsbA1 [80] 337 ± 0.05 331 ± 0.05 4.7 ± 0.08 2.2 ± 0.27 × 10-3 -163 
CtDsbA 339 ± 0.2 335 ± 0.1 ND 3.7 ± 0.8 × 10-4 -229 
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Notably an uncharged aliphatic Ala at position X2 of the active site dipeptide in CtDsbA would not 
destabilise the N-helix dipole as per His 32 in EcDsbA [218]. Nor can it offer direct electrostatic 
stabilisation of the thiolate anion as per a basic [63] or aromatic amino acid (via a sulfur-aromatic 
ring interaction [213] at this position). Similarly the lack of a helix breaking proline in the active site 
dipeptide removes enhancement of the H1 dipole proposed to occur in other more oxidising DsbA 
proteins [69, 213]. Together the apparent lack of factors in CtDsbA to destabilise the oxidised form 
of the protein, or conversely to stabilise the nucleophilic thiolate in the reduced state, is consistent 
with both the relatively small difference in Tm between oxidised and reduced CtDsbA, and the less 
oxidising redox potential relative to EcDsbA and other CPHC dipeptide containing DsbA proteins.  
 
CtDsbA, WpDsbA1, PaDsbA2 and MtbDsbA all have a non-catalytic disulfide in the helical domain, 
in addition to the active site catalytic disulfide [75, 78, 80]. The functional consequence of the second 
disulfide bond in CtDsbA is unknown but in WpDsbA1 it may play a regulatory role by autoinhibiting 
its reoxidation by WpDsbB (25). In PaDsbA2 it is reported to influence the redox potential of the 
active site cysteines [75] as mutation of the second disulfide results in reduction of redox potential 
from -67 mV to -118 mV [75]. However, this is not the case in WpDsbA1 where deletion of the 
additional cysteines has a very modest effect on redox potential (-170 mV for wild-type and -163 mV 
for the mutant [80]), although it is associated with a small increase in the pKa (pKa of 4.7 for the wild-
type and 5.0 for the mutant) of the nucleophilic cysteine [80]. MtbDsbA and wild-type PaDsbA2 have 
strongly oxidising redox potentials (-99 mV and -67 mV respectively) whereas WpDsbA1 and 
CtDsbA are the two most reducing DsbA proteins characterised to date. Together this suggests that 
the second disulfide is not a significant modifier of redox potential for enzymes containing two 
disulfides. Instead it is more likely that differences in redox character are a composite of contributing 
factors including the nature of the dipeptide sequence in the catalytic motif. 
 
In the present study, we used a recombinant expression construct with five cysteines (one unpaired). 
In the full-length gene there is an additional cysteine in a predicted transmembrane region. In light of 
the predicted location of the additional cysteine, and the relative inaccessibility of the unpaired Cys 
70 it appears unlikely that the N-terminal transmembrane cysteine and Cys 70 would interact with 
one another in the native protein. The high cysteine content is notable relative to other DsbAs, and 
may be a feature of chlamydial DSB proteins more generally; Chlamydia pneumoniae DsbH, a 
reducing dithiol oxidoreductase with structural similarity to thioredoxin and EcDsbDγ has seven 
cysteine residues, of which only two are engaged in a disulfide bond [107]. Interestingly the 
chlamydial proteome has striking cysteine and disulfide features more generally; for example, during 
its unique developmental cycle the bacteria adopt an extracellular infectious form called an 
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elementary body which is encapsulated by a highly complex envelope of disulfide cross linked 
proteins [146]. Upon infection of a host cell, these disulfide bonded proteins are reduced and the 
elementary body differentiates into reticulate bodies [146]. Additionally, a greater proportion of 
secreted proteins in C. pneumoniae have an unpaired number of cysteines (57 %) compared to that 
of E. coli (39 %). This has led to a hypothesis that chlamydial species may maintain a particularly 
reducing periplasmic environment in order to prevent misfolding of cysteine rich proteins. If so, this 
may be supported in C. trachomatis by the relatively low redox potential of CtDsbA.  
 
Based on its topology we assign CtDsbA to the DsbA-II class of enzymes. DsbA-II type enzymes can 
be further separated into two sub-divisions (DsbA-IIa and DsbA-IIb) on the basis of catalytic surface 
loop configurations and surface features. The archetypal DsbA-IIa protein is MtbDsbA in which Loop 
1 is oriented towards the active site motif and the protein surface is decorated with negative potential 
[96]. Until now WpDsbA1 has been the single representative member of the DsbA-IIb subdivision 
distinguished primarily from DsbA-IIa by its strikingly positive electrostatic potential around the 
active site, and Gram negative origin. Notably the L1 configuration in DsbA-IIb also points towards 
the active site; and the same conformation is adopted in CtDsbA. Similar to currently identified 
DsbA-II proteins the surface of CtDsbA lacks the canonical grooves observed in DsbA-I (either along 
the catalytic surface (DsbA-Ia) or the posterior face of the protein (more typical of DsbA-Ib.) CtDsbA 
is strikingly charged near its active site with a pronounced patch of negative potential in this region. 
Taken together the structural features of CtDsbA and similarity to other DsbA-II proteins do not 
definitively assign CtDsbA to one of the two DsbA-II subclasses: whilst structurally more similar 
overall to DsbA-IIa’s MtbDsbA with a similarly negatively charged catalytic surface, its Gram 
negative origin and more reducing redox potential is more consistent with that of WpDsbA1 and 
DsbA-IIb. It is possible that DsbA-II proteins represent a broader continuum of structural features 
not yet fully captured by the current repertoire of structures. We await further population of the DsbA-
II class before definitively sub-categorising CtDsbA.  
 
In conclusion, we have demonstrated that C. trachomatis encodes a DsbA protein with oxidase 
activity. The structure of CtDsbA yields new insight into the protein’s relatively negative redox 
potential and our observation that the oxidised form of CtDsbA is only mildly destabilised relative to 
the reduced form. This characterisation of CtDsbA expands our understanding of the range of redox 
activities exhibited by DsbAs. Further it is a significant addition to a growing structural library of 
DsbA proteins, supporting ongoing exploration of the potential for development of narrow or broad 
spectrum antimicrobials against this important family of virulence-associated proteins [111], 
[112],[74],[96].  
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3.1 Introduction 
My studies of a soluble CtDsbA construct presented in Chapter 2 revealed that CtDsbA is a protein 
dithiol oxidase, though it is less oxidising than other characterised DsbAs. Identification of a homolog 
of EcDsbB in C. trachomatis (CtDsbB) suggests that CtDsbA and CtDsbB constitute a redox pair in 
the oxidative pathway of C. trachomatis thereby resembling the oxidative pathway in E. coli and 
other Gram-negative bacteria. Consequently, the role of CtDsbA would be to catalyse the formation 
of disulfide bonds in folding proteins. Considering the important role of disulfide cross-linking in 
chlamydial infection and its developmental cycle, it is possible that CtDsbA has a specialised role in 
C. trachomatis. For example, oxidising the cysteines in the Chlamydial Outer Membrane Complex 
(COMC). If CtDsbA is involved in disulfide formation of the COMC, regulation of CtDsbA oxidase 
activity might be important to ensure that oxidation of the COMC proteins occurs at the correct time 
in the developmental cycle.  
 
Interestingly, CtDsbA is one of three characterised DsbAs with an extra disulfide i.e. additional to 
the active site disulfide. The effect of the second disulfide on redox properties has been characterised 
in WpDsbA1 and PaDsbA2. In WpDsbA1 the additional disulfide has been shown to inhibit the 
interaction with the partner protein WpDsbB, but has limited to no effect on intrinsic redox properties 
[108]. In contrast the second disulfide increases the redox potential of PaDsbA2 to           -68 mV 
from -118 mV for a construct with only the active site cysteine present [75]. The additional disulfide 
of CtDsbA could potentially play a role in regulating CtDsbA activity or the interaction with CtDsbB. 
Alternatively, it might stabilise the fold of CtDsbA.  
 
In this chapter the interaction between CtDsbA and CtDsbB is investigated to shed light on 
similarities as well as differences between the oxidative pathways in E. coli and C. trachomatis. To 
gain insight into the potential role of DsbA in regulating the redox state of the COMC proteins, the 
expression levels of CtDsbA are determined during replication, and during reticulate body (RB) to 
elementary body (EB) differentiation. Further, the role of the second disulfide in stability, as well as 
regulation of the interaction with CtDsbB, is studied. 
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3.2 Materials and methods 
3.2.1 Expression and purification of soluble proteins 
CtDsbA and CtDsbA-SSS were produced as described in Chapter 2 section 2.5.1 
3.2.2 Expression, membrane preparation, solubilisation and purification of 
membrane proteins 
CtDsbB SSCC was designed by mutating Cys36 and Cys39 in CtDsbB (NCBI Gene ID 471472) to 
serines. CtDsbB CCSS was designed by mutating Cys98 and Cys104 in CtDsbB to serines. CtDsbB 
and mutants were purchased as gBlocks (Integrated DNA technologies) with a 5’ XhoI and a 3’ NdeI 
restriction site for insertion to a pET21a vector. All constructs were expressed in E. coli C41 cells 
using PASM 5052 autoinduction media [199] containing ampicillin and grown at 30 °C for 18-24 h 
with orbital shaking at 200 rpm. Harvested cells were resuspended in 25 mM Tris pH 8.5,  150 mM 
NaCl and lysed using a cell disrupter (Constant Systems Ltd) (one passage at 28 Kpsi followed by a 
second passage at 30 Kpsi). Unbroken cells and debris were removed by centrifugation at 16,000 x 
rpm for 10 min. Membranes were harvested from the supernatant by ultracentrifugation (40,000 x 
rpm for one hour) at 4 °C. The pellet was resuspended in 25 mM Tris pH 7.5, 150 mM NaCl using a 
glass homogeniser. Membranes were solubilised in 137 mM, 10 mM phosphate, 2.7 mM KCl, pH 7.4 
(PBS) with 1 % n-dodecyl-β-D-maltoside (DDM) by vigorous stirring at 4 °C. Solubilised 
membranes were ultracentrifuged for one hour at 40,000 x rpm at 4 °C. Protein purity, size and 
quantification were verified by NuPage 12% Bis-Tris SDS PAGE (Thermofisher). Solubilised 
membranes were loaded onto a 5 mL HisTrapTM HP column (GE Healthcare) equilibrated in 1 x PBS, 
0.03 % DDM and 20 mM imidazole.  The column was washed with the above buffer plus 40 mM 
imidazole (10 x column volume (CV)), 80 mM imidazole (10 x CV) and eluted with 160 mM 
imidazole (5 x CV). Eluted protein was further purified by size exclusion chromatography using a 
SuperdexTM 200 16/60 column (GE Healthcare). Protein purity was evaluated on a NuPAGE 12% 
Bis-Tris SDS PAGE (Thermofisher) with MES running buffer (50 mM 2-(N-morpholino) 
ethanesulfonic acid (MES) pH 7.3, 50 mM Tris, 0.1 % sodium dodecyl sulfate (SDS) and 1 mM 
Ethylenediaminetetraacetic acid (EDTA). 
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3.2.3 Peptide oxidation assay  
The peptide oxidation assay was performed as described in Chapter 2 section 2.5.3. Membranes 
containing CtDsbB, CtDsbB SSCC or CtDsbB CCSS (8 µM) were used instead of oxidised 
glutathione (GSSG).  
3.2.4 Determination of redox state of CtDsbA, CtDsbA-SSS and EcDsbA 
Reduced EcDsbA, CtDsbA or CtDsbA-SSS (30 µM) were mixed with EcDsbB or CtDsbB (50 nM) 
and UQ-1 (30 µM) in 50 mM NaPO4 pH 8.0, 100 mM NaCl, and 0.1 % DDM in a total volume of 
100 µL. 5 µl samples were taken immediately after adding EcDsbB/CtDsbB, and then after 5, 20, 60 
and 120 min incubation, before trichloroacetic acid (TCA) mediated precipitation and labelling with 
4-acetamido-4’-maleimidylstilbene-2,2’-disulfonic acid (AMS) as described in Chapter 2 section 
2.5.7.  
3.2.5 Relative stability of oxidised and reduced forms of CtDsbA-SSS 
The thermal stability of reduced and oxidised CtDsbA-SSS was determined by Circular Dichroism 
(CD) spectroscopy as described in Chapter 2 section 2.5.6. 
3.2.6 Absorbance spectrum of DsbB proteins 
Absorbance was measured on a Cary WinUV spectrophotometer (Agilent) between 800 nm and 300 
nm with a scan speed of 300 nm/min. The absorbance spectrum for the CtDsbB constructs and 
EcDsbB were measured in 1 x PBS and 0.03 % DDM. The spectrum for BpsDsbB was measured in 
1 x PBS, 0.3 % DM and 10 % glycerol. BpsDsbB SSCC and BpsDsbB CCSS were measured in 25 
mM MES pH 6.5, 150 mM NaCl and 0.15 % Decyl Maltoside. Absorbance spectra were taken for 
the buffers alone as a baseline control. The plotted data shows the buffer subtracted spectra.  
3.2.7 Investigation of CtDsbA expression levels by confocal microscopy 
Coverslip cultures of C. trachomatis LGV-2 infected McCoy cells were fixed with 100 % methanol 
for 10 min after 20 h, 32 h and 44 h of infection and imaged using immunofluorescence with a Nikon 
A1 microscope. Cultures were stained with an anti-CtDsbA monoclonal antibody raised in rabbit and 
a secondary goat anti-rabbit IgG fluorescein isothiocyanate (FITC) antibody. The host cell nucleus 
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was stained with DAPI, and host cell cytoskeleton was stained with Alexa Fluor 594 Phalloidin. 
Coverslips were mounted on slides in Prolong Gold (Invitrogen) prior to visualisation. 
3.3 Results 
3.3.1 The C. trachomatis genome encodes a protein with 22 % sequence identity 
to EcDsbB 
A BLAST search for EcDsbB against the C. trachomatis genome (NCBI Taxid: 813) revealed a 
protein of 136 amino acids with 22 % sequence identity with EcDsbB (Figure 3.1). This protein will 
be referred to as CtDsbB. 
 
CtDsbB is predicted to have four transmembrane helices (TM1-4) and two periplasmic loops 
(TMHMM [93]) equivalent to the topology in EcDsbB. However, loop P2 is significantly shorter in 
CtDsbB than in EcDsbB (Figure 3.1).  
 
 
Figure 3.1 Sequence alignment of DsbB from E. coli and C. trachomatis.  
Sequence alignment of EcDsbB and CtDsbB performed in Clustal Omega [105]. Membrane topology 
prediction (TMHMM [93]) shows that CtDsbB, like EcDsbB, has four predicted transmembrane 
helices, TM1-4 (blue) and two predicted periplasmic regions, P1 and P2 (black arrow) each 
containing two cysteine residues (yellow). Other cysteines are highlighted in green. “*” indicates 
fully conserved residues. Residues with highly similar properties (above 0.5 in the Gonnet PAM 250 
matrix) are marked with “:”. Residues with weakly similar properties (below 0.5 in the Gonnet PAM 
250 matrix) are marked with “.”. 
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CtDsbB has ten cysteine residues compared to six cysteine residues in EcDsbB. Five of the cysteines 
in CtDsbB are embedded in the predicted transmembrane regions and one is located in the 
cytoplasmic N-terminal region. Similar to the arrangement of the catalytic cysteines in EcDsbB, the 
remaining four cysteines are located in the two periplasmic loops and at the N-terminal end of TM2. 
The location of Cys36 in loop P1 and Cys39 in the N-terminal of TM2 is equivalent to the location 
of the CXXC motif in EcDsbB. By comparison to EcDsbB, the periplasmic exposed cysteines Cys98 
and Cys 104 are likely to be equivalent to the Cys104-Cys130 redox pair in loop P2 of EcDsbB 
(Figure 3.1). The similarity in sequence and topology with EcDsbB suggests that CtDsbB is a redox 
partner for CtDsbA. However, the difference in P2 loop length between CtDsbB and EcDsbB might 
influence the specific mechanism of CtDsbB catalysis. Loop P2 in EcDsbB contains a membrane 
parallel helix separating Cys104 and Cys130 of EcDsbB [101]. As Cys104 and Cys130 are 10 Å apart 
when the intermolecular disulfide bond between EcDsbA and EcDsbB are present, the physical 
separation of Cys104 and Cys130 prevents reoxidation of the Cys104-Cys130 disulfide. This ensures 
that oxidation of the active site disulfide of EcDsbA proceeds despite this reaction being less 
energetically favourable than reoxidation of the Cys104-Cys130 disulfide bond of EcDsbB [64]. Due 
to the short P2 loop in CtDsbB, a membrane-parallel helix is unlikely to be formed in CtDsbB. 
Secondary topology prediction of loop P2 by Jpred [220] supports the lack of a helix in loop P2 in 
CtDsbB. The proposed catalytic cysteines in loop P2 of CtDsbB, Cys98 and Cys104, are only 
separated by four residues compared to 25 residues separating Cys104 and Cys130 in EcDsbB. The 
short distance between Cys98 and Cys104 further impairs separation of the two cysteines. 
Considering the important role of loop P2 in separating the cysteines for EcDsbB catalysis, the shorter 
loop might suggest a modified mechanism of CtDsbB mediated oxidation of CtDsbA compared with 
that of EcDsbB and EcDsbA. Conservation of Arg48 and Met142, residues proposed to be involved 
in ubiquinone (UQ) binding in EcDsbB, suggests that CtDsbB is likewise capable of binding UQ. 
 
Both periplasmic loop disulfides in EcDsbB are required for oxidation of EcDsbA. To investigate 
whether the mechanism of CtDsbA oxidation by CtDsbB is similar to that seen in E. coli, two CtDsbB 
mutants were designed with the cysteines in loop P1 and loop P2, respectively, mutated to serines 
(Figure 3.2). In CtDsbB SSCC Cys36 and Cys39 are mutated to serines. In CtDsbB CCSS Cys98 and 
Cys104 are mutated to serines. 
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Figure 3.2 Design of CtDsbB periplasmic loop mutants. 
 CtDsbB (blue) is predicted to have four transmembrane helices (TM1-4) with two short periplasmic 
loops between TM1 and TM2 and between TM3 and TM4 respectively (P1 and P2). Each of the 
periplasmic loops contains two cysteines (yellow). In CtDsbB SSCC the cysteines in periplasmic loop 
P1 are mutated to serines (red). In CtDsbB CCSS the cysteines in periplasmic loop P2 are mutated 
to serines (red). EcDsbB (green) has four transmembrane helices and a periplasmic loop P1 of 
similar length to CtDsbA. Periplasmic loop P2 is significantly longer in EcDsbB and contains a short 
membrane parallel helix, which is likely absent in CtDsbB. 
3.3.2 Membranes containing CtDsbB facilitate CtDsbA activity 
E. coli membranes containing heterologously expressed CtDsbB, CtDsbB SSCC or CtDsbB CCSS 
were prepared and tested for their ability to facilitate CtDsbA oxidation of a synthetic fluorescently 
labelled peptide substrate (Figure 3.3). Adding membranes containing CtDsbB to CtDsbA gives rise 
to an increase in fluorescence as the peptide is oxidised. This indicates that the two proteins form a 
functional redox relay that enables CtDsbA to oxidise the cysteines in the peptide (Figure 3.3). 
However, the initial reaction rate is only 234±23 relative fluorescence unit (RFU)/s for CtDsbA and 
CtDsbB containing membranes (Table 3.1), compared to 2110 ±250 RFU/s for the redox relay formed 
between EcDsbA and membranes containing EcDsbB (Table 3.1). This suggests that CtDsbA is less 
active in the assay upon interaction with CtDsbB than the EcDsbA and EcDsbB counterparts. The 
initial rate for reactions containing only CtDsbA, or only membranes containing CtDsbB is 2.7±0.3 
RFU/s and 9.5±0.2 RFU/s, respectively. These values are equivalent to the initial rate measured for 
the buffer only control (6.2±0.2 RFU/s) confirming that neither CtDsbA nor the membranes 
containing CtDsbB can significantly oxidise the synthetic peptide on their own (Figure 3.3 and Table 
3.1). 
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Table 3.1 Initial rates, VI, of peptide oxidation catalysed by DsbA upon interaction with DsbB 
constructs. 
 
DsbA DsbB VI (RFU/s) 
None None 6.2±0.2 
EcDsbA EcDsbB 2110±250 
CtDsbA None 2.7±0.3 
BpsDsbB SSSS 0.24±0.2 
CtDsbB SSCC  2.8±0.2 
CtDsbB CCSS 4.5±0.1 
CtDsbB 234±23 
None CtDsbB 9.5±0.2 
Mean and SD for two biological replicates are presented 
 
Adding membranes containing CtDsbB SSCC or CtDsbB CCSS to CtDsbA gives rise to initial rates 
of 2.8±0.2 RFU/s and 4.5±0.1 RFU/s, respectively (Figure 3.3B and Table 3.1). The fact that CtDsbA 
is significantly less active in the presence of CtDsbB SSCC and CtDsbB CCSS, than in the presence 
of CtDsbB suggests that the two disulfide bonds in the periplasmic loops are both required for 
complete oxidation of CtDsbA. 
 
To exclude the possibility that other factors present in the E. coli membranes facilitate CtDsbA 
activity, a construct of a DsbB from another organism, B. pseudomallei (BpsDsbB) with all four 
cysteines in the two periplasmic loops mutated to serines (BpsDsbB SSSS) was included as a negative 
control. Replacing the cysteines in loop P1 and P2 with serines eliminates the ability of BpsDsbB to 
form a redox relay with any DsbA enzyme, including CtDsbA. This construct, rather than a cysteine-
less mutant of CtDsbB, was chosen as a negative control as it was readily available and proven to be 
unable to facilitate BpsDsbA activity in the peptide oxidation assay [221].With an initial reaction rate 
of 0.24±0.2 RFU/s BpsDsbB SSSS containing membranes were not able to facilitate CtDsbA activity. 
Consequently, the observed CtDsbA activity arises from a specific interaction with CtDsbB, and other 
factors in the membrane preparation contribute minimally to CtDsbA activity.  
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Figure 3.3 Both periplasmic disulfide bonds are required for CtDsbB to form a redox relay with 
CtDsbA. 
 An increase in fluorescence as a function of time is seen as a result of CtDsbA and CtDsbB catalysed 
oxidation of a fluorescently labelled peptide containing two cysteines. A) A rapid increase in 
fluorescence is seen for 80 nM EcDsbA with membranes containing 8 µM EcDsbB (green). 640 nM 
CtDsbA with membranes containing 8 µM CtDsbB (red) gives a slower increase in fluorescence. 
Fluorescence only increases minimally for control reactions containing only CtDsbB (8 µM) 
membranes (grey dotted line), 640 nM CtDsbA (dashed line) or buffer only (black). B) The increase 
in fluorescence for 640 nM CtDsbA with membranes containing 8 µM CtDsbB CCSS (blue) and 640 
nM CtDsbA with membranes containing 8 µM CtDsbB SSCC (purple) are significantly slower than 
640 nM CtDsbA with membranes containing 8 µM CtDsbB (red), but marginally faster than 640 nM 
CtDsbA with membranes containing 8 µM BpsDsbB SSSS (pink) and buffer only (black). The curves 
for 80 nM EcDsbA with membranes containing 8 µM EcDsbB (green), 640 nM CtDsbA with 
membranes containing 8 µM CtDsbB (red) and buffer only (black) are the same as in A. Plotted data 
show mean and SD for two biological replicates. 
3.3.3 Purified, DDM-solubilised CtDsbB does not oxidise CtDsbA 
To follow up on the hypothesis that the CtDsbA activity is due to oxidation by CtDsbB, the redox 
state of CtDsbA after incubation with purified detergent solubilised CtDsbB was studied in a gel shift 
assay. In vivo EcDsbB derives its oxidising power from a quinone cofactor and ultimately the electron 
transport chain [222]. For E. coli, V. cholerae, W. pipientis and M. tuberculosis systems, ubiquinone 
1 (UQ-1) is able to accept electrons from DsbB in in vitro experiments [76, 78, 104, 108]. Thus UQ-
1 was chosen as the quinone cofactor to use in CtDsbB in vitro experiments as well. 
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Initially a construct of the soluble CtDsbA in which the three cysteines outside of the active site were 
replaced with serine (CtDsbA-SSS) was chosen for this assay as the active site disulfide is the likely 
target for CtDsbB oxidation.  
 
CtDsbA-SSS was incubated with UQ-1 in the presence or absence of purified, DDM-solubilised 
CtDsbB, and samples were taken after 0, 5, 20, 60 and 120 min (Figure 3.4A). The reaction was 
quenched by precipitation with TCA and samples were treated with AMS adding 0.5 KDa for every 
free cysteine. Consequently, the oxidation of CtDsbA-SSS can be monitored as a shift in 
electrophoretic motility on SDS-PAGE. 
 
For CtDsbA-SSS incubated with CtDsbB and UQ-1, all of the protein migrates at a molecular weight 
corresponding to reduced CtDsbA-SSS up until 20 minutes after the reaction is started. At 60 and 
120 minutes after the reaction is initiated, a small proportion of CtDsbA-SSS migrates at a molecular 
weight corresponding to oxidised CtDsbA-SSS indicating that the active site cysteines of CtDsbA are 
oxidised in the presence of CtDsbB and UQ-1 (Figure 3.4A). However, an equivalent proportion of 
CtDsbA-SSS becomes oxidised upon incubation with UQ-1 in the absence of CtDsbB (Figure 3.4A). 
This indicates that UQ-1 directly, rather than bound to CtDsbB, is responsible for the partial 
oxidisation of CtDsbA-SSS. No shift in migration of CtDsbA-SSS is observed upon incubation with 
CtDsbB in the absence of UQ-1 confirming that CtDsbB alone has no effect on the redox state of 
CtDsbA-SSS (Figure 3.4B). Without addition of CtDsbB or UQ-1 CtDsbA-SSS stays reduced over 
the course of 120 minutes confirming that CtDsbA-SSS does not spontaneously oxidise (Figure 
3.4B). 
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Figure 3.4 Purified and detergent solubilised CtDsbB does not fully oxidise CtDsbA-SSS. 
 The redox state of CtDsbA-SSS over time was monitored by a shift in electrophoretic mobility after 
treatment with the alkylating agent AMS that adds 0.5 kDa per reduced cysteine. A) Reduced CtDsbA-
SSS (30 µM) was incubated with UQ-1 (30 µM) in the absence or presence of purified detergent 
solubilised CtDsbB (50 nM) and incubated for 0, 5, 20, 60 and 120 min. CtDsbA-SSS is partly 
oxidised after 60 min both in the absence and presence of CtDsbB. Reduced and oxidised CtDsbA-
SSS were included on the SDS-PAGE for reference. B) In the absence of UQ-1, CtDsbA-SSS does not 
change redox state over the course of 120 min in either the absence or presence of CtDsbB. Oxidised 
CtDsbA-SSS is included as a reference. Data shown represents one of three biological replicates. 
To determine whether oxidation of DsbA directly by UQ-1 is specific for CtDsbA-SSS, the ability of 
UQ-1 to oxidise EcDsbA was investigated. In contrast to what I found with CtDsbA-SSS reduced 
EcDsbA is partially oxidised immediately upon addition of EcDsbB and UQ-1, and fully oxidised 
after 5 min (Figure 3.5). This is consistent with what is reported in the literature [60]. In the absence 
of EcDsbB, EcDsbA is partly oxidised by UQ-1 after 20 min and gets slightly more oxidised at 60 
min and 120 min. However, as also observed for CtDsbA-SSS, UQ-1 is not able to fully oxidise 
EcDsbA in the absence of EcDsbB (Figure 3.5). 
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Figure 3.5 EcDsbA is partly oxidised by UQ-1 in the absence of EcDsbB. 
 The redox state of EcDsbA over time was monitored by a shift in electrophoretic mobility after 
treatment with the alkylating agent AMS that adds 0.5 kDa per reduced cysteine. Reduced EcDsbA 
(30 µM) was incubated with UQ-1 (30 µM) in the absence or presence of purified detergent 
solubilised EcDsbB (50 nM) and incubated for 0, 5, 20, 60 and 120 min.  Data shown represents one 
of two biological replicates. 
The second disulfide of CtDsbA might be important for the interaction with CtDsbB and could 
perhaps be responsible for the lack of oxidation of the CtDsbA-SSS mutant where this disulfide bond 
cannot form. Therefore the ability of CtDsbB to oxidise CtDsbA was investigated as well. Similar to 
the experiment using CtDsbA-SSS, no spontaneous oxidation of CtDsbA occurs over 120 minutes 
(Figure 3.6B). Neither does CtDsbB oxidise CtDsbA in the absence of UQ-1 (Figure 3.6B). 
Interestingly, no shift in migration is observed upon incubating of CtDsbA with UQ-1, neither in the 
absence or presence of CtDsbB (Figure 3.6A). In these experiments, CtDsbA, contrary to CtDsbA-
SSS, is not oxidised by UQ-1 in a time course of 120 minutes.  
 
Figure 3.6 Purified and detergent solubilised CtDsbB is not able to oxidise CtDsbA. 
The redox state of CtDsbA over time was monitored by a shift in electrophoretic mobility after 
treatment with the alkylating agent AMS that adds 0.5 kDa per reduced cysteine. Reduced and 
oxidised CtDsbA is included as reference. A) The redox state of CtDsbA does not change after 
incubation with UQ-1 in the presence or absence of CtDsbB. B) Reduced CtDsbA is not oxidised in 
the absence or presence of CtDsbB in the course of 120 min. Data shown represents one of three 
biological replicates. 
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UQ-1 facilitated CtDsbA activity was studied in the peptide oxidation assay to confirm that CtDsbA-
SSS is oxidised by UQ-1. However, the increase in relative fluorescence over 140 minutes is the same 
for CtDsbA-SSS in the absence and presence of UQ-1 (Figure 3.7) indicating that UQ-1 is not able 
to oxidise CtDsbA sufficiently to support substrate oxidation in this assay. This is inconsistent with 
the observed shift in electrophoretic motility of CtDsbA-SSS upon incubation with UQ-1. As 
CtDsbA-SSS has intrinsically lower activity in the peptide oxidation assay compared to EcDsbA, the 
partial oxidation of CtDsbA-SSS observed in the gel shift assay is most likely insufficient to oxidise 
the peptide substrate. Consequently, any oxidation of CtDsbA-SSS is not reflected in an increase in 
fluorescence as the signal-to-noise ratio is too low.  
 
Figure 3.7 UQ-1 does not regenerate CtDsbA-SSS activity. 
 The increase in fluorescence with 640nM CtDsbA-SSS and UQ-1 (10 µM) is equivalent to that of 
CtDsbA-SSS alone, and of the buffer only control and significantly lower than when using CtDsbB 
containing membranes (8 µM) as a redox partner. Plotted data show mean and SD for two biological 
replicates. 
3.3.4 CtDsbB binds UQ differently than EcDsbB 
Two possible explanations for the observation that purified CtDsbB does not oxidise CtDsbA are (i) 
that CtDsbB is inactive in DDM micelles or (ii) that UQ-1 is not able to act as an electron acceptor 
for CtDsbB. To shed further light on the latter, the interaction with UQ was investigated further. 
 
Reduced UQ (ubiquinol) is colourless, whereas oxidised UQ is yellow and gives rise to a peak in 
absorbance at 400 nm (Figure 3.8). Upon binding to EcDsbB the spectrum of UQ is red-shifted giving 
rise to a broad shoulder around 500 nm and a characteristic pink colour [104] (Figure 3.8).  A charge-
transfer complex between UQ and Cys44 of EcDsbB is responsible for the red-shift in UQ absorbance 
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[104] and the red-shift is more pronounced when EcDsbB is bound to EcDsbA [104]. Addition of the 
reducing agent dithiothreitol (DTT) to a preparation of UQ-bound DsbB results in the solution turning 
colourless due to reduction of UQ [104].  
 
 
Figure 3.8 Colour of reduced and oxidised UQ and the charge-transfer complex formed between 
Cys44 of EcDsbB and UQ. 
 UQ consists of a 1,4 benzoquinone head group and an isoprenoid tail of varying length. Reduced 
ubiquinone (ubiquinol) is colourless whereas oxidised ubiquinone is yellow. Oxidised ubiquinone can 
form a charge-transfer complex with Cys44 of EcDsbB, which is characterised by a pink colour. 
DsbB constructs from E. coli, B. pseudomallei and C. trachomatis were recombinantly expressed in 
E. coli, then detergent solubilised and purified. Detection of bound endogenous UQ acquired during 
expression in E. coli was studied by colour observations and absorbance spectrum properties.  
 
Both EcDsbB and BpsDsbB have the characteristic pink colour of a charge-transfer complex formed 
between UQ and cysteine (Table 3.2). The spectra for EcDsbB and BpsDsbB also exhibit a peak at 
410 nm and a shoulder around 500-550 nm in agreement with the spectra for a charge-transfer 
complex between UQ and DsbB as reported in the literature [104] (Table 3.2 and Figure 3.9). The 
protein solution of both BpsDsbB SSCC and BpsDsbB CCSS are faint yellow indicating potential 
binding of oxidised UQ (Table 3.2). The spectrum of BpsDsbB SSCC has no local maxima at 410 or 
500 nm suggesting that UQ is bound in the reduced state or is not bound at all. The spectrum of 
BpsDsbB CCSS, on the other hand, is equivalent to BpsDsbB although lower in intensity. As the 
quinone binding site, by homology to EcDsbB, is intact in BpsDsbB CCSS, this most likely reflects 
limited binding of UQ in BpsDsbB CCSS, but no formation of a charge-transfer complex.  
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Table 3.2 Colour and absorbance spectral properties of DsbB constructs from E. coli, B. 
pseudomallei and C. trachomatis 
 
 
 
 
 
 
 
 
 
 
 
 
 
Interestingly, CtDsbB, CtDsbB SSCC and CtDsbB CCSS are all dark orange (Table 3.2). This can 
either be indicative of UQ binding, without formation of a charge-transfer complex with Cys38, or 
potentially binding of a metal [223-225]. CtDsbB turns colourless upon addition of DTT. As reduced 
UQ (ubiquinol) is colourless (Figure 3.8) this observation is consistent with binding of UQ to CtDsbB 
and its mutants. 
 
Two factors could contribute to the orange colour of UQ bound to CtDsbB, CtDsbB SSCC and 
CtDsbB CCSS. One possibility is that oxidised ubiquinone binds without forming a charge-transfer 
complex with Cys36. Another possibility is that ubiquinone forms a quinhydrone-like charge-transfer 
complex with Tyr40 or Tyr41 that both are in close proximity to the predicted UQ binding site in 
CtDsbB. The charge-transfer complex with tyrosine gives rise to a brown-red colour [226]. Both 
theories are consistent with CtDsbB turning colourless upon addition of DTT, which would reduce 
bound UQ. 
 
Protein Colour Local max 410 nm Shoulder 500 nm 
EcDsbB Pink Yes Yes 
BpsDsbB Pink Yes Yes 
BpsDsbB 
SSCC 
Faint yellow No No 
BpsDsbB 
CCSS 
Faint yellow Yes Yes 
CtDsbB  Orange Yes No 
CtDsbB SSCC Orange Yes No 
CtDsbB CCSS Orange Yes No 
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Figure 3.9 Absorbance spectrum of DsbB constructs. 
 Absorbance spectra were obtained for 1 mg/ml purified detergent solubilised EcDsbB (green) and 
1.9 mg/ml purified detergent solubilised BpsDsbB (blue solid line), BpsDsbB SSCC (blue dashed 
line), BpsDsbB CCSS (blue dashed-dotted line), CtDsbB (red solid line), CtDsbB SSCC (red dashed 
line) and CtDsbB CCSS (red dashed-dotted line). A maximum at 410 nm indicates binding of 
ubiquinone in the oxidised state. A shoulder around 500 nm indicates presence of a charge-transfer 
complex between ubiquinone and cysteine. Data shown represent one of three repeats. 
The absorbance spectra are equivalent for all three CtDsbB (Figure 3.9). This is consistent with the 
colour of the solution being the same for the three protein preparations. The spectra for the CtDsbB 
constructs exhibit a peak at 410 nm, but in contrast to the spectra for BpsDsbB and EcDsbB, does not 
have a shoulder at 500 nm. The spectra are consistent with binding of oxidised ubiquinone, but not 
with the presence of a ubiquinone-tyrosine quinhydrone-like charge-transfer complex as this complex 
would give rise to peaks at 360 nm and 455 nm [226]. Unlike EcDsbB and BpsDsbB, there is no 
evidence of a charge-transfer complex with cysteine in any of the spectra obtained for the three 
CtDsbB constructs indicating that CtDsbB may bind UQ differently to EcDsbB and BpsDsbB. 
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3.3.5 CtDsbA is expressed late in the C. trachomatis developmental cycle 
To get an indication of the biological role of CtDsbA, I investigated at what point in the 
developmental cycle CtDsbA is expressed. An antibody against CtDsbA was raised in rabbit and used 
to monitor the expression levels of CtDsbA in C. trachomatis via confocal microscopy (Figure 3.10). 
McCoy cells were infected with C. trachomatis LGV-2 and the infected McCoy cells were harvested 
20 hours, 32 hours and 44 hours post infection.  
 
Figure 3.10 Expression levels of CtDsbA in C. trachomatis.  
Confocal images were obtained of C. trachomatis LGV-2 infected McCoy cells harvested at 20 h, 32 
h and 44 h post infection. A non-infected McCoy cell is included as a negative control. CtDsbA is 
stained with anti-CtDsbA antibody raised in rabbit with a secondary goat anti-rabbit IgG - Alexa 
Fluor 488 (green). The host cell nucleus is stained with the fluorescent dye DAPI (blue) that binds 
strongly to A-T rich regions in DNA. Host cell cytoskeleton is stained with Alexa Fluor 594 Phalloidin 
(red) that has high affinity for F-actin.  
The 20 h time point represents the middle to late replicative phase of the chlamydial life cycle. 
Confocal imaging with an anti-CtDsbA antibody coupled with a green fluorescent secondary antibody 
shows low levels of green fluorescently labelled protein at 20 h post infection suggesting that small 
amounts of CtDsbA are present in McCoy cells infected with C. trachomatis (Figure 3.10B). At 32 h 
post infection the expression of CtDsbA is significantly increased as judged by elevated amounts of 
green fluorescence in the confocal image of a C. trachomatis infected McCoy cell. These observations 
suggest that CtDsbA expression is upregulated between 20 h and 32 h post infection. It is noteworthy 
that at this point RB to EB differentiation has begun including oxidation of the cysteines in the 
COMC. Little to no additional increase in CtDsbA expression levels is observed between 32 hours 
and 44 hours. 
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3.3.6 The additional disulfide in CtDsbA contributes to a slight stabilisation of 
the oxidised state 
A characteristic feature of CtDsbA is the presence of a second disulfide linking helix H2 and helix 
H5. An equivalent disulfide bond is found in MtbDsbA, PaDsbA2 and in DsbA proteins from alpha-
proteobacteria such as WpDsbA1. The role of the second disulfide is not established for CtDsbA, but 
has different roles in WpDsbA1 and PaDsbA2 [75, 108]. To determine a possible role of the second 
disulfide in CtDsbA the effect of this second disulfide on thermal stability as well as interaction with 
CtDsbB was studied. 
 
In Chapter 2 the melting temperature for reduced and oxidised CtDsbA was determined to be 339 ± 
0.2 K and 335 ± 0.1 K, respectively. The melting temperature of reduced CtDsbA-SSS (336K ± 0.1) 
is also higher than its oxidised state (334K ± 0.2) (Figure 3.11A and Table 3.3). In the CtDsbA-SSS 
mutant the cysteines forming the disulfide bond between helix H2 and helix H5 as well as the free 
cysteine in the core of the protein (Cys70) are mutated to serines. Consequently oxidised CtDsbA-
SSS only contains the active site disulfide bond compared to CtDsbA that has two disulfide bonds in 
the oxidised state. As the only difference between reduced CtDsbA and CtDsbA-SSS is the three 
cysteine-to-serine mutations (mimicking a state where the second disulfide is reduced) it was 
surprising that the melting temperature for reduced CtDsbA-SSS differs from the melting temperature 
of reduced CtDsbA (Table 3.3). This is most likely a reflection of the different biochemical properties 
of the serines compared to the cysteine residues that they are replacing. In particular, replacing the 
free cysteine (Cys70) in the core with the more polar serine residue might decrease the stability of 
CtDsbA-SSS and contribute to the decrease in melting temperature of reduced CtDsbA-SSS 
compared to reduced CtDsbA.  
 
Table 3.3 Melting temperatures of CtDsbA and CtDsbA-SSS. 
 CtDsbA CtDsbA-SSS 
Tm Reduced (K) 339 ± 0.2  336 ± 0.1 
Tm Oxidised (K) 335 ± 0.1 334 ± 0.2 
Melting temperatures for CtDsbA-SSS were obtained from Figure 3.11. Melting temperatures for 
CtDsbA are from Chapter 2 section 2.6.5. Mean and SD for three biological replicates are presented. 
The difference in thermal stability between the reduced and oxidised states for CtDsbA-SSS is only 
2 K compared to 4 K for CtDsbA suggesting that the second disulfide contributes to stabilising the 
active state of CtDsbA slightly (Figure 3.11A and Table 3.3).  
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Figure 3.11 The second disulfide of CtDsbA has a small effect on protein stability, but does not 
appear to affect CtDsbA’s interaction with CtDsbB. 
 A) The thermal unfolding of reduced and oxidised CtDsbA-SSS was monitored by CD spectroscopy 
and the fraction of unfolded CtDsbA-SSS is plotted as a function of temperature. With a melting 
temperature of 336 K ± 0.1, reduced CtDsbA-SSS is slightly more stable than oxidised CtDsbA-SSS 
that has a melting temperature of 334 K ± 0.2. Plotted data show mean and SD for three biological 
replicates. B) An increase in fluorescence as a function of time is seen as a result of CtDsbA or 
CtDsbA-SSS catalysed oxidation of a fluorescently labelled peptide containing two cysteines. A rapid 
increase in fluorescence is seen for positive control 80 nM EcDsbA with membranes containing 8 µM 
EcDsbB (green). The activity of 640 nM CtDsbA (red) and 640 nM CtDsbA-SSS (blue) is equivalent 
upon interaction with membranes containing 8 µM CtDsbB. The activity of CtDsbB (grey) is only 
minimally higher than fluorescence for the buffer only control (black). Plotted data show mean and 
SD for three biological replicates, except for the EcDsbA + EcDsbB control where data from a single 
experiment was used. 
 
In the peptide oxidation assay (Figure 3.11B) the equivalent slope in fluorescence increase over time 
for CtDsbA and CtDsbA-SSS upon interaction with CtDsbB, indicates that CtDsbA and CtDsbA-
SSS exhibit the same ability to oxidise a synthetic peptide upon interaction with CtDsbB containing 
membranes (Figure 3.11B). Consequently, the minor increase in stability of the oxidised state 
introduced by the second disulfide does not have an effect on CtDsbB-facilitated CtDsbA activity, at 
least not under these experimental conditions. 
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3.4 Discussion 
3.4.1 Discrepancies in the CtDsbA-CtDsbB interaction suggests limitations in 
experimental design or purification 
Despite the observation that crude membranes containing CtDsbB are able to facilitate CtDsbA 
oxidative folding activity, detergent solubilised purified CtDsbB was unable to oxidise CtDsbA in 
the presence of UQ-1. Considering the homology to the EcDsbA-EcDsbB redox pair, the inability of 
CtDsbB/UQ-1 to form an active redox relay with CtDsbA most likely reflects limitations in the 
experimental set-up or CtDsbB being inactivated in the purification protocol used, rather than 
CtDsbA and CtDsbB not being a genuine redox pair. This is supported by the ability of crude 
membranes containing CtDsbB to facilitate CtDsbA oxidative folding activity.  
3.4.1.1 UQ binding diverting from EcDsbB might influence CtDsbB catalysis 
Even though residues involved in UQ binding in EcDsbB are conserved in CtDsbB, CtDsbB is not 
able to oxidise CtDsbA in the presence of UQ-1. This might be a reflection of the observed difference 
in binding of endogenous UQ from E. coli. The peptide oxidation assay and the gel shift assay utilises 
two different UQs; in the gel shift assay UQ-1 is added, whereas in the peptide oxidation assay 
endogenous UQ from E. coli is present in the crude membranes. Despite the indications that CtDsbB 
is able to bind oxidised endogenous UQ expressed in E. coli, the difference in binding mechanisms 
might hinder binding of UQ-1 to EcDsbB. The main ubiquinone in E. coli is UQ-8, although smaller 
amounts of UQ 1-7 are also synthesised [227]. Even though most organisms use a highly specific 
ubiquinone, in many microorganisms the organism-specific UQ can be replaced with UQs with 
variable side chain length. For example, UQ-5-10 are able to replace UQ-6 in S. cerevisiae in vivo 
[228]. Further UQ-1 has successfully replaced ubiquinone with longer side chains in in vitro 
biochemical assays [76, 83, 104, 108, 229, 230] suggesting that UQ-1 would also be an appropriate 
cofactor for CtDsbB. However, small changes in side-chain length have also proven detrimental in 
other in vitro and in vivo studies [231, 232]. Interestingly, neither of the two DsbBs encoded in P. 
aeruginosa are able to oxidise PaDsbA2 to completion in a time course of an hour in the presence of 
the UQ analogue decylubiquione, further emphasising that the UQ side chain has potential impact on 
activity [75]. Potentially the endogenous UQ in E. coli is a more suitable cofactor for CtDsbB than 
UQ-1. This would explain the activity I observed in the peptide oxidation assay where endogenous 
E. coli UQ is used, and the lack of activity in the gel shift assay where UQ-1 was used. Although a 
potential UQ biosynthesis pathway has been identified in C. trachomatis [233, 234] the side-chain 
length of UQ has not been determined. To investigate whether the lack of CtDsbB catalysed oxidation 
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of CtDsbA is due to the inability of UQ-1 to act as electron acceptor for CtDsbB, different UQ 
molecules should be screened. CtDsbB’s ability to oxidise CtDsbA in the presence of UQ can also 
be studied in a UQ reduction assay by monitoring a decrease in absorbance at 275 nm following 
reduction of UQ. As CtDsbB has been shown to facilitate CtDsbA activity in the presence of 
endogenous UQ from E. coli, UQ-8 would be a good starting point, as it is the dominant UQ in E. 
coli. However, UQ molecules with shorter and longer side-chains should be considered too. 
Menaquinone (MK) is the electron acceptor for EcDsbB under anaerobic conditions [230] and many 
Gram-negative and Gram-positive bacteria rely on MK entirely [234, 235]. Genomic sequencing of 
C. trachomatis identified four enzymes common to UQ and MK biosynthesis pathways [233]. 
Moreover, an intermediate in the futolosine pathway for MK biosynthesis has been identified and 
characterised structurally as well as functionally [234]. Accordingly, the possibility of CtDsbA 
oxidation by CtDsbB in the presence of MK should be explored too.  
3.4.1.2 Optimising solubilisation conditions might improve activity of CtDsbB 
 
When working with membrane proteins it is essential to provide an environment in which the protein 
is folded, active and solubilised outside the lipid bilayer. Detergents are often used for this purpose 
as they mimic the hydrophobic environment of the lipid bilayer. Whereas ionic detergents effectively 
solubilise most membrane proteins, they can also disrupt protein-protein interactions and therefore 
can sometimes denature the target protein [236-239]. Non-ionic detergents, such as DDM, primarily 
disrupt lipid-lipid interactions and are less denaturing of proteins [240-243]. A further potential 
complication is that an excessive presence of a micellar phase can interfere with many assay 
techniques [244]. Consequently, choosing the right detergent, as well as optimisation of detergent 
concentration and protein-to-detergent ratio is important for identifying the best condition for 
membrane protein stability and activity.  
 
In this work CtDsbB was extracted from crude E. coli membranes by the non-ionic detergent DDM, 
which is generally considered a mild and non-denaturing detergent [244]. However, the detergent 
micelles may lack lipids that could be important for activity of the membrane protein, as seen for e.g. 
Na+, K+-ATPase [245, 246], the cytochrome b6f complex [247] and G protein-coupled signalling 
[248].  
 
To obtain active solubilised CtDsbB the purification and solubilisation protocol should be further 
optimised. Screening of different detergents, as well as adjusting the protein-to-detergent ratios could 
potentially identify better detergent conditions for CtDsbB. However, introducing an environment 
that more closely resembles the membrane of C. trachomatis might have a greater effect on CtDsbB 
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activity. C. trachomatis produces lipids required for the formation of the inner and outer membrane 
[249], and the membrane mimics the bilayer of the eukaryotic host [250-256]. Consequently, a more 
native-like environment might be accomplished by including lipids such as phosphatidylcholine, 
phosphatidylinositol, sphingomyelin, or cholesterol, which are present in the chlamydial membrane 
[250-254, 256]. 
 
Nanodiscs (discoidal lipid bilayers that are stable and soluble in aqueous solutions) [257] might 
provide a better environment for CtDsbB than detergent micelles as they better control the oligomeric 
state of the target protein than detergent micelles. Moreover, CtDsbB is expressed with a His-tag, 
which allows for selection of nanodiscs containing CtDsbB. Purifying out empty nanodiscs will limit 
assay interference [258].  
3.4.2 The potential role of CtDsbA in chlamydial infection 
The observations presented in section 3.3.5 suggest that the CtDsbA protein expression onset occurs 
between 20 h and 32 h post infection. This is inconsistent with the onset of gene expression reported 
by a transcriptional profiling study in which CtDsbA expression (referred to as DsbG in the study) 
occurs 8 hours post infection [147]. This discrepancy could arise from the use of C. trachomatis 
serovar D (strain UW3/dx) in the transcriptional study compared to C. trachomatis LGV-2 here, but 
more likely reflects a difference in methodology. Confocal imaging reports on the protein levels 
whereas transcriptional profiling using quantitative reverse-transcription PCR (qPCR) reports 
expression levels of mRNA. Due to factors such as mRNA stability, transcription, and translation 
rates as well as protein degradation, the mRNA expression levels can differ by up to 60 % from the 
observed protein levels in both eukaryotes and prokaryotes [259, 260].  
 
The Major Outer Membrane Protein (MOMP) in C. trachomatis is synthesised early in the replicative 
phase but is not oxidised until the onset of RB to EB differentiation [143, 145, 147-149, 152]. In 
contrast, the two cysteine-rich proteins, OmcA and OmcB are synthesised late in the replicative phase 
simultaneous with their oxidation [143, 145, 147-149]. The correlation between CtDsbA expression 
and onset of oxidation of the COMC proteins is interesting in terms of a potential role for CtDsbA in 
the redox regulation of the COMC. Although the role of CtDsbA in chlamydial infection is to be 
determined, the correlation between CtDsbA expression and oxidation of the COMC proteins 
suggests the intriguing possibility that CtDsbA is involved in the redox regulation of the chlamydial 
developmental cycle. 
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The disulfide bond formed between helices H2 and H5 is conserved in DsbAs from alpha-
proteobacteria including W. pipientis [108]. It is also found in the DsbA from the acid-fast M. 
tuberculosis [78] and one of the two DsbAs (PaDsbA2) encoded by P. aeruginosa [75]. However, in 
two of the characterised DsbAs the second disulfide influences the interaction with the redox partner 
or the intrinsic redox properties, respectively [75, 108]. I found no apparent effect of the second 
disulfide on CtDsbA catalysis in the peptide oxidation assay. I also found that CtDsbA-SSS is partly 
oxidised by UQ-1 in the gel shift assay whereas no oxidation of CtDsbA is observed, suggesting that 
the second disulfide might influence the redox properties of CtDsbA. This might be a reflection of 
the small decrease in thermal stability between the reduced and oxidised state in CtDsbA-SSS 
compared to CtDsbA. This is consistent with what is seen for SaDsbA that does not have a 
destabilising active site disulfide and can be oxidised by extracellular oxidants [84]. A potential 
inhibitory effect on the interaction with CtDsbB could be followed directly in a UQ reduction assay 
as described above, assuming the appropriate UQ cofactor for CtDsbB can be identified. The redox 
potential of the active site disulfide in the absence of the second disulfide was determined in Chapter 
2, section 2.6.6. Determining the redox potential of the active site disulfide with the second disulfide 
present might give important insight to the impact of the second disulfide on the intrinsic redox 
properties of CtDsbA.   
 
The potential effect of the second disulfide on the redox properties of CtDsbA leaves an open question 
of the relevance of the second disulfide in vivo. If CtDsbA, as proposed in section 1.4, is involved in 
oxidation of the COMC proteins, regulation of CtDsbA oxidase activity is crucial for chlamydial 
infection. The second disulfide might be involved, somehow, in regulation of CtDsbA activity either 
by influencing the interaction with CtDsbB or modifying the interaction with substrates. AMS 
labelling of samples taken immediately upon infection with C. trachomatis as well as during EB to 
RB differentiation, replication, and RB to EB differentiation, followed by western blotting with anti-
CtDsbA antibody could give important information about potential developmental stage specific 
regulation of CtDsbA. This technique has previously proven successful for determining the in vivo 
redox state of PaDsbA1 [75]. 
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3.5 Conclusion 
The identification of a DsbB homolog in C. trachomatis and the observation that CtDsbB is capable 
of facilitating CtDsbA activity in a mechanism dependent on the cysteines in both periplasmic loops 
indicates that the oxidative pathway in C. trachomatis resembles that of E. coli in some respects. 
However, the lack of oxidation of CtDsbA in the gel shift assay and the apparent differences in 
binding of UQ calls for further investigation of the interaction between CtDsbA and CtDsbB as the 
redox pair in the oxidative pathway of C. trachomatis. The role of the second disulfide in regulating 
CtDsbA activity also needs further investigation. The impact of the second disulfide is an important 
step in elucidating the role of the oxidative pathway of C. trachomatis infection. Further 
investigations, especially of the role of CtDsbA in C. trachomatis infection are required to explore 
the theory that the oxidative pathway is involved in oxidation of the COMC.  
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Chapter 4: Towards studying the biological 
role of CtDsbA 
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4.1 Introduction 
The oxidase DsbA is important for the oxidative folding of virulence factors in many pathogens such 
as E. coli [48], S. enterica Typhimurium [46, 53], C. jejuni [54], Y. pestis [47], P. aeruginosa [55, 
56], Vibrio cholerae [50] and B. pseudomallei [57]. However, the role of CtDsbA in C. trachomatis 
has not been explored. The characterisation of CtDsbA presented in Chapter 2 reveals that CtDsbA 
has oxidase activity, although weak, and adopts the same overall structure as other DsbA enzymes. 
The structural and functional similarities between CtDsbA and DsbA in other organisms suggest that 
CtDsbA might be important for oxidative folding of virulence factors in C. trachomatis. Further, the 
correlation between CtDsbA expression and onset of oxidation of the chlamydial outer membrane 
complex (COMC) presented in Chapter 3 suggests a specialised role for CtDsbA in C. trachomatis 
virulence. Creation of a C. trachomatis strain with a disruption in the dsbA gene would allow a more 
direct study of the role of CtDsbA in C. trachomatis infection and development.  
 
The impermeable nature of Chlamydia hinders DNA uptake, stable DNA integration and bacterial 
propagation and selection [261]. Consequently, Chlamydia was, until recently, considered refractory 
to routine genetic manipulation tools such as shuttle plasmids, transposons and transducing phages 
[261]. The inaccessible nature of C. trachomatis arises from the biphasic life cycle of this obligate 
intracellular pathogen. The two cell types in the chlamydial life cycle - the elementary body (EB) and 
the reticulate body (RB) - can both be considered targets for DNA uptake. However, the outer 
membrane of the extracellular, infectious EB is highly cross-linked with disulfide bonds making the 
EB extremely rigid and consequently difficult to permeabilise [131]. Upon EB to RB differentiation 
the disulfide cross-linking of the membrane is reduced making the RB less rigid than the EB. 
However, as the RBs replicate within a membrane-enclosed inclusion inside the host cell, the 
chromosomal DNA is enclosed by the host cell membrane, the inclusion membrane and the outer and 
inner bacterial membrane. Accordingly, directing DNA to the target compartment is challenging. 
Electroporation has been explored as a strategy for insertion of DNA to the EB, and has been 
successful in two reported cases [262, 263]. However, due to low plasmid stability and poor 
transformation efficiency this is not an optimal strategy for introducing DNA into the EB. The first 
stable transformation of plasmid DNA into Chlamydia was achieved by the use of a shuttle vector. 
This method led to the development of expression vectors expressing Chlamydia open reading frames 
[264, 265], exogenous glycogen synthase kinase [81], as well as reporter proteins such as, green- and 
cyan- fluorescent proteins [266].  
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Despite the advances in stable DNA transformation, only a few examples of genetic manipulation of 
Chlamydia spp. have been reported in the literature; e.g. insertion of a group II intron has been used 
to induce gene disruption [267], but this technique is limited to sites where integration is evaluated 
to be efficient and requires the use of proprietary software.  
 
The most successful strategy for genetic manipulation of Chlamydia spp to date combines the 
introduction of random mutations by chemical mutagenesis with whole genome sequencing. This has 
gained interest as a way of studying the effect of gene products with critical functions [261, 268]. 
Chlamydiaceae, the chlamydial family to which C. trachomatis belongs, lack an effective polymerase 
V error-prone repair system, a defect which typically increases mutation rate [269]. As Chlamydia 
species have a high gene density, an inefficient proofreading system increases the mutation frequency 
and consequently increases the ratio of gene disruption caused by point- or frame-shift mutations. 
Consequently, chemical mutagenesis is a valuable tool for studying gene functions in Chlamydia even 
though it does not offer the option to selectively inactivate individual genes. Chemical mutagenesis 
combined with whole genome sequencing has proven successful for identifying virulence factors 
using both a reverse and forward genetic approach [268, 270, 271].  
 
In this chapter I report on this approach to study the role of CtDsbA in C. trachomatis. C. trachomatis 
was treated with the carcinogenic compound ethyl methanesulfonate (EMS) that introduces G to A 
and C to T base mutations in DNA [272] to create a library of EMS mutants. Both a forward and a 
reverse genetic approach were used to search for possible mutations introduced into the dsbA gene 
(Figure 4.1).  
 
Figure 4.1 Screening of the EMS mutation libraries of C. trachomatis LGV-2 or C. trachomatis 
LGV-2 tmp in a reverse and forward genetic approach. 
 C. trachomatis LGV-2 or C. trachomatis LGV-2tmp were treated with EMS, which introduces 
randomly positioned base pair (G:C to A:T) mutations thereby creating a library of EMS mutants. In 
the reverse genetics approach (right) McCoy cells are infected with 15 inclusion-forming units (IFU) 
per well of the EMS library and grown continuously for eight days without passaging the infected 
cells. After eight days the dsbA genes were amplified with dsbA specific primers and treated with the 
endonuclease Cel-1 that cleaves specifically at base pair mismatches. If a base pair mismatch is 
identified the PCR products obtained from that specific well are sequenced with dsbA specific 
primers. In the forward genetic approach (left) McCoy cells are infected with 2 IFU per well of the 
EMS library. The infected cells are passaged every 48 h for eight days and then harvested. One third 
of the harvest was treated with 10 mM dithiotrethreitol (DTT) and used to infect a fresh monolayer 
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of McCoy cells. As a control McCoy cells were infected with harvest that had not been treated with 
DTT. Wells with an altered phenotype upon DTT treatment were subjected to sequencing. 
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In the forward genetics approach, an EMS library was screened for increased sensitivity to the 
reducing agent dithiotrethreitol (DTT) (Figure 4.1). Treatment of EBs with DTT decreases infectivity 
significantly [131]. I hypothesised that mutations in a gene encoding a redox protein are therefore 
likely to result in altered sensitivity to DTT treatment. As such, a mutation will interfere with the 
formation of disulfide bonds. Reduction of the disulfide bonds in the extracellular EB decreases 
infectivity as shown by Hackstadt et al. [131]. Consequently, if CtDsbA is involved in oxidation of 
the COMC proteins, loss of CtDsbA activity might cause increased sensitivity to DTT as the disulfide 
bond cross-linking cannot be re-established. Even though increased DTT sensitivity might be 
observed for mutations in genes other than dsbA, this phenotypic screening approach was anticipated 
to significantly decrease the pool of potential mutants from which to identify a dsbA mutation. 
 
 
Figure 4.2 Schematic representation of TILLING. 
 A DNA heteroduplex with one base pair mismatch is created by melting and then annealing two PCR 
products, one of which is wild type (green) and one of which contains a point mutation (red). Cel-1 
cleaves at the site of the base pair mismatch. 
Targeting Induced Local Lesions IN Genomes (TILLING) was used to screen the library of EMS 
mutants in the reverse genetics approach (Figure 4.1). TILLING relies on the formation of a DNA 
heteroduplex between a native DNA strand and a strand with a single point mutation (Figure 4.2). 
The mismatch between the two strands creates a “bubble” that is recognised by the endonuclease Cel-
1. Cel-1 can be easily extracted from celery making the approach cost-effective. Following Cel-1 
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digestion the DNA is separated by agarose gel electrophoresis to identify those samples that have 
been susceptible to Cel-1 activity. 
4.2 Materials and methods 
4.2.1  Cel-1 extraction from celery 
Cel-1 was extracted from celery by ammonium sulphate precipitation [273]. Fresh clean celery stalks 
with the leaves removed were juiced at 4 °C using a household juicer and filtered through cloth. 1 M 
Tris-HCl pH 7.7 with protease inhibitor (1/1000 dilution of Merck Millipore inhibitor cocktail set III, 
EDTA free) was added to the celery juice to a final concentration of 0.1 M Tris-HCl. The celery juice 
was centrifuged at 4 °C, 2600 × g for 15 minutes. Solid (NH4)2SO4 was added slowly to the 
supernatant with agitation to 25 % saturation (144 g/L). Following incubation with agitation at 4 °C 
for 30 minutes, the solution was centrifuged (4 °C at 15,000 × g for one hour) to remove protein of 
low solubility. (NH4)2SO4 was added slowly to the supernatant under agitation to 80 % saturation 
(390 g/L). Following incubation with agitation at 4 °C for 30 minutes the solution was centrifuged 4 
°C at 15,000 × g for one hour. The resulting pellet was resuspended in 1/10 of the starting volume of 
0.1 M Tris-HCl pH 7.7 with protease inhibitor, and dialysed against 0.1 M Tris-HCl pH 7.7 with 
protease inhibitor. The buffer was exchanged hourly, seven times. After centrifugation at 20,000 × g 
for 20 minutes at 4 °C, the supernatant was aliquoted and stored at -20 °C.  
4.2.2  Test of Cel-1 endonuclease activity of celery extract 
A DNA heteroduplex was created between two PCR products encoding wt bpsdsbA and bpsdsbA 
carrying a single C to A point mutation resulting in the mutation of Lys133 to Met (bpsdsbA L133M). 
The heteroduplex was created by mixing the PCR products in 1:1 molar ratio and subjecting the mix 
to series of denaturing and annealing temperature conditions. Firstly, the products were heated to 99 
°C for 10 minutes followed by a gradual decreasing temperature ramp (initial temperature of 70 °C, 
decreasing 0.3 °C each cycle for a total of 70 cycles of 20 seconds with a final temperature of 49 °C.) 
As a control, a homoduplex of bpsdsbA was subjected to the same treatment. Cel-1 endonuclease 
activity was tested by mixing 10 µL homo- or heteroduplex product with 100 mM HEPES pH 7.5, 
100 mM KCl, 100 mM MgSO4, 0.02 % Triton X-100 and 2 µg/mL BSA with varying volumes (0.5 
µL to 8 µL) of celery extract at a final volume of 20 µL [273]. Cel-1 activity was confirmed by cutting 
at mismatch in heteroduplex. Cel-1 activity was confirmed by cutting of the mismatch in the DNA 
heteroduplex, and no cutting of the matched DNA homoduplex. 
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4.2.3  Test of primer specificity 
Primers specific for the dsbA gene (Forward: 5’GACTCATAAGAAGTCTGAGAG and reverse: 5’ 
CATAAGCGTTCCTATACAAG) were synthesised by Integrated DNA Technologies. Primer 
specificity was tested by amplifying the dsbA gene from heat-inactivated genomic DNA purified from 
C. trachomatis LGV-2. In a final volume of 50 µL, 50 ng of DNA was mixed with 0.2 µM of forward 
and reverse primer and 25 µL of JumpStart RedTaq Readymix (Sigma-Aldrich) containing JumpStart 
Taq DNA polymerase, 99 % pure deoxynucleotides and buffer.  
4.2.4  Routine maintenance of McCoy cultures 
Dulbecco Modified Eagle Media (DMEM) enriched with 10 % heat-inactivated Fetal Calf Serum 
(FCS), 2 % GlutamaxTM, 100 µg/mL streptomycin and 50 µg/mL gentamycin were used for all cell 
suspensions and infections. 
 
Unless otherwise noted, infected and non-infected cells were incubated at 37 °C/5 % CO2 in a 
humidified incubator. 
 
McCoy cells were cultured in T75 culture flasks. Confluent cells were harvested by treatment with 1 
mL of a 0.05 % trypsin/0.02 % EDTA solution and incubated 10 minutes at room temperature. Cells 
were dislodged by gentle tapping and resuspended in 9 mL fresh media. Cell density was determined 
by mixing a 10 µL cell suspension with 10 µL tryphan blue and counting using a haemocytometer 
under a microscope with a 10x objective. The resulting cell suspension was used to seed new T75 
culture flasks, 6-well plates (1,500,000 cells/well) or 96-well plates (20,000 cells/well). 
4.2.5 Infection of McCoy cells with C. trachomatis 
24 h after seeding 6-well or 96-well plates with McCoy cells, the cells were infected with C. 
trachomatis LGV-2 or C. trachomatis LGV-2tmp. For infection, bacterial cells were diluted to the 
appropriate multiplicity of infection (MOI) in media. Bacteria were applied to McCoy cells and 
centrifuged at 28 °C at 500 × g for 30 min. After four hours incubation, the media was replaced with 
fresh media containing 1 µg/mL cyclohexamide and incubated for another 44 h. Unless otherwise 
stated infected McCoy cells were passaged every 48 h. 
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4.2.6  Passaging of infected McCoy cells 
Infected McCoy cells grown in 96-well plates were passaged every 48 h by removing media from 
wells and harvested in 100 µL cold sucrose-phosphate-glutamic acid (SPG). The 100 µL SPG harvest 
was used to infect a fresh monolayer of McCoy seeded 96-well plates. 
4.2.7  Continuous growth of infected McCoy cells 
Infected McCoy cells were grown in 96-well plates with a media change four hours post infection. 
The infected cells were grown without passaging for eight days, but media was replaced with fresh 
media after four days. 
4.2.8 Methanol fixing of infected McCoy cells 
Media was removed from the wells, and the cells washed one time with 200 µL 137 mM NaCl, 2.7 
mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.4 (PBS). Cells were fixed by filling each well to 
the top of the well with 100 % methanol and incubating at room temperature for 10 min. Subsequently 
each well was washed twice with PBS. Plates were stained immediately, or stored in PBS for staining 
at a later stage. 
4.2.9  HtrA and DAPI Antibody staining 
In a 96-well plate containing C. trachomatis LGV-2 or C. trachomatis LGV-2tmp infected McCoy 
cells, the cells were permeabilised by adding 100-200 µL 0.5 % Triton X-100 in PBS to each well, 
followed by incubation for 15 min at room temperature. Permeabilisation buffer was removed and 
the infected cells were blocked with 1% Bovine Serum Albumin (BSA) in PBS for one hour at room 
temperature. After this point plates were kept in the dark by covering the plates with aluminium foil. 
The host cell nuclei were stained with 4',6-Diamidine-2'-phenylindole dihydrochloride (DAPI) 
antibody (1:40,000 dilution in 1 % BSA in PBS). The chlamydial inclusion was stained first with the 
primary antibody anti-HtrA rabbit sera (1:500 in 1 % BSA in PBS) and then with a secondary 
antibody: goat anti-rabbit IgG (H+L) – Alexa Fluor 488 (1:600 in 1 % BSA in PBS) [274-276]. Plates 
were imaged on IN Cell Analyzer 2200 (GE Healthcare) in the 2D acquisition mode. HtrA was 
imaged using the Fluorescein isothiocyanate (FITC) channel (excitation filter: 475/28x and emission 
filter 512/23m). DAPI was imaged using the DAPI channel (excitation filter: 590/18x and emission 
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filter 432/48m). Infectivity was calculated as the number of host cell nuclei with an associated 
chlamydial inclusion. 
4.2.10 Titration of C. trachomatis infection 
In a 96-well plate seeded with McCoy cells, individual wells were infected with 25 µl of C. 
trachomatis SPG stock in dilutions from 10-1 to 10-6 in duplicates. Infected cells were methanol-fixed, 
stained with anti-HtraA and DAPI. The number of inclusions was counted in four fields of view 
(FOV) per well (0.556 mm2) using the multipoint tool in ImageJ. Titre (Inclusion forming Units (IFU) 
per mL) was calculated by multiplying the average number of inclusions per FOV with the total 
FOV/well (54.29 FOV per one well in a 96-well plate, instrument specific) and adjusting for the 
dilution and the volume of infection. 
4.2.11 Establishment of mutation frequency 
Six-well plates were seeded with 1.2 x 106 McCoy cells and infected with C. trachomatis LGV-2 in 
enriched DMEM media containing 0 µg/mL, 0.025 µg/mL, 0.05, µg/mL 0.1 µg/mL, 0.3 µg/mL or 
0.5 µg/mL rifampicin to establish the lethal concentration of rifampicin. Following infection, the 
inoculum was removed and the cell layers overlayed with 2 mL 0.55 % agar in enriched DMEM. 
After the agarose had solidified, the infected McCoy cells were overlayed with enriched DMEM 
media containing 0 µg/mL, 0.025 µg/mL, 0.05 µg/mL, 0.1 µg/mL, 0.3 µg/mL or 0.5 µg/mL 
rifampicin and incubated with a change of the non-agarose overlay every third day. After 14 days, 
plaque formation was evaluated. The lethal concentration was determined as the concentration were 
plaque formation is absence. The experiment was performed in duplicate. 
 
To determine mutation frequency, six-well plates seeded with 1.2 x 106 McCoy cells were infected 
with 5 mg/mL or 6 mg/mL C. trachomatis LGV-2 or C. trachomatis LGV-2 tmp libraries in enriched 
DMEM media containing the lethal dose of rifampicin identified above. Following infection, the 
inoculum was removed and the cell layers overlayed with 2 mL 0.55 % agar in enriched DMEM. 
After the agarose had solidified, infected McCoy cells overlayed with enriched DMEM media 
containing the lethal dose of rifampicin were incubated with change of the non-agarose overlay every 
third day. After 14 days, plaque forming was evaluated. This experiment was performed in duplicate. 
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4.2.12 Generation of EMS treated C. trachomatis library  
McCoy cells were infected with C. trachomatis LGV-2 or C. trachomatis LGV-2tmp at an MOI of 5 
in 6-well plates. 19 h post infection, infected cells were treated with concentrated EMS in enriched 
DMEM media (1:10 v/v dilution) to give final concentrations of 0, 2, 3, 4, 5, 6, 7 and 8 mg/mL. The 
plates were incubated at 37 °C for one hour, before replacing with fresh media containing 1 µg/ml 
cyclohexamide. 44 h post infection the cells were harvested in 1 mL cold SPG. The EMS libraries 
were titrated to determine IFU/well. 
4.2.13 Comparison of passaging and continuous growth of infected McCoy cells 
McCoy cells were infected with 2 IFU/well, 5 IFU/well, 10 IFU/well or 15 IFU/well of C. trachomatis 
LGV-2 in triplicates. After four hours the media was replaced with fresh media containing 1 µg/mL 
of cyclohexamide. Subsequently the plates were incubated for eight days, with a media change after 
four days. As a control McCoy cells were infected with 2 IFU/well, 5 IFU/well, 10 IFU/well or 15 
IFU/well C. trachomatis LGV-2 in triplicate and passaged every 48 h for eight days. Both plates were 
fixed with methanol and stained with anti-HtraA and DAPI. Inclusions were counted using the multi-
point selection tool in ImageJ and a student’s T-test for two independent mean were calculated. 
4.2.14 Initial investigation of C. trachomatis LGV-2 sensitivity towards DTT 
24 h after infecting McCoy cells with C. trachomatis LGV-2 (MOI: 0.5) each well was harvested in 
100 µL cold SPG. 50 µL of SPG harvested cells was treated with a final DTT concentration of 10 
mM, 25 mM or 100 mM in PBS and was incubated for two hours. Subsequently the DTT treated SPG 
harvest was used to infect a fresh layer of McCoy cells. After one hour the media was replaced with 
fresh media containing 1 µg/ml of cyclohexamide and incubated for another 30 h. Cells were fixed 
with methanol and stained with DAPI and a HtrA specific antibody. 
4.2.15 Screening of EMS library for increased DTT sensitivity 
24 h after seeding, McCoy cells were infected with 2 IFU/well of the 5 mg/mL EMS treated C. 
trachomatis LGV-2 library with a media change after four hours. After eight days of passaging every 
48 h, the infected cells were harvested in 100 µL SPG. 30 µL of SPG suspended cells were treated 
with 10 mM DTT as described in section 4.2.13 and used to infect a fresh monolayer of McCoy cells. 
As a control, 30 µL of SPG suspended cells were used to infect a fresh monolayer of McCoy cells 
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without DTT treatment. The remaining 40 µL of SPG suspended cells was frozen at  -80 °C. Incubated 
cells were incubated for six days with passaging every 48 h. Cells were fixed with methanol and 
stained with DAPI and a HtrA specific antibody. Wells with an altered phenotype upon DTT 
treatment were subjected to Sanger sequencing outsourced to Australian Genome Research Facility 
and samples were prepared as per their recommendations. 
4.2.16 EMS library screen using TILLING 
In a 96-well plate, McCoy cells were infected with 15 IFU/well of 6 mg/mL EMS treated C. 
trachomatis LGV-2 or C. trachomatis LGV-2tmp chlamydial library with a media change after four 
hours. After eight days of continuous growth, with a media change after four days, each well was 
harvested with 80 µl SPG. 1 µl SPG harvested cells was amplified by PCR using CtDsbA specific 
oligonucleotides at a final volume of 10 µL and subjected to Cel-1 treatment. Wells with a potential 
mutation in the dsbA gene, as evaluated by Cel-1 cleavage, were subjected to Sanger sequencing 
outsourced to Australian Genome Research Facility and samples were prepared as per their 
recommendations.  
4.3 Results 
4.3.1  Introduction of random mutations by EMS  
Treatment with the carcinogenic organic compound EMS introduces randomly positioned mutations 
in DNA. The ethyl group of EMS reacts with guanine in DNA resulting in the formation of O6-
ethylguanine. O6-ethylguanine frequently pairs with thymine, rather than cytosine, which is the 
natural partner of guanine. Consequently, following EMS exposure, the original G:C is replaced with 
an A:T pair after several rounds of replication [272]. 
 
The full-length C. trachomatis dsbA gene has 237 codons. Of these, 189 contain a guanine or cytosine 
base and can therefore be mutated upon treatment with EMS (Table 4.1). However, EMS mutagenesis 
is only an appropriate strategy for obtaining a loss-of-function dsbA mutant if EMS is capable of 
introducing nonsense mutations in the dsbA gene. Alternatively, introduction of missense mutations 
in the cysteine codons can potentially give insight into the importance of these particular residues for 
CtDsbA activity. Analysis of the dsbA gene reveals that the number of possible mutations is 285, of 
which 210 are non-synonymous and 66 are synonymous and therefore silent (Table 4.1).  
 
 112 
Table 4.1 Potential for EMS induced mutations in CtDsbA and their effect. 
Codons Codons with 
mutations 
Mutations Synonymous 
mutations 
Non-
synonymous 
mutations 
Nonsense 
mutations 
Non-
synonymous 
mutations in 
Cys codons  
237 189 285 66 210 9 6 
There are 237 codons in the full-length dsbA gene in C. trachomatis of which 189 have the potential 
to be mutated by EMS. Out of 285 possible mutations 66 are synonymous, 210 are non-synonymous 
and nine are nonsense mutations. All six cysteine residues are potential targets for EMS mutation. 
There are nine options for nonsense mutations in the dsbA gene (Table 4.1). The full-length dsbA 
gene contains six codons for cysteines, all of which can potentially be mutated to tyrosine upon 
treatment with EMS (Table 4.1). As shown in Chapters 2 and 3 the truncated, soluble construct of 
CtDsbA has oxidase activity in the absence of the non-catalytic disulfide and the unpaired Cys70. 
Consequently, only disruption of the two codons corresponding to the active site cysteines is likely 
to result in loss of function of CtDsbA. 
4.3.2  Establishment of EMS library  
McCoy cells infected with C. trachomatis LGV-2 or C. trachomatis LGV-2tmp were treated with 2 
mg/mL to 8mg/mL of EMS to create a library of EMS mutants. However, treatment with EMS 
concentration above 7 mg/mL resulted in a complete loss of infectivity and no bacteria could be 
harvested (Figure 4.3). To enhance the probability of obtaining a loss-of-function mutation in the 
dsbA gene, the libraries obtained from treating with 5 mg/mL and 6 mg/mL of EMS were screened. 
 
Efforts were made to establish the mutation frequency of EMS treatment, by evaluating the frequency 
of acquired rifampicin resistance in EMS-treated cells. The lethal dose of rifampicin was determined 
to be 0.3 mg/mL as evaluated by the absence of plaques at this concentration. Unfortunately, 
evaluation of acquired rifampicin resistance failed due to disruption of the soft agar overlay. Due to 
time pressure this experiment was not repeated. The protocol has previously been used successfully 
in the laboratory of Dr. Wilhelmina Huston, where this experiment was performed. In previous 
experiments the mutation frequency was established to be 0.9 mutations for the C. trachomatis D 
UW-3/Cx genome treated with 2 mg/mL EMS [277]. Another study by Kari et al. showed that treating 
C. trachomatis D UW-3/Cx with 5 mg/mL EMS leads to a mutation frequency of approximately 2.5 
mutations per chlamydial genome [271]. As there are 4.3 x 105 possible mutation sites in C. 
trachomatis and 11 possible mutation sites in the dsbA gene that result in a loss-of-function mutation, 
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an estimated 16,300 subpopulations should be screened to identify one loss-of function mutation in 
the dsbA gene.  
 
   
Figure 4.3 Titration of EMS libraries. 
 To establish the titre of the EMS library, McCoy cells were infected with C. trachomatis LGV-2 
treated with 0, 2, 3, 4, 5, 6, 7 or 8 mg/mL EMS. 30 h post infection the cells were fixed with methanol 
and host cell nuclei were stained with the fluorescent dye DAPI that binds strongly to A-T rich regions 
in DNA. Chlamydial inclusions were stained for the chlamydial inclusion protein HtrA with an anti-
HtrA antibody with secondary antibody goat anti-rabbit IgG (H+L) – Alexa Fluor 488. The titre 
(IFU/mL) of each library was established by calculating the number of inclusions in each well and 
adjusting for the volume used to infect. 
4.3.3 Test of Cel1 activity 
Identification of a dsbA mutation in the TILLING screen of the EMS library requires extraction of 
active Cel-1 from celery. Cel-1 was extracted from fresh celery by ammonium sulfate precipitation. 
The Cel-1 endonuclease activity of the celery extract was tested by assessing its ability to cleave at a 
base pair mismatch in a DNA heteroduplex (Figure 4.4). The heteroduplex was formed between PCR 
products of bpsdsbA wt and bpsdsbA carrying a single C to A point mutation resulting in a Lysine to 
Methionine mutation (bpsdsbA L133M). The heteroduplex was formed by subjecting bpsdsbA and 
bpsdsbA L133M to several rounds of melting and annealing conditions. The heteroduplex has a size 
of 636 bp and cleaving at the base pair corresponding to the C-A mismatch results in two fragments 
of 400 bp and 236 bp, respectively. The heteroduplex was treated with between 0.5 µL and 8 µL of 
celery extract for 15 minutes at 45 °C and analysed by 2 % agarose gel electrophoresis (Figure 4.4). 
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A homoduplex of bpsdsbA was included as a negative control and treated with 8 µL celery extract. 
Only a band corresponding to the uncleaved heteroduplex (~600bp) is present upon treatment with 
0.5 µL celery extract (Figure 4.4). Treatment with 2 µL celery extract results in a faint band at 
approximately 400 bp corresponding to the larger of the cleaved fragments, however the smaller 
fragment is not visible (Figure 4.4). Three bands are present upon treatment with 4 µL celery extract. 
The band at 600 bp represents the uncleaved heteroduplex, whereas the presence of two bands at 
approximately 400 bp and 200 bp are in agreement with cleaving at the C-A mismatch by Cel-1 
(Figure 4.4). The intensity of the two smaller bands increases with treatment with 6 µL and 8 µL 
celery extract indicating that a greater fraction of the heteroduplex is cleaved (Figure 4.4). For the 
homoduplex of bpsdsbA wt, only a band at approximately 600 bp is present after treatment with 8 µL 
celery extract confirming that Cel-1 is present and cleaves specifically at the mismatch (Figure 4.4). 
 
A smear is present in all lanes of the agarose gel. Despite the smear, treatment with 4 µL celery extract 
led to easy recognition and good separation of the two bands corresponding to Cel-1 digestion. 
Therefore 4 µL was used in the TILLING screen. 
 
Figure 4.4 Test for Cel-1 endonuclease activity of celery extract. 
 Cel-1 endonuclease activity was confirmed by testing the ability of increasing volumes of celery 
extract (0.5 µL to 8 µL) to cut at mismatches in DNA heteroduplex formed between bpsdsbA wt and 
bpsdsbA L133M containing a single base pair mismatch. A bpsdsbA wt homoduplex was included 
as a negative control. Both the heteroduplex and homoduplex are 636 bp long. Cel-1 cleavage of the 
heteroduplex results in two additional bands at ~400 bp and ~ 200 bp. 
 115 
4.3.4 Initial screen of C. trachomatis LGV-2 sensitivity towards DTT 
DTT sensitivity was chosen as a phenotypic readout for a potential mutation in the dsbA gene in the 
forward genetics approach. Upon prior treatment of C. trachomatis LGV-434 with 10 mM DTT, 
infection of HeLa cells with the bacteria decreases to 22 % of the infection achieved in the absence 
of DTT [131]. If the EMS library contains a loss-of-function mutation in the dsbA gene this mutant 
is likely to show increased sensitivity to treatment with DTT. To identify an appropriate DTT 
concentration to use in the screen, C. trachomatis LGV-2 infected McCoy cells were treated with 0, 
5, 10, 25 or 100 mM DTT (Figure 4.5).  
 
 
Figure 4.5 Effect of DTT on infectivity. 
 McCoy cells were infected with C. trachomatis LGV-2 and treated with 0, 5, 10, 25 or 100 mM DTT 
in triplicate. 30 h post infection the cells were fixed with methanol and host cell nuclei were stained 
with the fluorescent dye DAPI. Chlamydial inclusions were stained for the chlamydial inclusion 
protein HtrA with an anti-HtrA antibody with secondary antibody goat anti-rabbit IgG (H+L) – Alexa 
Fluor 488. The titre (IFU/mL) of each DTT treated infection was established by calculating the 
number of inclusions in each well and adjusting for the volume used to infect. The titre is indicated 
as % of the titre of the infection treated with 0 DTT. Mean and standard deviation of three individual 
experiments are shown. 
 
Treatment with 5 mM DTT resulted in 25 ± 7 % decrease in IFU compared to the untreated control 
(Figure 4.5). Due to the relatively limited effect on infection observed upon treatment with 5 mM 
DTT this condition was not used further in the DTT sensitivity screen of the EMS library. For 25 mM 
and 100 mM DTT the IFU count was decreased by 90 ± 1 % and 99 ± 0.1 %, respectively (Figure 
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4.5). As infectivity was almost abolished after treatment with 25 mM DTT, and completely abolished 
with 100 mM DTT, a further decrease of infection would be difficult to evaluate. Upon treatment 
with 10 mM DTT the IFU count was 46 ± 1 % of the untreated control (Figure 4.5). This is a 
significant decrease in infectivity, but would also allow observation of further decrease in infectivity 
resulting from a mutant with increased sensitivity to DTT.  
 
High DTT concentrations can potentially directly influence the host cell in addition to affecting the 
infectivity of C. trachomatis. Therefore, the effect of DTT on the monolayer of infected McCoy cells 
was tested (Figure 4.6). 
 
 
Figure 4.6 The effect of DTT on the McCoy cell monolayer. 
 C. trachomatis LGV-2 infected McCoy cells were treated with 0, 10 and 100 mM DTT and the host 
cell nucleus (blue) was stained with DAPI.  
The condition of the McCoy cell monolayer was evaluated by staining DTT treated C. trachomatis 
LGV-2 infected McCoy cells with the fluorescent dye DAPI. As DAPI binds strongly to A-T rich 
regions in DNA, each blue spot in Figure 4.6 represents a host cell nucleus. Consequently, the number 
of host cells surviving the DTT treatment can be visualised. Treatment with 100 mM DTT has a 
significant effect on the monolayer as judged by the severe disruption of the monolayer. In contrast, 
the number of nuclei after treatment with 10 mM DTT is equivalent to the untreated control (Figure 
4.6), suggesting that treatment with 10 mM DTT has limited or no effect on the host cell viability. As 
treatment with 10 mM DTT leads to an appropriate decrease in infectivity of C. trachomatis but does 
not affect host cell viability, 10 mM DTT was chosen for screening the EMS library for increased 
DTT sensitivity. 
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4.3.5  Comparing suitability of continuous growth vs. passage of infected 
McCoy cells for screening 
In the forward and reverse genetic approach McCoy cells were infected with a limited number of 
IFUs and grown for eight days to increase the number of McCoy cells infected by the EMS mutants. 
This allows observation of decreased infectivity as a result of increased DTT sensitivity in the forward 
genetics approach or amplification of the dsbA gene in the reverse genetics approach, respectively. 
In the DTT sensitivity screen, McCoy cells were infected with 2 IFU/well in a 96-well plate. 2 IFUs 
were chosen as this number allows for observation of a decrease in infectivity compared to the 
untreated control. Infecting with more than 2 IFUs increases the possibility that a healthy 
subpopulation without a mutation in the dsbA gene might outgrow the subpopulation containing a 
mutation in the dsbA gene, thereby making observation of a decrease in infectivity challenging. 
Evaluation of decreased infectivity would be simpler if infecting with 1 IFU/well, however infecting 
with 2 IFU/well doubles the number of subpopulations screened in each well without significantly 
interfering with evaluation of the effect of DTT treatment. 2 IFU/well was thus chosen for 
experimental efficiency.  
 
As the TILLING approach does not select for a specific phenotype of the McCoy cells, it allows for 
infection with a higher IFU. However, infecting with more than 15 IFU could potentially complicate 
identification of a mutant by sequencing. As each well would contain more than 15 subpopulations, 
of which only one is likely to contain a specific point mutation, the ratio of wild type (wt) to mutant 
base is potentially too small to identify the mutation. 
 
To minimise handling it would be advantageous if the number of infected McCoy cells can be 
increased by continuous growth rather than passaging every 48 h. To identify an appropriate IFU for 
continuous growth, McCoy cells were infected with C. trachomatis at an IFU of 2 IFU/wells, 5 
IFU/wells, 10 IFU/wells or 15 IFU/wells and grown continuously for eight days with a media change 
after four days. Control infections with 2 IFU/wells, 5 IFU/wells, 10 IFU/wells or 15 IFU/wells were 
passaged every 48 h by harvesting in SPG and using the SPG harvest to infect a fresh monolayer of 
McCoy cells. After eight days, the cells were fixed and the chlamydial inclusion protein HtrA was 
stained with an anti-HtrA antibody and secondary goat anti-rabbit IgG (H+L) – Alexa Fluor 488 
antibody to identify chlamydial inclusions (Figure 4.7). 
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There are on average 6.3 ± 1.5 inclusions per FOV when imaging the wells containing McCoy cells 
infected with 2 IFU/well and cultured continuously for eight days (Figure 4.7A). In comparison wells 
that had been passaged every 48 h had on average 236 ± 73 inclusions per FOV (Figure 4.7B). When 
comparing the passaged and continuously cultured cells infected with 2 IFU/well in a students t-test 
for comparison of two independent means, a p-value of 0.005 is obtained. Similar results are found 
for infections of 5 IFU/well (p=0.002) (Figure 4.7C+D). When McCoy cells are infected with 10 
IFU/well the yield after eight days of continuous growth without passaging (Figure 4.7E) is 
approximately half of the yield compared to when the cells are passaged every 48 h for eight days 
(Figure 4.7F), but the difference is not statistically significant (p=0.1). Infecting with 15 IFU/well 
gives approximately the same yield of chlamydial inclusions (p=0.2) after eight days of continuous 
growth as passaging every 48 h (Figure 4.7G+H). Consequently, it was decided to infect with 2 
IFU/well and to passage the infected cells when assessing the EMS library for DTT sensitivity. When 
assessing the library using the TILLING approach the cells can be infected with 15 IFU/well and 
grown continuously without passaging. 
 
Figure 4.7 Yield of chlamydial inclusions eight days post infection after continuous growth 
compared to passaging. 
 The chlamydial inclusion protein, HtrA (green), is stained with anti-HtrA antibody with secondary 
antibody goat anti-rabbit IgG (H+L) – Alexa Fluor 488 and imaged using an IN Cell Analyzer 2200. 
Each green spot represents a single chlamydial inclusion. McCoy cells infected with 2 IFU/well had 
a significantly lower (p=0.005) yield of inclusions after 8 days of continuous growth (A) than when 
passaged every 48 h (B). McCoy cells infected with 5 IFU/well had a significantly lower yield 
(p=0.002) of inclusions after 8 days of continuous growth (C) than when passaged every 48 h (D). 
McCoy cells infected with 10 IFU/well had a slightly lower yield of inclusions after 8 days of 
continuous growth (E) than when passaged every 48 h (F), but this was not statistically significant 
(p=0.1). McCoy cells infected with 15 IFU/well had a similar yield of inclusions (p=0.2) after 8 days 
of continuous growth (G) as when passaged every 48 h (H). 
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4.3.6 Forward genetics approach of screening EMS library for increased DTT 
sensitivity  
In the forward genetics approach the EMS library was screened for increased sensitivity to DTT to 
decrease the pool of potential EMS mutants with a loss-of-function mutation in the dsbA gene. 
 
McCoy cells in 96-well plates were infected with the 5 mg/mL EMS-treated library of C. trachomatis 
LGV-2 at 2 IFU/well and passaged every 48 h for eight days. After harvesting in SPG, one third of 
the harvest was treated with 10 mM DTT and used to infect a fresh monolayer of McCoy cells. As a 
control, another third of the harvest was used to infect McCoy cells without prior treatment with DTT. 
Both DTT treated and control infections were passaged for six days before cells were fixed and 
stained. The host cell nucleus was stained with DAPI and the inclusions were stained with an antibody 
specific for the inclusion protein HtrA with a secondary antibody goat anti-rabbit IgG (H+L) – Alexa 
Fluor 488 antibody. Infectivity was calculated as the number of host cell nuclei (blue) associated with 
a chlamydial inclusion (green) (Figure 4.8).  
 
Treating C. trachomatis LGV-2 with 10 mM DTT led to a 46 % decrease in infectivity (Figure 4.5). 
The hypothesis is that a loss-of-function mutation in the dsbA gene will lead to increased sensitivity 
to DTT treatment and consequently decreased infectivity. In this screen infections showing more than 
60 % decrease in infectivity upon DTT treatment were regarded as hits for increased DTT sensitivity. 
 
Four different phenotypes were observed upon treatment of the EMS library with 10 mM DTT; (i) a 
decrease in infectivity upon treatment of the EMS library with DTT equivalent to the 46 % decrease 
in infectivity observed for DTT treatment of C. trachomatis LGV-2 wt (Figure 4.8A); (ii) a decrease 
in infectivity greater than 60 % of the DTT treated infections compared to the untreated controls 
(Figure 4.8B); (iii) an increase in infectivity of DTT treated infections compared to the untreated 
control (Figure 4.8C); (iv) a decrease in inclusion size in the DTT treated infections compared to the 
untreated control (Figure 4.8D).  
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Figure 4.8 Four different phenotypes were observed upon treatment of EMS library with 10 mM 
DTT. 
 McCoy cells were infected with the 5 mg/mL EMS treated library of C. trachomatis LGV-2 at 2 
IFU/well and passaged every 48 h and harvested in SPG. One third of the harvest was treated with 
10 mM DTT and used to infect a fresh monolayer of McCoy cells. As a control, another third of the 
harvest was used to infect McCoy cells without prior treatment with DTT. Infections were cultured 
for six days with passaging every 48 h.  After fixing the cells with methanol the host cell nucleus 
(blue) was stained with DAPI. The chlamydial inclusion protein HtrA (green) was stained with anti-
HtrA antibody with secondary antibody goat anti-rabbit IgG (H+L) – Alexa Fluor 488 and imaged 
on IN Cell Analyzer 2200. A) DTT treatment of one well of the EMS library results in decrease in 
infectivity of 51 % compared to the corresponding untreated well. This is equivalent to a decrease in 
infectivity of 46 % observed for C. trachomatis LGV-2 treated with 10 mM DTT. B) DTT treatment 
of one well of the EMS library leads to a decrease in infectivity of 70 % compared to the untreated 
control. C) DTT treatment of one well of the EMS library leads to an increase in infectivity compared 
to an untreated control. D) DTT treatment of one well of the EMS library leads to a decreased 
inclusion size compared to the untreated control. For ease of comparison the host cell nucleus is 
omitted from this image.  
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Out of 963 wells screened, 927 wells showed no significant change in DTT sensitivity of the EMS 
library compared to control C. trachomatis LGV-2 (Table 4.2). An example of this is shown in Figure 
4.8A, where treatment with DTT led to a decrease in infectivity of 51 % compared to the untreated 
control, which is roughly equivalent to the 46 % decrease observed upon DTT treatment of C. 
trachomatis LGV-2 (Figure 4.5). 36 wells showed altered phenotype upon treatment with DTT 
compared to the untreated control (Table 4.2). Increased sensitivity for DTT was observed in 28 wells 
as evaluated by a decrease in infectivity greater than 60 % upon DTT treatment (Table 4.2), including 
one well where the infectivity decreased by 70 % upon DTT treatment compared to the untreated 
control (Figure 4.8B). In one of five wells with increased infectivity, the infectivity of the DTT 
treated control is 51 % higher than in the untreated control (Figure 4.8C). Figure 4.8D shows one 
example out of three infections that exhibited reduced inclusion size compared to the untreated 
control (Table 4.2).  
 
Table 4.2 EMS treated C. trachomatis LGV-2 library phenotypes observed upon DTT treatment. 
Phenotype Observations Confirmation of Phenotype 
No difference  927 - 
Decrease in infectivity  28 14 
Increase in infectivity  5 0 
Decrease in inclusion size 3 0 
 
To investigate the robustness of the phenotype, DTT treatment was repeated for the 36 wells showing 
an altered phenotype. The phenotype was confirmed for 14 of the 36 infections showing altered 
phenotype in the original screen (Table 4.2). All cases of confirmed phenotype in the screen of the 5 
mg/mL EMS treated library of C. trachomatis LGV-2 showed a decrease in infectivity upon DTT 
treatment larger than the 60 %. The 14 infections with a confirmed phenotype were subjected to 
Sanger sequencing with dsbA specific primers, but none contained C. trachomatis with a mutation in 
the dsbA gene.  
4.3.7  Reverse genetics approach for screening of EMS Library using TILLING 
McCoy cells were infected with 15 IFU/well of the EMS libraries derived from treating C. 
trachomatis LGV-2 or C. trachomatis LGV-2tmp with 6 mg/mL EMS. As per the previously 
described experiment (Section 4.3.5) the number of McCoy cells infected with 15 subpopulations of 
EMS mutants were increased by continuous growth for eight days and harvested. The harvested cells 
were heat-inactivated and the dsbA gene was amplified with primers specific for the dsbA gene. As 
only one subpopulation out of 15 in each infection is likely to have a specific mutation in the dsbA 
gene, a heteroduplex will form after melting and annealing of the 15 subpopulations if any of the 
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subpopulations harbours a mutation in the dsbA gene. A potential mutation can subsequently be 
identified by treatment with celery extract with Cel-1 endonuclease activity. 
 
The specificity of the primer set was tested by amplifying the dsbA gene from heat-inactivated C. 
trachomatis LGV-2 EBs by PCR. Different annealing temperatures were investigated to identify the 
correct annealing temperature for the PCR reaction. Annealing temperatures from 40-50 °C resulted 
in a single band on a 2 % agarose gel corresponding to the length of the PCR product of dsbA (733 
bp) (Figure 4.9). 41.9 °C was chosen as the annealing temperature to use for amplifying dsbA from 
the EMS library by TILLING as this temperature resulted in the highest quantity of PCR product as 
indicated by the intensity of the band (Figure 4.9).  
 
Figure 4.9 Control of amplification specificity of dsbA primers. 
 Heat-inactivated C. trachomatis LGV-2 EBs were subjected to PCR with annealing temperature 
ranging from 40 °C to 50 °C. The band circled in red corresponds to an annealing temperature of 
41.9 °C. 
Ten 96-well plates of McCoy cells infected with 15 IFU per well were screened by TILLING after 
eight days of continuous growth. The dsbA gene was isolated by PCR with primers specific for the 
dsbA gene. Subsequently the PCR products from each infection were subjected to several rounds of 
melting and annealing conditions creating a pool of DNA homo- and heteroduplexes. Homo-and 
heteroduplexes of the dsbA gene were isolated by PCR. Cel-1 digestion was used to identify potential 
heteroduplexes of the dsbA gene. Cel-1 digested PCR products were run on agarose gels to identify 
lower molecular weight bands corresponding to Cel-1 digestion at a point mutation. However dsbA 
was not amplified for all infections and evaluation of Cel-1 digestion was complicated by the 
appearance of a smear on the agarose gel for most of the PCR products (Figure 4.10).  
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Out of 960 wells screened only eight pools of DNA duplexes had what appeared to be a very faint 
band resulting from Cel-1 cleavage. The pool of DNA duplexes from these eight infections was 
Sanger sequenced with both the forward and reverse dsbA specific primers, resulting in a total 16 
reads. For 5 of the 16 reads the sequence quality was too poor to evaluate potential mutations. For 
one well (pool of duplexes), both the forward and reverse sequencing was of poor quality, but for 
three others wells the sequencing with only the reverse primer was of poor quality. However, even 
the remaining 11 high quality reads (with sequence information for 7 pools of duplexes) did not reveal 
any mutations in the dsbA gene. In conclusion seven pools of duplexes with an apparent mutation as 
judged by Cel-1 digestion were false positives as sequencing identified no mutation in the dsbA gene. 
In the remaining pool of duplexes the sequencing quality was too poor to be conclusive. 
 
 
 
Figure 4.10 Cel-1 digest of dsbA PCR products. 
 McCoy cells infected with mutants from the EMS library were harvested and subjected to PCR with 
dsbA specific primers. The PCR product was treated with celery extract and Cel-1 digestion was 
evaluated on 2 % agarose gel. The white arrow indicates the appearance of a faint band 
corresponding to a lower molecular weight than the dsbA gene (CtDsbA). 
4.4 Discussion 
A C. trachomatis strain with a disruption in the dsbA gene would be a valuable tool for gaining insight 
into the role of CtDsbA in C. trachomatis virulence. Random mutagenesis by EMS was chosen as a 
strategy to obtain a loss-of-function mutation in the dsbA gene of C. trachomatis. A library of EMS 
mutants was created by treating C. trachomatis LGV-2 and C. trachomatis LGV-2tmp with EMS and 
EMS concentrations of 5 and 6 mg/mL were chosen as that gave the highest mutation frequency 
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without suppressing infectivity significantly. As EMS libraries obtained by treating C. trachomatis 
D UW-3/Cx with 5 to 6 mg/mL EMS have approximately 2.5 mutations per genome, a subpopulation 
with a loss-of-function mutation in the dsbA gene is also likely to have at least one more mutation 
elsewhere in the genome. However, as approximately one third of all mutations introduced by EMS 
in the genome of C. trachomatis are synonymous and less than 10 % are nonsense mutations [270] it 
is unlikely that a loss-of-function mutation in the dsbA gene would be accompanied by a mutation in 
another gene severely influencing infection. Consequently, a mutation rate of 2.5 mutations per 
genome increases the likelihood of obtaining a loss-of-function mutation in the dsbA gene with 
minimal risk of creating a severe disruption of an additional critical gene. However, C. trachomatis 
D UW-3/Cx and C. trachomatis LGV-2 exhibit different susceptibility to antibiotics. Consequently 
the frequency of acquired rifampicin resistance, and thus mutation frequency, determined for C. 
trachomatis D UW-3/Cx might not accurately reflect the mutation frequency in C. trachomatis LGV-
2 although treated with the same concentration of EMS. Therefore, the mutation frequency of the 
EMS treated C. trachomatis LGV-2 library should be determined to confirm the mutation rate in this 
specific library. 
 
A total of approximately 16,000 EMS treated subpopulations of C. trachomatis LGV-2 and C. 
trachomatis LGV-2tmp were screened in the TILLING approach and the DTT sensitivity screen 
combined. With 2.5 mutations per genome and 4.3 x 105 mutations sites in the genome of C. 
trachomatis, in theory one of 16,300 subpopulations from the EMS library should contain a loss-of-
function mutation in the dsbA gene. Unfortunately, even though 16,000 subpopulations out of the 
estimated 16,300 subpopulations were screened, no mutations in the dsbA gene were identified either 
in the forward or reverse genetic approach. As 16,300 is an estimation of the subpopulation needed 
to screen to obtain one loss-of-function mutation in the dsbA gene, it might be that EMS random 
mutagenesis resulted in no mutations in dsbA in the screened subpopulations. Alternatively, a 
mutation did occur in the dsbA gene but was not detected in either of the two screens. As there are 
289 potential mutation sites in the dsbA gene screen, approximately 25 point mutations should have 
been introduced into the dsbA gene in the 16,000 subpopulations screened. Synonymous mutations 
as well as non-disruptive non-synonymous point mutations in the dsbA gene would not show up in 
the DTT sensitivity screen, but would still be recognised by Cel-1 digestion and should consequently 
be detected when sequencing the dsbA gene. Approximately 14,000 of the 16,000 subpopulations 
screened were screened using the TILLING approach and accordingly about 22 mutations in the dsbA 
are likely to be present in the subpopulations screened. The failure to identify any mutations in the 
dsbA gene suggests that either the mutation frequency is significantly lower than anticipated or the 
TILLING approach is not sensitive enough to report the mutations.  
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To test whether the assumption of 2.5 mutations per genome is correct, the mutation frequency of the 
screened EMS libraries should be experimentally determined. The mutation rate can be determined 
by finding the frequency of acquired rifampicin resistance in the EMS library. There is a total of 37 
points that can introduce nonsense mutations to the trpBA operon and thus introduce rifampicin 
resistance [271]. Accordingly, one in approximately 5,000 subpopulations would gain resistance to 
rifampicin with a mutation frequency of 2.5 mutations. The rifampicin resistance frequency of an 
EMS library is established by infecting a monolayer of McCoy cells with the EMS library at a known 
MOI. Infected McCoy cells are treated with a lethal dose of rifampicin and the number of 
subpopulations that survive the treatment is determined.  
4.4.1 Evaluation of the TILLING screen 
Alternatively, the lack of identification of a mutation in the dsbA gene could be due to the weaknesses 
in detection of mutations in the TILLING approach. This is further emphasised by the high ratio of 
false positives in the Cel-1 digestion. The identification of bands corresponding to Cel-1 digestion 
products was challenging due to the smear on the agarose gel. Although the smear is also present on 
the agarose gel testing for endonuclease activity of the celery extract, the smear did not interfere with 
identification of digestion products. However, in the TILLING screen, the PCR product of dsbA is 
derived from 15 subpopulations, where it is expected that one subpopulation potentially contains a 
mutation in the dsbA gene. Accordingly, the bands corresponding to the digestion products will be 
very faint and more difficult to distinguish on a smeared gel. As the observed digested bands are 
extremely faint, it is possible that they may be artefacts arising from the presence of smear. Similarly, 
it is highly likely that bands corresponding to Cel-1 digestion products in other reactions are not 
recognised on the gel due to the smear. Reducing the number of IFUs screened per well may solve 
the issue of detection of digestion products. Smearing is a common occurrence when running Cel-1 
digested PCR products on agarose gel [273]. Optimising the ratio of Cel-1 to target DNA can 
potentially reduce the smear. Alternatively, Cel-1 can be replaced with a different endonuclease 
digesting specifically at base pair mismatches. The endonuclease Guide-it Resolvase does reduce the 
occurrence of smear and is also less sensitive to buffers used in the PCR reaction, according to the 
manufacturer (TaKaRa). In High Resolution Melting (HRM) analysis, a mutation in a PCR product 
can be identified by change in melting temperature and this offers a high-throughput alternative to 
evaluating mutations by endonucleases. Although the method is reliable, the sensitivity decreases 
with amplicon length and the impact on melting temperature of a single mutation in PCR products 
larger than 300 bp is close to zero [278]. Furthermore, the sensitivity of the method is highest when 
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50 % of the population contains the mutant, but the difference in melting temperature can still be 
detected with around 5 % of mutant DNA in the population [278].  Considering the length of the dsbA 
PCR product (636 bp) and a frequency of mutation of 6.7 % (i.e. if one of 15 subpopulations contains 
a mutation) the sensitivity of HRM is likely too low to be a suitable method for identifying a mutant 
in the dsbA gene. 
 
The high ratio of false positives in the TILLING screen could also arise from failure to identify the 
base pair mismatch in the manual evaluation of the Sanger sequencing reads. In recent years, 
sequencing by next generation sequencing platforms have gained popularity as a high-throughput, 
deep sequencing alternative to Sanger sequencing. The most common and suitable option for an 
application such as this would be the Illumina miSeq using a PCR amplicon sequencing approach. 
However, read lengths are limited to 2x300 bp [278]. Consequently, the dsbA gene (636 bp) pushes 
the limit on read length by this method, or two separate amplicons would be needed for each well. 
The newest Illumina platform, Illumina HiSeq, and the benchtop sequencer, Illumina MiSeq, both  
have error rates of ~0.3 error per 100 bp [279], which give on average 1.9 misreads in the dsbA gene. 
Given the low representation of mutants with wild-type in the pools, this error rate is higher than the 
dsbA mutation rate in the population. So, although this is a promising strategy the limitations in read 
length and the relatively high error rate mean that this method is not yet compatible with the TILLING 
screen for mutations in the dsbA gene. 
4.4.2 Evaluation of the screen for increased DTT sensitivity 
In the DTT sensitivity approach, 960 wells each containing two subpopulations of the EMS library 
were screened. Out of 36 wells exhibiting an altered phenotype upon DTT treatment, the phenotype 
was confirmed for 14 wells. In all confirmed cases the wells contain subpopulations that exhibit 
decreased infectivity upon DTT treatment suggesting that these wells contain a subpopulation with 
increased sensitivity to DTT. Sequencing of the dsbA gene in the subpopulations with increased 
sensitivity to DTT did not reveal any mutations in the dsbA gene. The DTT sensitivity screen was 
developed based on the hypothesis that infection would be reduced upon treatment with DTT of C. 
trachomatis lacking the DsbA oxidase activity. An EMS mutant harbouring a loss-of-function 
mutation in the dsbA gene might potentially cause complete loss of infection upon DTT treatment. 
Consequently, the amount of DNA arising from this subpopulation is minimal compared to the 
healthy subpopulation in the well and the signal-to-noise ratio might be too low to identify the 
mutation. As C. trachomatis is highly dependent on the redox regulation of the disulfide bonds in the 
outer membrane [81, 131] it is possible that disruption of oxidase activity could abolish infection 
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completely. Further it is possible that the increased sensitivity to DTT treatment arises from 
disruption of an alternative redox protein. Consequently the 14 wells should be subjected to whole-
genome sequencing to identify which gene is responsible for the increased sensitivity to DTT. 
4.4.3  Future directions for studying the biological role of CtDsbA 
Obtaining a loss-of-function mutation in the dsbA gene of C. trachomatis was not possible using the 
approaches and conditions reported here. Unfortunately, this delays our understanding of the potential 
role of CtDsbA in C. trachomatis infection and development. More effort should be put towards 
obtaining a loss-of-function mutation in the dsbA gene. In addition to the undirected approach 
presented in this thesis, directed approaches could be attempted to obtain a loss-of-function mutation 
in the dsbA gene e.g by site-specific inactivation of the dsbA gene by insertion of a group II intron 
using the TargeTronTM approach which has proven successful in C. trachomatis LGV-2 [267]. A 
recent paper discusses the feasibility of using Clustered Regularly Interspaced Short Palindromic 
Repeats interference (CRISPRi) to create knockout mutants in Chlamydia. Although creation of a 
single plasmid system for CRISPR, targeting the inclusion membrane protein incA (dCas9) was 
succesfull, it failed to knockout expression of incA. Reversible inhibition of incA was, however, 
accomplished by inducing dCas9 in the presence of guide RNA (gRNA) targeting the 5’ UTR of incA 
[281]. The succesfull inhibition of incA expression shows that CRISPRi is promising strategy for 
creating knockout mutations in Chlamydia and should be explored as an alternative strategy for 
creating a knockout mutation of the dsbA gene. However, for the method to be suitable, issues with 
low plasmid stability and leaky expression of the tet promoter and low efficiency of transformation 
would need to be addressed. 
 
Until a loss-of-function mutation for dsbA has been created characterisation of CtDsbA in C. 
trachomatis could contribute to the understanding of the role of CtDsbA without directly studying 
the effect of a lack of CtDsbA oxidase activity on C. trachomatis. Most importantly, the subcellular 
localisation of CtDsbA has not yet been determined. Whereas most Gram-negative DsbA enzymes 
are located in the periplasm, CtDsbA has a putative transmembrane region and localisation software 
tools predict CtDsbA to be either membrane-anchored or periplasmic (Section 2.6.1). The subcellular 
localisation of CtDsbA could be determined by cell fractionation in which the periplasmic 
compartment is separated from the cytosol and membrane fraction by centrifugation at 8,000 x g. 
Subsequently the cytoplasmic and membrane fractions can be separated by ultracentrifugation [282]. 
The fraction containing CtDsbA can be identified by western blotting with an antibody specific for 
CtDsbA. 
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Two of the three DsbAs in N. meningitidis are lipid proteins anchored to the membrane and 
inactivation of these (NmDsbA1 and NmDsbA2) have a greater effect on sensitivity towards reducing 
agents as well as proteins involved in adhesion compared to inactivation of the periplasmic NmDsbA3 
[283]. Similarly, PaDsbA2, which is predicted to be membrane-anchored, is thought to have a 
different substrate range to that of periplasmic PaDsbA1 [75]. Consequently, membrane anchoring 
of CtDsbA could indicate a different substrate range than periplasmic DsbAs. Considering the 
disulfide-cross linking of the outer membrane in C. trachomatis, a different substrate range of 
CtDsbA compared to periplasmic DsbAs might be linked to a role in regulating the redox state of the 
outer membrane proteins. However, even if CtDsbA is membrane-anchored and interacts with 
proteins in the chlamydial outer membrane complex (COMC) it is not most likely directly involved 
in the COMC as it has not been identified in a previous analysis of the isolated COMC proteins [130]. 
4.5 Conclusions 
Although no dsbA mutation was identified in the subpopulations screened, chemical mutagenesis 
remains the most promising strategy for obtaining a loss-of-function CtDsbA mutation. Whereas the 
reverse genetic approach using TILLING to identify mutations in the dsbA gene allows for screening 
of more IFU per infection, false positives in Cel-1 digestion products and a failure to identify true 
positive bands complicates the identification of a dsbA mutant. In the forward genetics approach, 
screening for increased DTT sensitivity can potentially lead to identification of redox protein mutants 
other than dsbA mutants. As fewer subpopulations are screened in each well this is a more 
cumbersome approach. However, since other redox sensitive proteins are likely to be affected by 
treatment with DTT the forward genetics approach can potentially identify other proteins important 
for the redox regulation of C. trachomatis.  
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The goal of this thesis was to characterise the oxidative pathway of the obligate intracellular pathogen 
C. trachomatis, specifically to investigate the structure and function of the putative primary oxidase 
CtDsbA and the interaction between CtDsbA and its predicted redox partner CtDsbB.  
 
As a member of the Chlamydia phylum, C. trachomatis has a biphasic developmental cycle 
alternating between the infectious extracellular EB and the replicating intracellular RB. 
Differentiation from EB to RB is dependent on reduction of the disulfide cross-linking network of 
the chlamydial envelope [143-145, 148]. Conversely, restoration of the disulfide cross-linking 
network is required for RB to EB differentiation at the late stages of C. trachomatis infection [145, 
284]. This developmental cycle led to the hypothesis that the oxidative pathway in C. trachomatis 
may play a specialised role in oxidising the outer membrane and outer membrane associated proteins. 
5.1 Expansion of the structural library of DsbA enzymes 
The first aim of this thesis was to structurally and functionally characterise CtDsbA to shed new light 
on the diversity amongst DsbA enzymes. I found that the truncated soluble construct of CtDsbA is 
structurally and functionally similar to other characterised DsbA proteins, but is distinguished by 
being the least oxidising DsbA characterised to date and by having an active site disulfide that is only 
mildly destabilising (Chapter 2). Further, CtDsbA has an unusually high number of cysteines. The 
soluble construct of CtDsbA has, apart from the active site cysteines, a disulfide bond linking helix 
H1 and helix H5 and an unpaired cysteine (Cys70) in loop L1. An additional cysteine is found in the 
predicted transmembrane helix of the predicted full-length translated CtDsbA enzyme. The crystal 
structure of CtDsbA represents the first structural characterisation of a DsbA having two small 
uncharged amino acids in the dipeptide motif separating the catalytic cysteines.  
 
The catalytic site dipeptide has been shown to modulate the redox properties of thioredoxin enzymes 
[71]; the proline residue found in position X1 in the CX1X2C catalytic motif of EcDsbA favours 
electrostatic stabilisation of the thiolate anion by the helix dipole of helix H1. The serine in the 
equivalent position in CtDsbA does not offer this stabilisation, which is consistent with the low redox 
potential of CtDsbA. Other DsbAs that lack a proline in position X1 include WpDsbA1 [108] and 
FtDsbA type A and type B [29]. These also have low redox potentials. WpDsbA1 contains a histidine 
in position X2 (as does EcDsbA) that offers stabilisation of the thiolate anion. FtDsbA (type A and 
B) contains a tyrosine residue in position X2 that would also be able to offer direct electrostatic 
stabilisation of the thiolate anion, which is consistent with a redox potential equivalent with that of 
WpDsbA1. However, as the structure of FtDsbA has not been determined the spatial arrangement of 
 133 
the residues has not been determined. NmDsbA3 has a valine rather than a proline in position X1 [65] 
and yet has a relatively high redox potential. In addition to the lack of a proline residue in position 
X1, the alanine in position X2 of CtDsbA offers no equivalent electrostatic stabilisation of the thiolate 
anion to that provided by the histidine in EcDsbA. The lack of factors contributing to stabilisation of 
the thiolate anion in CtDsbA is consistent with the low redox potential of the protein, and with the 
observation by Huber-Wünderlich and co-workers that the dipeptide separating the active site 
cysteines are pivotal for determination of redox properties [71]. 
 
Structurally, CtDsbA is most closely related to PaDsbA2, WpDsbA1 (DsbA-IIb) and BsDsbA 
(DsbA-IIa). On the basis of its β-sheet topology, CtDsbA belongs in the DsbA-II class with 
WpDsbA1, BsDsbA, MtbDsbA and SaDsbA. The surface of CtDsbA has no pockets adjacent to the 
active site, but several smaller pockets on the posterior face of the protein. Similar to the Gram-
positive members of the DsbA-IIa subgroup, the surface of CtDsbA is predominantly negatively 
charged. In particular, the surface surrounding the active site is highly acidic. Characterisation of 
CtDsbA expands the number of structurally characterised DsbA enzymes with a charged catalytic 
surface and no identifiable pocket at the catalytic surface (Chapter 2). 
5.2 Exploration of the oxidative pathway in C. trachomatis 
The second goal of this thesis was to explore the potential similarities and differences between the 
oxidative pathway in C. trachomatis and the canonical oxidative pathway of E. coli (Chapter 3). The 
overall similarities between CtDsbA and other DsbA enzymes, as well as the identification of a DsbB 
homolog in C. trachomatis indicates that the oxidative pathway in C. trachomatis resembles the 
canonical DSB oxidative pathway of E. coli (Chapter 2 and 3). This is supported by the observation 
that crude membranes containing CtDsbB facilitate the oxidase activity of CtDsbA (Chapter 3, 
section 3.3.2). In contrast to this finding, purified detergent-solubilised CtDsbB was not able to 
oxidise truncated CtDsbA in the presence or absence of ubiquinone-1 (UQ-1) (Chapter 3, section 
3.3.3). This is most likely due to CtDsbB being inactive in the n-Dodecyl β-D-maltoside (DDM) 
micelles used to prepare detergent-solubilised protein. Alternatively, UQ-1 may not be a suitable co-
factor for CtDsbB. This would be in contrast to what is observed for other DsbB enzymes, where 
UQ-1 is able to facilitate DsbB mediated oxidation of DsbA from E. coli, V. cholerae, W. pipientis 
and M. tuberculosis [76, 78, 108, 230]. However, it might be explained by the difference in UQ 
binding observed between CtDsbB and EcDsbB (Chapter 3, section 3.3.4). 
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5.2.1 The role of the second disulfide of CtDsbA in the interaction with CtDsbB 
CtDsbA contains a second disulfide bond linking helix H2 and helix H5. A similarly placed disulfide 
is present in three other structurally characterised DsbA enzymes: WpDsbA1, PaDsbA2 and 
MtbDsbA and appears to be conserved in DsbAs from alpha-proteobacteria [80]. In WpDsbA1, the 
second disulfide has an inhibitory effect on the interaction with WpDsbB, but no effect on redox 
potential [108], whereas it reduces the oxidase activity of PaDsbA2 significantly [75]. In MtbDsbA, 
the second disulfide is believed to play a structural role [78, 88]. The effect of the second disulfide 
on the interaction with the cognate redox partner (PaDsbB1 or VKOR, respectively) has not been 
investigated for PaDsbA2 and MtbDsbA. 
 
Curiously I found that the second disulfide of CtDsbA does not have an inhibitory effect on its 
interaction with CtDsbB and has only a minimal effect on protein stability (Chapter 3, section 3.3.6). 
However, the second disulfide did contribute slightly to stabilisation of the active, oxidised state over 
the reduced state. Thus it is possible that the second disulfide of CtDsbA might influence the intrinsic 
redox properties of CtDsbA. 
5.3 Forward and reverse genetics approaches to obtain a loss-of-
function mutant of the dsbA gene in C. trachomatis 
The third aim was to explore a forward and a reverse genetics approach to obtain a loss-of-function 
mutation in the dsbA gene in C. trachomatis (Chapter 4). Considering the importance of disulfide 
bonds in C. trachomatis infection and development, I hypothesised that CtDsbA is involved in 
oxidation of at least some of the proteins in the Chlamydial Outer Membrane Complex (COMC). The 
finding in Chapter 3, section 3.3.5 that CtDsbA expression correlates with the onset of oxidation of 
the COMC proteins supports the hypothesis that CtDsbA is involved in the oxidation of the COMC 
proteins. Obtaining a loss-of-function mutant of CtDsbA would enable investigation of the effect of 
the loss of CtDsbA activity on C. trachomatis infection and development, and provide insight into 
the role of CtDsbA in vivo. Altered dithiothreitol (DTT) susceptibility was verified as a phenotypic 
marker in the forward genetics approach (Chapter 4, section 4.3.6). Out of 1920 subpopulations 
screened, 14 exhibited reproducible sensitivity to DTT, but sequencing revealed no mutations in the 
dsbA gene. In the reverse genetic approach, approximately 14,000 subpopulations were screened for 
mutations in the dsbA gene (Chapter 4, section 4.3.7). Potential mutations in dsbA were searched by 
digestion with the endonuclease Cel-1 that cleaves specifically at base-pair mismatches followed by 
PCR amplification of the gene. Despite identification of Cel-1 cleavage of dsbA for eight infections 
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sequencing identified no mutations in the dsbA gene. The failure to obtain a loss-of-function CtDsbA 
mutant delays our understanding of the role of CtDsbA in chlamydial infections. 
5.4 Future perspectives for developing antimicrobial drugs targeting 
DsbA enzymes 
DsbA enzymes introduce disulfide bonds to a broad range of virulence factors. Consequently, 
inhibition of DsbA will lead to attenuation of virulence, while the bacteria remain viable. The 
structural library of DsbA enzymes that has been assembled, now including CtDsbA, provides a 
foundation for structure-guided drug development for an antimicrobial drug targeting virulence. 
DsbA homologs have been identified in commensal bacteria, such as Streptococcus gordonii [285] 
and commensal Neisseriae [94]. Consequently, targeting DsbA could potentially have off-target 
effects on the commensal microbiome. However, the structural library of DsbA enzymes shows that 
the active site pocket varies in length and depth and the electrostatic surface potential at the catalytic 
surface is different in DsbA-I and DsbA-II enzymes. The diverse characteristics of the DsbA enzymes 
potentially allows for development of highly specific DsbA inhibitors, which might limit the effect 
on the commensal microbiome. Furthermore, even if commensal bacteria are affected by an anti-
DsbA compound they could still persist after such treatment, whereas this is not the case for antibiotic 
treatment. Disrupting DsbA activity has the potential to disrupt processes such as motility, adhesion 
and secretion without affecting bacterial growth as seen for compounds identified Adams et al. [111]. 
Consequently, clearing of an infection upon treatment with anti-DsbA compounds would also be 
dependent on the host cell immune system. Pathogenic bacteria trigger a strong immune response 
causing the host cell immune system to clear the infection, whereas commensal bacteria do not trigger 
an immune response to nearly the same degree [286,287]. This discrimination between pathogenic 
and commensal bacteria might potentially mean that anti-DsbA compounds can facilitate clearance 
of infections with pathogenic bacteria while the commensal microbiome persists. 
 
Whereas the hydrophobic groove or pocket of EcDsbA and other members of the DsbA-I subgroup 
contributes to the druggable nature of the DsbA-I enzymes, CtDsbA and PaDsbA2 as well as the 
majority of the type II enzymes lack a binding pocket at the catalytic surface which could be 
challenging for developing inhibitors targeting DsbA. However, inhibitors containing a cysteine have 
been developed against EcDsbA [112]. As covalent linking, rather than hydrophobic contacts with 
the residues at the protein surface, facilitates binding of a cysteine containing inhibitor, inhibitors for 
DsbA enzymes could potentially be developed despite the lack of an identifiable binding pocket. In 
fact, a cysteine-containing peptide developed based on the sequence of the redox partner, VKOR, of 
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MtbDsbA has been shown to bind to the catalytic surface of MtbDsbA in a cysteine dependent manner 
with a KD of 2.9 µM [78]. However, the rapid turnover of the substrate-DsbA disulfide bond due to 
the reactivity of the thiolate anion, as seen for EcDsbA [288] represents a challenge for development 
of a potent drug with binding of high specificity and affinity. 
 
The inhibitory binding of EFTu to the non-catalytic surface of AbDsbA [82] presents the possibility 
of developing allosteric inhibitors that don’t bind to the catalytic surface. This is a promising strategy 
for development of drugs for proteins such as CtDsbA that have no apparent pocket at the catalytic 
surface, but two pockets on the posterior surface. 
 
Alternatively, development of inhibitors for the redox partner DsbB offers a mechanism to target 
oxidative folding by hindering recycling of active DsbA. As 60 % of marketed drugs target membrane 
proteins [289], this might represent a promising strategy, and indeed inhibitors have been developed 
against EcDsbB in fragment-based drug discovery approaches [113, 114] and a cell-based high-
throughput screen [115]. However, the technical difficulties of working with membrane proteins 
outside of their native lipid environment represent a challenge. Further, apart from the thorough 
structural characterisation of EcDsbB [64, 101, 102], structural information is lacking for other DsbB 
enzymes making it a less ideal target for a structure-guided drug discovery approach. Screening for a 
phenotypic read-out, such as gain of β-galactosidase activity upon inhibition of EcDsbB [115], offers 
a way of screening compounds for specific inhibition of DsbB mediated oxidative folding without 
extracting DsbB from the native lipid environment. An equivalent cell-based high throughput screen 
might be a valuable approach for initial identification of inhibitors for DsbB lacking structural 
characterisation. 
5.4.1 Development of drugs targeting the oxidative pathway in C. trachomatis 
Due to the high degree of treatment failure and off-target effects on the gut and vaginal microbiome, 
new drugs for treating infections with C. trachomatis are needed. As the oxidative pathway has 
proven a promising target for development of drugs against E. coli, targeting the oxidative pathway 
might also serve as a strategy for development of drugs against C. trachomatis. 
 
The correct redox state of the COMC is not only crucial for infection, but also pivotal for progression 
through the biphasic life cycle of C. trachomatis [131, 145, 148, 284]. If CtDsbA is, in fact, involved 
in regulating the redox state of the COMC it is likely that inhibition of CtDsbA will not just attenuate 
infection, but will compromise the viability of C. trachomatis. This doesn’t prevent a CtDsbA 
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inhibitor from being a potent antibacterial drug, but it will not necessarily possess the advantages of 
an anti-virulence drug. One advantage of targeting virulence rather than viability is the potentially 
limited effect on the commensal microbiome. Lactobacillus, the predominant species in the vaginal 
microbiome [189], reduces the infectivity of C. trachomatis. Consequently, abolishing the 
Lactobacilli subpopulation in the vagina is associated with a higher risk of reinfection [190, 191]. 
Whereas antibiotics currently used for treating infections with C. trachomatis affects the viability of 
Lactobacilli [290], Lactobacilli do not encode a dsbA homolog and loss of CtDsbA activity is 
therefore not likely to affect the Lactobacilli subpopulation. This represents an advantage of a drug 
targeting CtDsbA compared to the drugs currently used to treat infections with C. trachomatis as it 
potentially reduces the risk of reinfection.  
 
Another issue with treating C. trachomatis infections is the risk of inducing persistence and thereby 
creating a subpopulation that is able to escape treatment. Cysteine-depletion of C. trachomatis leads 
to disruption of RB to EB differentiation and consequently persistence [284]. If CtDsbA is involved 
in oxidation of the COMC, inhibition of CtDsbA is likely to affect RB to EB differentiation in a 
similar manner to cysteine depletion. Consequently, targeting CtDsbA might lead to persistence.  
 
Knowledge of the structure and function of CtDsbA provides a foundation for development of 
inhibitors of CtDsbA in a fragment-based drug discovery approach. Especially, the possibility of 
allosteric inhibition should be explored considering the two pockets at the posterior surface of 
CtDsbA. As CtDsbA has no identifiable pocket at the catalytic surface the most attractive strategy 
for development of inhibitors is design of peptides capable of covalently binding to Cys38 e.g. based 
on the sequence of the interacting region for CtDsbB. This strategy has proven successful for 
identification of a peptide with inhibitory effect on MtbDsbA that, similar to CtDsbA, lacks an 
apparent binding pocket at the catalytic surface [78]. 
 
Targeting the oxidative pathway by disrupting the ability of CtDsbB to oxidise CtDsbA offers an 
alternative approach too and has proven successful for EcDsbB [115]. Targeting CtDsbB gives rise 
to the same challenges discussed for DsbB enzymes generally (Chapter 5, section 5.4). The molecular 
nature of the interaction between CtDsbA and CtDsbB is still poorly characterised, which makes 
evaluation of the structure-activity relationship challenging.  
 
As an alternative for a Fragment-Based Drug Discovery approach guided by structural information 
about the target enzymes, inhibitors of C. trachomatis oxidative folding can be identified in cell-
based assays. Little is known about the substrate range of CtDsbA in C. trachomatis and the biphasic 
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developmental cycle impairs genetic engineering. Consequently, development of a cell-based assay, 
like the β-galactosidase activity screen used for screening inhibitors of EcDsbB [115] is difficult as 
there is no distinguishable phenotypic read-out for lack of CtDsbA activity in C. trachomatis. 
However, if CtDsbB is able to complement a dsbB-null strain of E. coli, screening for inhibitors of 
CtDsbB may be possible in E. coli. Neither MtbDsbA nor CtDsbA rescue lack of EcDsbA in E. coli, 
but VKOR does rescue lack of EcDsbB activity [90]. Further, DsbB homologs from A. baumannii, 
K. pneumoniae, V. cholerae, P. aeruginosa, S. enterica Typhimurium (SeDsbB and DsbI) and from 
the distantly related F. tularensis and Haemophilus influenzae also complement a dsbB null strain in 
E. coli [115]. This suggests that CtDsbB may also do the same. Accordingly, if CtDsbB can be shown 
to complement EcDsbB null mutants, compounds could be screened for inhibition of CtDsbB in E. 
coli. Alternatively, CtDsbA and CtDsbB can both be recombinantly expressed in a dsbA/dsbB double 
mutant strain of E. coli and used for screening of inhibition of oxidative folding with a β-galactosidase 
activity read-out. Inhibition of the CtDsbA/CtDsbB activity can also be screened in the peptide 
oxidation assay, which is already established. However, the low signal-to-noise ratio in this assay for 
CtDsbA makes it difficult to detect the potential effect of an inhibitor. 
5.5 Future perspectives for studying disulfide bond formation in C. 
trachomatis 
Considering the important role of disulfides in the infection of C. trachomatis, more information is 
required to establish the role of the oxidative pathway in the regulation of the COMC redox state. 
Currently, whole genome sequencing of mutant libraries generated by chemical mutagenesis is the 
gold standard of genetic manipulations of C. trachomatis [270, 291]. Accordingly, more information 
should be directed towards screening of EMS libraries to identify a loss-of-function mutation of dsbA 
to study the effect of loss of oxidase activity. The forward genetics approach using DTT sensitivity 
as a phenotypic read-out did not lead to identification of dsbA mutants, so an alternative phenotypic 
marker could be explored. Under the assumption that the disulfide cross-linking network is 
compromised in C. trachomatis with a loss-of-function mutation in the dsbA gene, Machiavello stain 
could be used as a phenotypic marker. RBs stain blue with Machiavello screen whereas EBs stain 
red. However, it has been shown that upon disrupting the COMC disulfide cross-linking EBs stain 
blue with Machiavello stain [131]. As both RBs as well as EBs with a disrupted COMC will stain 
blue with Machiavello stain, the asynchronous differentiation from RB to EB complicates the 
phenotypic read-out but it should be possible to identify mutants with careful inspection and controls. 
Moreover, it is not established that CtDsbA does, in fact, oxidise the COMC. Even if CtDsbA does 
not oxidise the COMC cysteines, it is highly likely that CtDsbA is responsible for disulfide bond 
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formation in virulence factors as seen in e.g. E. coli [48], S. enterica Typhimurium [46, 53], C. jejuni 
[54], Y. pestis [47], P. aeruginosa [55, 56] and V. cholerae [50]. Consequently, a decrease in 
infectivity can be used as a phenotypic read out. However, as mutations in many other proteins is 
expected to be associated with a decrease in infectivity, this will still require sequencing of a large 
number of subpopulations to identify a mutation in the dsbA gene. The advantage of this approach is 
that other proteins important for virulence could be identified. As very few virulence factors in C. 
trachomatis have been identified this could aid the understanding of C. trachomatis infections. 
 
As the reverse genetics approach allows for more subpopulations to be screened in each well this 
approach offers an alternative to the forward genetics approach where more subpopulations can be 
screened with less handling. However, optimisation of the TILLING screen is required for this to be 
a suitable strategy. Firstly, reduction of smear after gel electrophoresis is essential for identification 
of an endonuclease digestion product. Using purified Cel-1, rather than celery extract containing Cel-
1, might reduce the smear. Alternatively, using a different endonuclease such as Guide-it Resolvase 
(TaKaRa) might solve the problem. Secondly, reducing the number of subpopulations screened in 
each well from 15 to 10 will allow for clearer identification of a mutation upon sequencing as 
discussed in Chapter 4 section 4.4.1.  
 
As genetic manipulation of C. trachomatis is notoriously difficult, other approaches might need to be 
utilised for unpicking the biological role of CtDsbA. Development of a potent inhibitor for CtDsbA 
in vitro, e.g. by a Fragment-Based Drug Discovery approach, potentially allows for the study of the 
role of CtDsbA in the infection and development of C. trachomatis. The EcDsbB inhibitors identified 
by Landeta et al also had inhibitory effect on the DsbB enzyme in nine other Gram-negative bacteria: 
A. baumannii, K. pneumoniae, V. cholerae, F. tularensis, H. influenzae, two DsbB homologs from P. 
aeruginosa and two DsbB homologs from S. enterica Typhimurium [115]. Consequently, these 
inhibitors might also have an inhibitory effect on CtDsbB and if so would inhibit the recycling of 
oxidised CtDsbA. In that case, this inhibitor could be used for studying the effect of loss of CtDsbA 
oxidase activity on C. trachomatis infection and progression through the biphasic life cycle of this 
pathogen. 
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5.5.1 Studying the biological role of CtDsbA  
Despite the unfruitful efforts to create a strain of C. trachomatis harbouring a loss-of-function 
mutation in the dsbA gene, my characterisation of CtDsbA has provided information about its redox 
character (Chapter 2), as well as expression levels of CtDsbA in vivo (Chapter 3), that allow for 
reflection on the biological relevance of CtDsbA oxidase activity. 
 
The redox potential of CtDsbA (-229 mV) approaches the redox potential of the dithiol reductase 
thioredoxin (-270 mV) [216]. The weak oxidising power of CtDsbA challenges the view of CtDsbA 
as an oxidase in vivo. However, an EcDsbA construct containing mutations that make it highly 
reducing, still functions as an oxidase in vivo as long as the overall rate-limiting step in oxidation of 
the folding substrate, and recycling of oxidised EcDsbA is not significantly altered [292]. 
Consequently, CtDsbA may indeed function as an oxidase in vivo for cysteine containing substrates 
if it is recycled to the active oxidised state e.g. by CtDsbB. 
 
Whereas the periplasm of Gram-negative bacteria is generally oxidising, the periplasmic space of C. 
trachomatis is highly reducing in the early stages of infection and oxidised later in the infection cycle 
[145]. DsbH and DsbJ (unique to the Chlamydia phylum) are two periplasmic oxidoreductases. It has 
been suggested that the periplasmic reductase DsbH contributes to keeping the periplasm reduced in 
a process regulated by DsbJ [145]. CtDsbB and ScsB (suppressor of copper sensitivity protein B) are 
both predicted to be integrated into the inner membrane and CtDsbA is predicted to be located in the 
periplasm, and potentially anchored to the inner membrane. The remaining oxidoreductases identified 
in C. trachomatis [147] are cytoplasmic. Based on the role of the well-studied Caulobacter crescentus 
ScsB, which is involved in a peroxide reduction pathway in the cell envelope [151], chlamydial ScsB 
is more likely to be involved in the reduction of peroxide than the regulation of the redox state of the 
disulfide bonds in the COMC. This would leave the oxidative pathway – the introduction of disulfide 
bonds - to CtDsbA and CtDsbB. 
 
CtDsbA is expressed late in the infection cycle, according to confocal microscopy analysis with 
CtDsbA specific antibodies (Chapter 3, section 3.3.5). Therefore, CtDsbA is a possible candidate 
responsible for contributing to the shift in the redox environment of the periplasm, and the outer 
membrane from reducing to oxidising. The Major Outer Membrane Protein (MOMP) are inserted in 
the membrane in the reduced state and oxidised later in the developmental cycle [143, 145, 148]. As 
the cysteines in MOMP are predicted to be located at the external side of the outer membrane [293], 
it is unlikely that CtDsbA is able to oxidise MOMP. But CtDsbA might oxidise the two membrane-
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anchored periplasmic cysteine-rich proteins OmcA and OmcB and the membrane bound polymorphic 
membrane proteins (Pmps) and Type III secretion system (T3SS). The predicted anchoring of 
CtDsbA to the inner membrane could potentially hinder oxidation of the proteins associated with the 
outer membrane. However, NmDsbA1 and NmDsbA2 are both anchored to the inner membrane and 
both are involved in oxidation of the outer membrane protein PilQ [94]. In contrast to MOMP, cross-
linking of OmcA and OmcB is observed shortly after onset of expression [148] and also unlike 
MOMP, OmcA and OmcB are not inserted in the membrane as monomers [143]. Consequently, 
CtDsbA-catalysed oxidation of OmcA and OmcB might occur after secretion to the periplasm, but 
before these two proteins are inserted into the outer membrane, which would explain how inner 
membrane-anchored CtDsbA could oxidise the outer membrane proteins of COMC. 
 
Traditionally, substrates for enzymes in the thioredoxin family, including FtDsbA, have been 
identified by trapping the substrate in an intermolecular disulfide bond by using a mutant with a 
CXXS catalytic motif [77, 294, 295]. Due to the C. trachomatis being refractory genetic manipulation, 
this is not a feasible strategy for CtDsbA. One way to circumvent the issues with genetic manipulation 
of C. trachomatis is to study the interaction between recombinantly expressed CtDsbA and potential 
substrates such as e.g. the COMC proteins OmcA or OmcB in vitro. This could be done by 
determining the redox state of OmcA/OmcB by AMS labelling and gel electrophoresis. Considering 
the general promiscuous nature of DsbA catalysis [48, 77, 90] this may involve the risk of identifying 
substrates that are not biologically relevant. 
 
If a loss-of-function mutation in the dsbA gene could be obtained or, alternatively, an inhibitor for 
CtDsbA developed, it would allow study of the effect on CtDsbA activity on the redox state of the 
COMC proteins. One approach would be to utilise the different staining properties of C. trachomatis 
dependent on whether the disulfide cross-linking is present or not. If CtDsbA activity is required for 
disulfide cross-linking of the COMC a loss of CtDsbA activity will result in C. trachomatis staining 
blue with Machiavello stain. The redox state of the COMC proteins can also be identified using 
immunoblotting after isolation of the membrane fraction. This has previously been done to study the 
redox state of MOMP [145]. 
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5.6  Conclusions 
Characterisation of CtDsbA expanded the structural library of DsbA enzymes; CtDsbA represents 
the first structural characterisation of a DsbA enzyme with a catalytic dipeptide sequence with two 
small uncharged amino acids and more than four cysteines. As a consequence of the lack of factors 
contributing to stabilisation of the thiolate anion of Cys38, CtDsbA is the weakest oxidase 
characterised to date, and in contrast to other DsbA enzymes the active site disulfide is only mildly 
destabilising. Consequently, these findings have provided new insights into the diversity of redox 
character amongst DsbA enzymes. 
 
The oxidative pathway of C. trachomatis awaits further study, but the finding that crude E. coli 
membranes containing recombinantly expressed CtDsbB can facilitate CtDsbA activity suggests that 
CtDsbA and CtDsbB constitute a functional redox relay. Accordingly, the oxidative pathway in C. 
trachomatis is likely to resemble the oxidative pathway in E. coli. 
 
Despite screening more than 16,000 subpopulations of EMS treated C. trachomatis for mutations in 
the dsbA gene, no dsbA mutation was obtained. This was disappointing as the failure to obtain a loss-
of-function mutation in the dsbA gene delays our understanding of the role of CtDsbA in C. 
trachomatis virulence. However, development of a phenotypic screen for DTT sensitivity of EMS 
mutants combined with the traditional reverse genetics approach using TILLING provides an 
excellent starting point for further efforts to obtain a loss-of-function mutant. 
 
This thesis has expanded our knowledge of the structural and functional diversity of DsbA enzymes. 
Moreover, data I presented herein suggests that CtDsbA and CtDsbB form a functional redox relay 
resembling the oxidative pathway in E. coli to some extent. The oxidative pathway in C. trachomatis 
is an attractive target for development of an antimicrobial drug with less impact than current 
treatments on the commensal vaginal microbiome.  However, more information about the substrate 
range in C. trachomatis is required before this potential can be further explored. Overall, this thesis 
provides the foundation for studying the biological role of CtDsbA in C. trachomatis infection and 
development. 
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